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There are multiple immune mechanisms identified for persistence of hepatitis B virus (HBV) 
infection.  This thesis considers the vital role that inhibitory receptors play in contributing to 
impairment of the adaptive immune system in chronic hepatitis B (CHB), and the potential role they 
play in the innate immune system, focusing on the inhibitory receptor leucocyte-associated 
immunoglobulin-like receptor (LAIR)-1. The unique aspect of this work is that for the first time 
LAIR-1 expression has been investigated on natural killer (NK) cells in CHB.   
 
Our striking findings of increased LAIR-1 expression on peripheral NK cells in CHB and an inverse 
correlation between expression and effector function suggest this inhibitory receptor could have a 
potential role in exhaustion of NK cells in CHB. We therefore additionally explored the expression of 
LAIR-1 on circulating NK cells from patients with hepatocellular carcinoma (HCC) and non-
alcoholic fatty liver disease (NAFLD). 
 
The particular relevance of LAIR-1 to liver disease is that one of its major ligands is collagen. We 
demonstrated a downregulation of LAIR-1 expression on intrahepatic NK cells, which we postulate 
might occur following repetitive engagement with abundant collagen within the liver. In line with 
this, intrahepatic NK cells with a liver-resident (CXCR6+) phenotype had even lower LAIR-1 
expression than liver infiltrating (non-resident, CXCR6-) NK cells. Furthermore, preliminary 
experiments display attenuation of the cytotoxic degranulation capacity (CD107a) by circulating NK 
cells from CHB patients upon exposure to plate-bound collagen. 
 
We demonstrate differential expression of LAIR-1 on NK cells in viral hepatitis, HCC and NAFLD 
and between peripheral and intrahepatic NK cells. Preliminary experiments demonstrate a role in 
inhibiting NK cell function suggesting this as a novel therapeutic target to harness the capacity of NK 
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Chapter 1: Introduction 
 
 
Our knowledge of Hepatitis B immunology and virology has advanced over the last 50 years since 
discovery of the antigen first isolated in the serum of an Australian Aboriginal (Blumberg et al., 
1965). The ‘Australia antigen’ is now termed ‘surface antigen’ and Baruch Blumberg won a Nobel 
Prize in 1976 for his outstanding efforts in uncovering the hallmark of Hepatitis B virus (HBV).  
 
HBV can cause both acute and chronic infection, for which there is no definitive curative treatment 
available. A vaccine was introduced in the 1990s, however there is still a considerable burden of 
chronic HBV infection affecting more than 240 million people worldwide (Ott et al., 2012).  The 
Global Burden of Disease Study highlights the worrying rise in mortality from all viral hepatitides in 
the last decade compared to other communicable diseases (Stanaway et al., 2016). The highest areas 
of prevalence include sub-Saharan Africa and East Asia, but due to migration patterns HBV can be 
branded a global concern. Up to a third of patients with persistent infection will develop cirrhosis 
and/or hepatocellular carcinoma (HCC). Approximately 780,000 people die each year as a 
consequence of these complications (Liaw and Chu, 2009), (Kanwal et al., 2015). HCC is the fifth 
commonest malignancy worldwide, associated with high mortality, and approximately 50% of these 
patients have HBV (Kim et al., 2016).  
 
The wider implications of these complications include costly long-term secondary care monitoring, 
including regular surveillance scans, and in some, liver transplantation. Current therapies are sub-
optimal and in the majority, long-term viral suppression is the mainstay of management. The goal of 
current pipeline therapies is functional cure i.e. sustained Hepatitis B surface antigen (HBsAg) loss 
with undetectable HBV DNA, and whether a ‘sterilising cure’ is achievable in chronic hepatitis B 
(CHB) is a subject of debate.  The definition of ‘sterilising cure’ is complete eradication of the virus 
from the host, which means undetectable HBsAg with eradication of HBV DNA including cccDNA 
within hepatocytes and integrated HBV DNA. Drugs specifically targeting cccDNA are in 
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development in experimental models, as well as development of assays to reliably measure 
intrahepatic cccDNA, however the feasibility of sterilising cure may not be practicable due to the 
presence of integrated HBV DNA (Lok et al., 2017). Currently, the two existing options employed in 
the clinic today are pegylated-interferon alpha (PEG-IFNα) or direct-acting antiviral (DAA) therapy. 
However, the exciting development of DAA therapies in hepatitis C virus (HCV) that offer a cure in 
more than 95% of chronically infected hepatitis C patients, tantalises clinicians and scientists of 




1.1 Innate and adaptive immunity are compromised in HBV 
 
Hepatitis B is a hepatotropic, and largely non-cytopathic virus, and liver damage occurs from ongoing 
immune-mediated damage.  Hepatitis B can be cytopathic in some rare circumstances such as 
fibrosing cholestatic hepatitis, which is a rapidly progressing liver injury that has been reported in 
liver transplant patients with recurrent hepatitis B.  
 
In CHB both arms of innate and adaptive immunity are impaired (Ferrari, 2015). It has been observed 
that altered phenotype and function of adaptive and innate immunity contribute to the persistence of 
viral infection. The immune status of the host is fundamental to viral replication and clearance; in the 
immune-compromised setting there may be reactivation of the virus. Age of acquisition is critical; 
young patients with HBV infection are much more likely to develop chronic infection. Age as a host 
factor is important in other viral infections, for example Cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), Measles, Mumps, Rubella etc. but most of these viruses do not develop chronicity and will 
resolve without tissue damage. Although HBV infection is transmitted via blood and body fluids, in 
highly endemic areas the main routes of transmission are vertical, perinatal or horizontal transmission; 
exposure from an infected child to an uninfected child during the first 5 years of life. In infants and 
children 90% will develop chronic infection if infected during their first year of life; conversely HBV 
acquired in adulthood will progress to chronic infection in less than 5%. Increased susceptibility at a 
young age is thought to be due to a less mature and less responsive immune system.  
 
There are multiple immune mechanisms identified for persistence of viral infection. This introductory 
chapter reviews the literature on the vital role inhibitory receptors play in contributing to impairment 
of the adaptive immune system in CHB, and the potential role they may play in the innate immune 




1.2 HBV Virology  
 
Prior to introducing the immunology of HBV it is fundamental to understand the virology. HBV is a 
double stranded DNA virus contained within a nucleocaspid formed by core protein (HBcAg) and 
viral polymerase (pol), surrounded by a lipid envelope composed of hepatitis B surface antigen 
(HBsAg). Virus particles are commonly referred to as “Dane particles”.  Original discovery of 
HBsAg, which facilitates the diagnosis of hepatitis B, was by Baruch Blumberg (1925-2011) in 1963, 
and later contributions by David Dane (1923-1998) and colleagues identified the infectious virions 
(Figure 1.1).  
 
Organisation of the genome is compactly packed to contain four open reading frames (ORFs) that 
overlap and encode viral proteins each with specific roles:  
 
(i) ’S’ ORF encodes the envelope protein HBsAg. There are three sizes of HBsAg proteins (small (S), 
medium (M) and large (L)). The largest, contains a domain, pre-S1, which has an important role in the 
HBV life cycle. HBsAg is historically described as the hallmark of CHB infection and used as a 
routine screening marker for the diagnosis of HBV infection. In recent years HBsAg assays have 
significantly improved so that levels can now be quantified and used to differentiate those considered 
at risk for disease progression or development of HCC (Chen et al., 2006) and for the assessment of 
on-treatment response with PEG-IFNα therapy (Martinot-Peignoux et al., 2014). It has been suggested 
that persistence of HBsAg at high titres tolerises the immune response in infected individuals, with 
the highest levels seen in childhood, which decrease over time (Winther et al., 2013). 
 
(ii) ‘C‘ ORF encodes the sequences for two proteins with separate functions: HBcAg and hepatitis B 
e antigen (HBeAg). During chronic HBV infection there is often loss of HBeAg synthesis, but 
HBeAg-negative variants/mutations may also occur, that are associated with increased viral activity 
and liver disease (Ganem and Prince, 2004). Whereas HBeAg can be readily detected in the serum, 
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HBcAg is located in the nucleus and therefore can only be measured quantitatively by 
immunohistochemical staining. HBcAg is a major component of the nucleocaspid containing the 
genome. Mason et al studied HBcAg in liver tissue in addition to HBV-DNA integration and clonal 
hepatocyte expansion, finding interesting differences in the percentage of nuclear HBcAg-positive 
hepatocytes in different disease phases of CHB (Mason et al., 2016). Although the biological 
significance of this is unclear, the authors proposed that their findings indicated, in line with other 
studies, that early phases are not disease free and perhaps merit treatment consideration at an earlier 
stage of the disease.   
 
(iii) ‘P’ ORF encodes polymerase protein, which is necessary to complete the cccDNA template. 
 
(iv) ‘X’ ORF encodes HBV-encoded X protein (HBx) essential for viral replication. It is the smallest 
of the ORFs. There is an increasing body of evidence pointing to the multifunctional role of HBx in 
cellular activities and importantly noted to be associated with the pathogenesis of viral HCC (Ng and 
Lee, 2011). HBx is involved in interfering with innate immunity by down regulating signalling 
pathways; cytoplasmic signalling and protein kinase C pathways, with a role in cell cycle regulation 
and repair (Dandri and Petersen, 2016).  
 
The host can generate antibodies to HBsAg, HBeAg and HBcAg, which help delineate which clinical 
phase a patient is in. This is described in more depth in chapter 2.1.2.  
 
Eight genotypes (A-H) have been identified, each specific to geographic areas. The genotypes are 
important as they can be utilised as a predictor of response to therapy (Janssen et al., 2005) and 








Figure 1.1: Hepatitis B virion  
 
The virus particles are approximately 42nm in diameter and infect hepatocytes. The 
structure is made up of an outer envelope called hepatitis B surface antigen (HBsAg) and 
the nucleocaspid core (HBcAg) that contains the viral DNA and DNA polymerase. HBeAg is 






Hepatocytes are infected with pools of covalently closed circular (ccc) DNA (Cheng et al., 2011). 
There are a number of steps to the HBV life cycle and each step involves the host machinery. The 
discovery of the receptor permitting viral entry in to hepatocytes was only made recently in 2012. 
Hepatitis B virus attaches to hepatocyte-associated heparan sulfate proteoglycans to initiate entry. Yan 
et al (2012) discovered the functional receptor to be sodium-taurocholate cotransporting polypeptide 
(NTCP), a bile acid transporter, and elegantly demonstrated binding of the virion to the NTCP via the 
pre-S1 segment of the HBV envelope protein (Yan et al., 2012).  
 
Simplistically, following viral entry, the HBV virion is uncoated and incorporated in to the nucleus 
where it is repaired by viral pol protein to form cccDNA enabling a template for transcription. The 
viral mechanism is sophisticated, enabling the virus to create a highly conserved copy but also 
cunningly concealing the assembly of cccDNA within the nucleus evading normal host immune 
defence mechanisms. cccDNA forms a highly stable structure that can lie dormant for years. HBV 
transcripts are exported in to the cytoplasm to undergo translation, producing a number of proteins 
and virions that are secreted from the cell in to the bloodstream. Novel therapies are targeted at the 
individual steps of the life cycle; however, theoretically boosting the immune system would be a 
useful adjunct. Current treatments for CHB comprise of antiviral agents directly inhibiting DNA 
polymerase, thereby preventing replication and release of virus particles, in addition to PEG-IFNα, 
which stimulates the host immune response.  
 
HBV is able to persist via mechanisms that fail to induce and overwhelm the host immune response; 
in line with this many patients are asymptomatic and don’t develop liver disease for many years. 
Chimpanzees (Wieland et al., 2004b) and human studies (Dunn et al., 2009) have demonstrated why it 
is often nicknamed a ‘stealth virus’, observing in early infection minimal activation of the innate 
response and of interferon-stimulated genes (ISG). The ongoing production of viral antigens has been 
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reported to induce T cell anergy and exhaustion. Clinically this has been observed in chronically 
infected patients who persistently have high titres of surface antigen. 
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1.3 Liver Immunology  
 
The liver is the largest solid organ in the body containing a large number of innate and adaptive 
immune cells. One of its major functions is involvement in host defence. Despite the continual influx 
of antigens from the gastrointestinal tract (80% of its blood flow is via the portal vein) it maintains a 
balance between tolerance to harmless antigens and the means to eliminate pathogens and toxins 
(Jenne and Kubes, 2013).  
 
Hepatocytes are arranged in a honeycomb pattern woven between hepatic sinusoids, surrounded by 
immune cells and held together by a collagen structure. A hepatic sinusoid is a type of blood vessel 
with open fenestrae where blood from hepatic artery and portal vein can mix. The sluggish blood flow 
allows exposure time to gut derived antigens and clearance of toxins by liver-resident cells, as well as 
circulating lymphocytes to traverse the hepatic sinusoidal endothelium. The hepatocytes being the 
major functional cell type of the liver account for two-thirds of the total parenchymal cell population, 
which are separated from the sinusoids by the space of Disse, where important subsets of immune 
cells such as liver sinusoidal endothelial cells (LSECs), kupffer cells, hepatic stellate cells (HSCs) and 
biliary cells reside (Crispe, 2016) (Figure 1.2). HBV replication takes place within hepatocytes, and 
they are always infected with virus due to their longevity (half-life approximately 6-12 months) as 
well as the continuous shedding of virions by infected host cells.   
 
Clearance of HBV is a coordinated response between innate, adaptive, humoral and cellular immune 
responses, however, the difficulty has been determining which is the most favourable to target as a 
therapeutic strategy.  
 
The introductory section provides an overview of our current understanding of impaired adaptive and 









Figure 1.2: Immune cells of the liver 
 
Schematic depicts the microanatomy of the sinusoidal space. Hepatocytes are the host of 
HBV replication and the major functional cell type of the liver. The space of Disse separates 
hepatocytes from the sinusoids, which are enriched with lymphocytes. Within the space of 
Disse important subsets of immune cells such as liver sinusoidal endothelial cells, kupffer 







1.4 Adaptive Immunity and HBV 
 
The adaptive immune system is an interplay of various immune cells; lymphocytes such as CD4+ and 
CD8+ T cells and antibody producing cells like B cells. It is important to point out that research 
within this field has been challenging because the only host of HBV is humans. Chimpanzees are also 
susceptible and can be infected with the virus, but most research has been yielded from animal models 
such as mouse, woodchuck, and duck in addition to cell culture systems.  
 
Due to the limited techniques in B cell analysis we have the most limited knowledge on this subset of 
immune cells in HBV infected patients, however, there is evidence to suggest that B cells are 
important in the clearance of HBV and prevention of reinfection (Bertoletti and Ferrari, 2016).  
Hepatitis B surface antibody (HBsAb) in serum is produced in response to a vaccine or natural 
infection. Patients with lymphoma and previous exposure to hepatitis B can experience HBV 
reactivation when treated with Rituximab, a monoclonal antibody (mAb) against CD20 that causes B 
cell depletion. Furthermore, the importance of B cells can be illustrated in chronic HBV infected 
patients receiving liver transplantation whereby the donor HBV immunity can clear remaining virus 
and protect the graft from re-infection (Shouval, 2007) 
 
We have a much greater depth of knowledge of T cell responses in HBV and research to date has 
emphasised the pivotal role of an effective CD8+ T cell response in controlling and eradicating viral 
infection (Maini et al., 2000), (Guidotti et al., 1999). Individuals with acute, self-limited HBV 
infection will mount a T cell response to epitopes of viral proteins, however, patients with CHB 
exhibit a weak or near undetectable HBV-specific response. Maini et al (2000) were able to show the 
absolute number of T cells did not impact the control of viral replication but the functionality of 
HBV-specific T cells was paramount. An elegant study by Thimme et al in chimpanzees examining 
the relationship between T cell-mediated viral clearance in acute HBV and disease pathogenesis 
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showed depletion of CD8+ T cells at the peak of infection, altered duration and outcome (Thimme et 
al., 2003). In the absence of CD8+ T cells, high HBV titres persisted for a longer time span, and viral 
clearance was prolonged. It was also noted that in infected chimps (Wieland et al., 2004a) and HBV 
transgenic mice (Guidotti et al., 1995) clearance is mediated by interferon-gamma (IFNγ). Further 
studies went on to illustrate that in chronic viral infection there is inefficiency of CD8+ effector T 
cells, resulting in a hierarchal loss of function such as IFNγ production, which was further confirmed 
as a mechanism also specific to CHB. One of the features noted of these ineffective CD8+ T cells was 
the overexpression of inhibitory receptors (see Figure 1.3). This panel of receptors has included 
Programmed death (PD)-1, Cytotoxic T-lymphocyte-associated antigen (CTLA)-4, T cell 
immunoglobulin- and mucin-domain-containing-molecule (TIM)-3, 2B4, CD160, Killer cell lectin-
like receptor subfamily G member (KLRG)-1 and Lymphocyte activation gene (LAG)-3 (Nguyen and 
Ohashi, 2015) (see Figure 1.4).  
 
The focus has therefore been on how to restore the function of exhausted T cells enabling them to 
mount an efficient antiviral response. This exhausted phenotype is important, as interestingly even 
therapeutic vaccines have had limited success in eliminating CHB due to their failure to limit the 










Figure 1.3: Phenotype and function of exhausted T cells in CHB 
 
CD8+ T cells produce effector molecules (left panel). However, in chronic infection, in the 
presence of persistent viral antigen they can become exhausted. Upregulated signalling 
through an array of inhibitory receptors such as PD-1, CTLA-4, LAG-3 and TIM-3 has been 
associated with hierarchical loss of T cell function and inefficient viral control (right panel). 










Figure 1.4: Inhibitory receptors on T cells.  
Figure adapted from Nguyen et al. Nature reviews immunology 2014.  
 
A panel of receptors known to negatively regulate function of T cells is depicted and their 
ligands on dendritic cells.  These receptors are upregulated after initial interaction between 
TCR and peptide-MHC class II. 
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During initial infection a naive T cell requires coordinated signalling from (i) antigen, presented by 
major histocompatibility complex (MHC)-peptide molecules to stimulate T cell receptor (TCR), (ii) 
co-stimulation through CD28 and (iii) signals from pro-inflammatory cytokines, to drive activation 
and differentiation of the cell in to an effector T cell. A subset of these effector T cells will become 
highly functional memory T cells, long-living and maintained without antigen. Upregulation of 
inhibitory receptors does not occur until after TCR interaction with antigen presenting cells (APC), 
clearly due to an evolutionary bias to protect from an excess inflammatory response or autoimmunity. 
However, in chronic infection in the presence of persistent viral antigen, T cells progress through 
stages of dysfunction, overexpressing a range of inhibitory receptors. A hierarchical loss of function 
ensues with reduction in IL-2 production, proliferation and ex vivo killing. Severe exhaustion results 
in failure to produce IFNγ, degranulate and finally deletion of much needed virus-specific T cells. 
Although the existing regulatory mechanisms are lacklustre for dealing with chronic infection, the 
evolutionary advantage of such a strategy where exhausted cells engage in a hierarchical switch off of 
function is the prevention of autoimmunity, with the functions of cytolysis and tumour necrosis factor 
alpha (TNFα) production switched off first, which have the potential to be more detrimental to the 
host (Wherry et al., 2003). Factors such as high viral antigen load, longer duration of infection and 
loss of help from CD4+ T cells contribute to severe exhaustion in CHB (Ye et al., 2015).  
 
Exhaustion of virus-specific T cells was first shown in the lymphocytic choriomeningitis virus 
(LCMV) mouse model.  The major advantage to this choice of animal model is that the two strains 
used to cause either acute or chronic infection differ in only two amino acids and as neither of these 
mutations affects any of the known T cell epitopes it is possible to identify the same CD8+ T cell 
responses after an acute or chronic viral infection enabling T cell mechanisms to be examined in both 
scenarios.  Mouse, woodchuck, squirrel and chimpanzee are all expensive models. Zajac et al studied 
acute and chronic LCMV infection in wild type and CD4-deficient mice (Zajac et al., 1998). They 
found that virus-specific CD8+ T cells persist in chronic infection but are functionally unresponsive 
thereby rendering them ineffective and unable to control the infection. The lack of CD4+ T cell help 
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resulted in complete loss of CD8 effector function. This study did not explore the molecular 
mechanisms of exhaustion but was a springboard for further work which has explored the key 
question regarding whether this phenotype can be altered to restore function, and thereby a potential 
target for immunotherapy.  
 
A number of studies have shown that inhibitory receptors such as PD-1, TIM-3 and CTLA-4 are 
highly expressed on CD8+ T cells in CHB patients and blockade of individual receptors or in 
combination can reinvigorate and restore T cell effector function, as in advanced cancer (Boni et al., 
2007), (Schurich et al., 2011), (Nebbia et al., 2012). A great deal of this work in vitro and in animal 
models looking at inhibitory receptors in viral infection has been done at a time in parallel with 
introduction of CTLA-4 and PD-1 blockade in cancer studies. The rationale for blockade therapy was 
based on studies demonstrating tumour cells exploit inhibitory mechanisms and evade the host 
immune response enabling them to expand and proliferate. In the treatment of metastatic melanoma 
and non-small cell lung cancer PD-1 and CTLA-4 blocking mAb have been approved for clinical use, 
to enhance anti-tumour responses. However, there is heterogeneity in blocking responses and some 
tumour types are refractory (Anderson et al., 2016). Similarly this pattern of partial restoration using 
blockade therapy has also been seen in vitro in CHB (Bertoletti and Ferrari, 2016).  
 
The repertoire of inhibitory receptors deemed significant has increased over the years and some of the 
receptors considered relevant to HBV are discussed further in the next section. The importance of 
their role in tolerance has been demonstrated in knock-out mouse models that develop 
lymphoproliferative disorders and autoimmune conditions. 
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1.4.1  Programmed death (PD)-1 
 
PD-1 is selectively upregulated on exhausted T cells. PD-1 is a member of the immunoglobulin 
superfamily and can bind two ligands (PD-L1 or PD-L2). The latter is mainly expressed on 
macrophages and dendritic cells. PD-1 knock-out mice develop glomerulonephritis and arthritis 
(Nishimura et al., 1999). Barber et al used a mouse model of infection with LCMV and demonstrated 
that PD-1 was upregulated at both the mRNA and protein level on LCMV-specific CD8+ T cells 
(Barber et al., 2006). The latter is important, as due to the complexities of transcription and 
translation, there is not always a corresponding change in both or guaranteed correlation. In summary 
they found high expression of PD-1 on functionally exhausted CD8+ T cells, and high expression of 
the ligand on infected cells suggesting a role in T cell dynamics. PD-L1 blockade restored function of 
CD8+ T cells and clearance of viral infection. The study methods were robust and addressed the issue 
that enhanced immune responses after blockade treatment might be due to de novo T cell responses 
from naive CD8+ T cells.  
 
These findings can be extended to chronic HBV infection, but it is important to be mindful that T cell 
experiments are particularly challenging due to the small number of HBV-specific T cells, which 
require in vitro expansion, the large number of HBV epitopes generated by antigen processing and 
therefore presented by HLA molecules, represent just a number of factors that can affect the results 
obtained. Boni et al (2007) found in vitro blockade of this pathway enhanced the function of HBV- 
specific T cells, however, perhaps due to the heterogeneity of CHB, blockade enhanced at differing 
levels (Boni et al., 2007).   
 
Tumours can upregulate PD-1 on T cells, and a number of tumour cell types express PD-L1. PD-L1 
expression can be induced by IFNγ. Although upregulation of PD-L1 on tumour cells has been shown 
to signify an active response of T cells with production of IFNγ or other such pro-inflammatory 
 40 
  
cytokines, equally it is considered to be a mechanism by which tumour cells can advantageously 
outwit the host response. Assays are in development to determine the potential of quantifying PD-L1 
as a biomarker to predict pathway blockade response, as clinical response is variable, as seen in CHB. 
However, it is more likely that although it can aid prediction it cannot be an absolute marker because 
expression is dynamic and altered by cytokines and the tumour microenvironment (Zou et al., 2016). 
 
Much of the excitement about inhibitory receptors relates to the clinical success in the cancer field of 
blocking antibodies targeting PD-1 and CTLA-4. Nivolumab, a human IgG4 mAb, has had favourable 
success in melanoma, non-small cell lung cancer, renal and bladder cancers and Hodgkin’s 
lymphoma. However, it is important to note that success rates are variable with survival rates superior 




1.4.2 T cell immunoglobulin- and mucin-domain-containing-molecule (TIM)-3 
 
TIM-3 expression on T cells has been linked to a number of inflammatory conditions like multiple 
sclerosis and systemic lupus erythematous (SLE) (Koguchi et al., 2006), (Wang et al., 2008), bacterial 
infections such as Tuberculosis (TB) (Jayaraman et al., 2016) as well as viral infections. In LCMV, 
Human immunodeficiency virus (HIV), HCV and HBV Tim-3+ T cells have the more dysfunctional 
phenotype (Jin et al., 2010, Jones et al., 2008, Golden-Mason et al., 2009, McMahan et al., 2010, 
Nebbia et al., 2012).  Nebbia et al investigated the relevance of the TIM-3 inhibitory receptor in CHB 
based on the interesting data presented by Oikawa et al (Oikawa et al., 2006).   
 
Oikawa et al showed in mice with acute graft versus host disease (aGVHD) there was high expression 
of TIM-3 on hepatic T cells and hypothesised this could play a role in hepatic tolerance and 
homeostasis as blockade of the receptor with mAb resulted in accelerated aGVHD (Oikawa et al., 
2006). The ligand of TIM-3 is galectin-9, which Nebbia et al noted is expressed on kupffer cells, and 
preferentially expressed in the liver of patients with active CHB. Receptor ligand interaction was 
suggested to inactivate or delete HBV-specific T cells, the exact mechanism is not clear but in vitro 
blockade of the pathway resulted in recovery of function. However, similar to attempts at pathway 
blockade of other receptors, the response was not uniform across all patients. The study nicely 
demonstrates the interaction of immune cells with liver cells. The authors found high levels of the 
ligand galectin-9 in serum samples from CHB patients versus healthy controls and suggested this 





1.4.3 Cytotoxic T-lymphocyte-associated antigen (CTLA)-4 
 
CTLA-4 competes with CD28 for CD80/86 binding. Similar to the other inhibitory receptors it is a 
mechanism that exists to halt further T cell activation and a protective response against an excessive 
inflammatory response. Knock-out mouse models display severe lymphoproliferative disease and 
autoimmune phenotypes as a result of both cell-intrinsic and extrinsic effects (Waterhouse et al., 
1995). mAb to CTLA-4 (Ipilimumab) was approved for clinical use in malignant melanoma in 2011. 
Similarly there have been promising developments of blockade eliciting anti-tumour effects to HCC. 
Promisingly, trials have not shown the development of immune-mediated fulminant hepatitis in 
patients.  
 
Schurich et al highlighted that although CTLA-4 blockade does allow for some T cell restoration in 
CHB patients, the lack of uniformity across patients suggests that blocking other receptors may play a 
role, implying a synergistic effect is needed (Schurich et al., 2011). Many studies have shown that 




1.4.4 Lymphocyte activation gene (LAG)-3 
    
LAG-3 is expressed on CD4+ and CD8+ T cells and natural killer (NK) cells (Anderson et al., 2016). 
It structurally resembles CD4 and will bind to MHC class II. Initially it appeared that LAG-3 knock-
out mice did not display any T cell defects but further exploration revealed that T cell expansion was 
affected (Workman et al., 2004). Upregulation only occurs several days after T cell activation (Triebel 
et al., 1990). Huard et al demonstrated in vitro blockade of LAG-3 boosted T cell function and 
proliferation (Huard et al., 1995). Further in vitro and in vivo experiments using healthy human cells 
confirmed the negative regulatory effect of LAG-3 on T cell function (Macon-Lemaitre and Triebel, 
2005).   
 
In LCMV, LAG-3 was shown to correlate with severity of infection although blockade of the receptor 
alone had little effect and synergised blocking with PD-L1 improved T cell response with a fall in 
viral load (Blackburn et al., 2009). Further studies in LCMV models have shown synergistic blockade 
of PD-1 and LAG-3 can reverse T cell exhaustion (Richter et al., 2010).  
 
Another ligand for LAG-3 was sought out given it could affect the function of CD8+ T cells and NK 
cells, both of which do not bind to MHC class II. Subsequently it was suggested liver and lymph node 
sinusoidal endothelial cell C-type lectin (LSECtin) found on tumour or liver cells is another ligand 
providing a mechanism of action and regulation (Xu et al., 2014). 
 
Similar to LAIR-1, which is the ultimate focus of this thesis, LAG-3 is an inhibitory receptor that also 
has a natural soluble form (sLAG-3), which has high affinity binding to the same ligand as membrane 
bound LAG-3. sLAG-3 has been described as functioning as an immune adjuvant (Nguyen and 
Ohashi, 2015). Triebel et al showed subgroups of patients with breast cancer who had detectable 
levels of sLAG-3 at time of diagnosis had better disease-free and overall survival rates (Triebel et al., 
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2006). Further studies in mice and phase 1 clinical trials have explored the potential of sLAG3-
immunoglobulin as an immune adjuvant, indirectly enhancing anti-tumour T cell function in 




There is a breadth of work providing strong evidence implicating the role of inhibitory receptors in 
the regulation of T cell immune responses, but undoubtedly there are added complexities. Impaired 
function of CD8+ T cells in CHB is multifactorial and there is emerging evidence of metabolic 
dysregulation contributing to exhaustion and interaction of other immune cells for example myeloid-
derived suppressor cells (MDSC). There are more MDSC in CHB livers and Pallett et al describe a 
suppressive role of MDSC on T cells contributing to dysfunction of HBV-specific CD8+ T cells 
(Pallett et al., 2015).  
 
Several challenging issues present themselves with regards to inhibitory pathways: 
i. Is modulating a single pathway enough? 
ii. How to minimise the side effects when targeting inhibitory pathways, especially of 
autoimmunity. 
iii. Which immune cell populations should be targeted as global targeting of any pathway where 
the receptor is expressed diversely can have mixed outcomes? 
iv. Treatment with oral antivirals or interferon treatment doesn’t appear to reprogram the 
phenotype of these ineffective T cells, hence more targeted approaches have been sought such 
as blocking these inhibitory pathways.  
 
Up to now, research has tended to focus on the role of inhibitory receptors in the impairment of 





1.5 Innate Immunity and HBV  
 
In CHB it remains unclear which is the superior population of immune cells that would benefit from 
immunotherapy and we do not have a potential biomarker to predict disease progression.  
 
NK cells are a main component of the innate immune system, originating from the bone marrow but 
independent of the thymus. NK cells use a different detection strategy to T cells to differentiate 
pathogen from healthy cells and this occurs via activatory and inhibitory receptors. These are surface 
receptors with a diverse repertoire originating from germ line, but they are not dynamic and do not 
undergo recombination (Lanier, 2005).  
 
NK cells are needed to control viral infection and are involved in liver pathogenesis (Tian et al., 
2013). They can kill virus by cytokine production and cytotoxic effects. The importance of this cell 
population is shown in studies of patients with rare genetic disorders with reduced NK cell frequency 
and function, who are found to be at increased risk of viral infection (Orange, 2002).  
 
As depicted in Figure 1.5 NK cells in CHB have been shown to contribute to viral persistence, 
shaping the adaptive immune response through various mechanisms (i) by reducing HBV-specific 
CD8+ T cells via TRAIL-R2 subsequently limiting the T cell response (Peppa et al., 2013), (ii) 
impaired cytokine response of CD56bright NK cells thereby failing to promote responses of 
lymphocytes of the adaptive immune system (Peppa et al., 2010), (iii) via crosstalk with other 
immune cells; cytolytic attacks against HSCs can prevent collagen deposition and fibrosis (Friedman, 






Figure 1.5: Emerging role for NK cells in HBV immunopathology 
 
There are a number of mechanisms by which NK cells in CHB have been identified as 
important players contributing to viral persistence and immune homeostasis. In summary 
they have an (i) antifibrotic effect, (ii) antiviral effect, (iii) role in deletion of HBV-specific T 





A normal NK cell will have inhibitory signals that outweigh activatory signals and thereby enable NK 
cell self-tolerance. In pathological conditions, this balance shifts. NK cells are effective and fast 
killers as they do not require priming to kill target cells and with no target cell MHC restriction, 
selective killing of any cells lacking MHC class I are targeted. On encountering their target, pro-
inflammatory cytokines are produced to enable recruitment of other innate cells and stimulate 
response of lymphocytes of the adaptive immune response. Unlike other inhibitory receptors, LAIR-1 
employs a human leucocyte antigen (HLA) class-1 independent mechanism (Meyaard et al., 1997).  
 
Since the discovery of NK cells in the mid-1970s, researchers have discovered new depths of the 
phenotype and evolving contribution of NK cells, and it is now believed that they share receptors and 
features such as memory and education similar to adaptive immune cells. Similarities begin at the 
developmental level. It was believed for some time that unlike T and B cells, NK cells do not express 
recombinant associate gene (RAG) proteins (Mombaerts et al., 1992) which are important for the 
rearrangement of genes of immunoglobulin and T cell receptor molecules. However, Karo et al 
showed that although the population of NK cells present in RAG knock-out mice were less 
competent, with ‘reduced cellular fitness’, when challenged with viral infection these proteins were 
still important in the developmental stage of NK cells (Karo et al., 2014).  
 
These new insights from a growing body of evidence suggest NK cells can contribute to persistence 
of infection, and if ‘NK cell fitness’ is impaired it potentially can be reversed.  
 
Importantly, inhibitory and activatory signal balance plays a role in memory and education as 
discussed below. Education and memory are key aspects of adaptive immunity, defined as cell 
capacity to learn, retain and then recall a response to a sensitiser. It was believed that as NK cell 
receptor genes do not undergo rearrangement, they do not have antigen specificity and lack memory. 
Although differences of opinion still exist, there is compelling data that this memory phenomenon 
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does exist in NK cells as evidenced using a mouse model of delayed type hypersensitivity (DTH) and 
enhanced immune responses in secondary challenge with virus. The DTH mouse model is based on 
exposure to a hapten, a chemical that alters self proteins so they then are recognised as foreign 
antigen, trigger an allergic response that on first exposure is mild and then on re-exposure generates a 
more pathological reaction. In a series of experiments in RAG deficient (no T or B cells) mice, NK 
DTH response was confined to CXCR6+ liver NK cells. CXCR6 is a liver specific adhesion molecule 
that can be used as a surface marker. These mice were able to recall the sensitising hapten for a few 
months and discriminate when exposed to a different hapten (Paust et al., 2010). Models of 
vaccination for herpes simplex virus (HSV)-2 (Abdul-Careem et al., 2012) and vaccinia virus (Gillard 
et al., 2011) have shown that protection from reinfection can occur independently of T and B 
lymphocytes. Experimental systems using mouse cytomegalovirus (MCMV) have demonstrated 
memory NK cells have a distinct transcriptional profile (Sun et al., 2011). These studies have shown 
NK cells can expand, and contract like T cells to generate memory cells after viral challenge 
conferring protection in adoptive-transfer models (O'Sullivan et al., 2015). However, the NK cell 
receptors that mediate these mechanisms have not yet been uncovered. Importantly in CHB, we have 
recently shown that upon viral suppression, following administration of PEG-IFNα, patients are able 
to maintain a population of functional NK cells, with long-lived potential, possibly due to the effect of 
the type-1 interferon exposure (Gill et al., 2016).
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1.5.1 Defining the role and activity of NK activatory and inhibitory receptors
  
In humans, the proportion of NK cells differs between peripheral blood and liver (Doherty and 
O'Farrelly, 2000). Second only to the lungs and the uterus liver tissue is highly enriched with NK cells 
(Bjorkstrom et al., 2016). NK cells are characterised via flow cytometry by the expression of CD56 
and CD16 but lack of CD3 and accordingly can be subdivided in to CD56bright (CD56hiCD16neg) and 
CD56dim (CD56loCD16pos) NK cells (Caligiuri, 2008). This differentiation is important, as the 
CD56bright NK cells are believed to be better at producing cytokine compared to the more cytotoxic 
CD56dim NK cells. As well as differing cytokine and intrinsic cytotoxic capacity they have diversity in 
NK cell surface receptor repertoire (Figure 1.6). It is unclear whether CD56bright NK cells are a 
precursor to CD56dim NK cells or a separate lineage. In persistent viral infection there is a marked 
change in the proportions of these subsets (Oliviero et al., 2009). 
 
What regulates the high proportion of NK cells in the liver is not known but they are placed in a key 
position for liver immune surveillance (Peng et al., 2016). They are the largest proportion of liver 
innate immune lymphocytes, which also include NK-T and gamma delta T cells.  In addition a unique 
subset of ‘liver-resident NK cells’, with different phenotype and functional characteristics, has been 
described in mouse and human livers. A decade ago Kim et al identified the presence of immature NK 
cells in the mouse liver that express low amounts of DX5 and Ly49 receptors (markers associated 
with NK cell maturity) (Kim et al., 2002). In humans these liver resident NK cells are CXCR6+ with 
a unique transcriptional profile of TBetloEomeshi differing to mice and peripheral circulating NK cells 
(conventional NK cells) (Stegmann et al., 2016). Stegmann et al observed this subset store fewer 
cytotoxic mediators, display an immature phenotype and upregulate TNF-related apoptosis inducing 
ligand (TRAIL). The mechanisms relating to the unique characteristics of liver NK cells still requires 
further probing and more intriguingly it is not known whether these tissue resident NK cells develop 




   CD56bright         CD56dim 
 
Figure 1.6: Summary of key receptors and function of CD56bright and CD56dim NK cells.  
 
NK cells are characterised by expression of CD56 and CD16. This schematic depicts the 
main receptors and functions of NK cells subsets. The two subsets have differing surface 
receptor repertoire and functional ability. The CD56bright NK cells (left panel) are abundant 






NK cells have a broad repertoire of activatory (NK cell activatory surface receptors include NKG2D, 
NKp46 and NKp30) and inhibitory receptors, which tightly regulate their effector functions (Sun et 
al., 2015a). These are not absolute “on/off” signalling receptors. They are better described in line with 
a ‘see-saw’ mechanism whereby cytotoxicity of NK cells against tumour cells for example is 
determined by effects of opposing NK cell receptors. In reality however, NK cells struggle in 
maintaining hosts as pathogen and tumour free. Employing theories used to examine inhibitory 
receptors in the adaptive immune system, it has been suggested boosting NK cell activity by removing 
the “hand-brake” of inhibitory receptors could be the key to clearance of HBV infection.  
 
There are two families of HLA class-I specific inhibitory receptors (i) CD94/NKG2 receptors - c-
type-like lectin family and (ii) killer-cell immunoglobulin-like receptors (KIRs) (Poggi and Zocchi, 
2014). The latter recognise polymorphic regions on HLA-A, -B, and -C as opposed to the former that 
only recognise HLA-E. More recently, immunoglobulin-like transcript (ILT), and leukocyte 
immunolobulin-like receptors (LIR) have been discovered, all clustered on chromosome 19.  
 
In humans these inhibitory receptors include KIRs and in mice the equivocal receptors as named 
Ly49. As described earlier NK cells have been shown to share features with adaptive cells such as 
memory and education and equally are subject to exhaustion/down-modulation through excess 
inhibitory signalling. Exhaustion of T cells has been extensively studied unlike exhaustion of NK 
cells. Below, outlined is some of the literature related to the ‘exhaustion’ of NK cells. 
 
1.5.2 Immunosuppressive cytokines 
 
Peppa et al were the first in this field to describe exhaustion and reversal of exhaustion in NK cells. 
They showed the CD56bright and CD56dim NK cell subsets have marked impaired capacity to produce 
IFNγ in CHB and immunosuppressive cytokines selectively suppress NK cell IFNγ production (Peppa 
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et al., 2010). IFNγ is a powerful method by which NK cells would normally be able to clear virus 
infected hepatocytes (Zhang et al., 2016). Blocking these immunosuppressive cytokines (IL-10 +/- 
transforming growth factor beta (TGFβ) blockade) restored NK cell capacity in vitro to produce IFNγ 
(Peppa et al., 2010). Heiberg et al (2015) identified CD56dim NK cell subset IFNγ impairment occurs 
at an early age by comparing IFNγ production in a young HBV infected cohort with healthy age 




Some studies have investigated the expression of single surface inhibitory receptors and their function 
on NK cells. Ndhlovu et al observed high expression of TIM-3 on NK cells from healthy donors and 
in cord blood, particularly on the mature CD56dim subset (Ndhlovu et al., 2012). Cytokine stimulation 
induced upregulation of TIM-3. In contrast to the findings on T cells where TIM-3 negatively 
modulated T cell function, TIM-3 positive NK cells were not found to be dysfunctional or exhausted. 
Despite this, functional assays demonstrated cross-linking of TIM-3 suppressed NK cell cytotoxicity 
(Ndhlovu et al., 2012). The authors were unable to shed light on the potential mechanism by which 
this could occur. It should be noted in the context of metastatic melanoma, TIM-3 on NK cells did 
mark a dysfunctional phenotype similar to T cells that are exhausted and upregulate inhibitory 
receptors. TIM-3 blockade was shown to similarly restore function (da Silva et al., 2014).  
 
Increased TIM-3 expression on NK cells has been described in HCV (Golden-Mason et al., 2015) and 
HIV (Finney et al., 2013). Golden-Mason et al demonstrated higher levels of TIM-3 on NK cells from 
HCV patients, particularly the CD56dim subset, but high expression of TIM-3 was associated with 
increased cytotoxicity, contrary to what one would expect, if cell fitness was exhausted by high 




Ju et al observed the expression of TIM-3 to be higher on circulating and liver infiltrating 
lymphocytes in HBV patients. It is obviously difficult to get access to healthy liver tissue and 
therefore they used non-alcoholic fatty liver disease (NAFLD) patients, as well as healthy controls 
(HC) as comparators. The authors did not show whether the TIM-3 positive subset were more 
dysfunctional, however, blockade of TIM-3 pathway led to increased cytotoxicity of NK cells and 
IFNγ production, however these increases were modest (Ju et al., 2010).   
 
Taken together these functional assays have consistently shown TIM-3 functions as an inhibitory 
receptor, however, the mechanism needs further investigation as this is difficult to explain when the 




A great deal is known about PD-1 expression on T cells but little is known about PD-1 expression on 
NK cells and their function. In humans higher PD-1 expression has been observed in HCV 
particularly the CD56bright NK cell subset (Golden-Mason et al., 2008) in TB (Alvarez et al., 2010), 
patients with multiple myeloma (Benson et al., 2010), and in post-transplant lymphoproliferative 
disease (Wiesmayr et al., 2012). However, these expression levels are relatively low overall. In 
regards to function, this inhibitory receptor appears to negatively regulate NK cell function. In 
patients infected with TB, PD-1 blockade in vitro resulted in increased NK cell IFNγ production 
(Alvarez et al., 2010).   
 
NK cell-mediated cytotoxicity is an important response mounted against tumour cells. Tumours can 
exploit the PD-1 pathway by over expressing the main ligand PD-L1, dampening both T and NK cell 
responses (Dong et al., 2016). Specific monoclonal antibodies such as Pidilizumab have shown 
blocking PD-1 in-vitro can enhance the activity of NK cells against autologous cancer cells (Benson 
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et al., 2010).  What remains unclear is whether the therapeutic effect is mainly due to reactivation of 
the exhausted T cells as the effects are not uniform across all patients.   
 
Inhibitory pathways such as PD-1 have been demonstrated to play a critical role in liver tolerance as 
loss of PD-1 signalling can lead to spontaneous allograft rejection in mice (Morita et al., 2010) and 
mouse HSCs can suppress T and B cells via PD-L1 to maintain tolerance (Li et al., 2016).  
 
1.5.5 LAG-3 
    
LAG-3 is expressed on CD8+ T cells and NK cells. It binds to LSECtin on tumour or liver cells (Xu 
et al., 2014). Expression on NK cells and its function is poorly understood on NK cells in chronic 
infection.   
 
1.5.6 NKG2A  
  
Expression of NKG2A is higher on NK cells in acute HBV compared to acute HCV but this may be a 
sign of disease activity rather than a feature of HBV infection (Lunemann et al., 2014). 
 
There is evidence of inhibitory receptors overriding the mechanisms of activation to dampen anti-
tumour and anti-viral responses. To date, little evidence has been found exploring the role of 
inhibitory receptor LAIR-1 in chronic viral infection. Our interest was piqued by recent studies 
revealing the ligand of LAIR-1 to be collagen. Collagen in the liver can be increased four to seven 
fold in a diseased state (Rojkind et al., 1979). We were interested in looking at LAIR-1 because 




1.6 Liver fibrosis and role of HSCs 
 
The liver has a unique capacity to regenerate (Ellis and Mann, 2012). The only other organ with 
similar features is skin. This particular feature enables orchestration of the complete restoration of 
architecture and function following acute injury in a short period of time (Fasbender et al., 2016). 
Fibrosis is universally defined as the deposition of excess extracellular matrix with death of 
hepatocytes. In fibrosis, initially there is only a slight deficit to hepatocyte function but over time, 
with repeated insult, this can progress to cirrhosis (Friedman, 2008). There are no approved anti-
fibrotic therapies available, although in CHB potent antivirals limit disease progression, with some 
evidence of fibrosis regression (Chang et al., 2010), (Marcellin et al., 2013), (Calvaruso and Craxi, 
2014).  
 
HSCs play a critical role in the pathogenesis of liver fibrosis. They are positioned in the space of 
Disse and in a healthy liver separated from NK cells by the LSECs, however in a diseased liver this 
barrier is broken, and HSCs will come in to contact with immune cells (Fasbender et al., 2016). Cell 
death activates HSCs and transdifferentiation to myofibroblasts (Iwaisako et al., 2012), (Brenner et 
al., 2012). The inflammatory microenvironment of numerous cytokines such as TGFβ-1, platelet-
derived growth factor (PDGF) and other chemokines released in the process of destruction cultivate 
an environment where activated HSCs can outbalance mechanisms in place to degrade collagen i.e. 
matrix metalloproteinases (MMPs). In chronic liver damage ongoing stimulation of activated HSC 
results in excess production of extracellular matrix (ECM) products, particularly type I collagen. Later 
in this chapter, the crystal structure of collagen and LAIR-1 interaction with different types of 
collagen are described. 
 
NK cells are a generous proportion of the liver lymphocyte population and the liver can become 
compromised in function with excess collagen deposition; therefore one might postulate that NK cells 
may play a role in controlling collagen deposition. In fact several studies have already highlighted a 
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role for receptor ligand interactions between NK cells and HSCs, driving increased NK cell 
stimulation and reduced NK cell inhibition, with a shift in the balance of activator and inhibitory 
signals, thereby reducing liver fibrosis by increasing HSC death (Melhem et al., 2006). NK cells 
therefore have a role in protecting the liver from fibrosis. Figure 1.7 describes a number of 
mechanisms by which this can occur. 
 
i. Activated phenotype of NK cell receptor expression 
An increase in NK cell activatory receptors NKp30, NKp46 and NKG2D has been described in HCV, 
and blocking these receptors reduced HSC apoptosis (Radaeva et al., 2006), (Kramer et al., 2012).  
Although the pathways by which these receptors influence HSC apoptosis is not entirely clear, it is 
likely that the presence of activated NK cells is protective (Glassner et al., 2012). In general, 
hepatocyte damage can trigger HSC activation, which results in increased NK cell activity and a key 
mechanism is the production of retinoic acid by early activated HSCs, giving rise to a higher 
expression of RAE-1 protein, which was originally isolated from mouse embryonic carcinoma cells 
and later identified as an NKG2D ligand that activates NK cells (Radaeva et al., 2007). High levels of 
RAE-1 have been detected in the liver of HBV transgenic mice (Chen et al., 2007). In addition, it is 
important to note the role of the liver microenvironment influencing regulation of receptor expression. 
In chronic liver injury the levels of TGFβ released by neighbouring LSECs and kupffer cells is 
increased and can downregulate NKG2D, inhibiting NK cell activity and allowing survival of HSCs.  
Studies in mouse models have shown dysregulated NK cell function is associated with worsening 
liver fibrosis (Muhanna et al., 2011).  
 
ii. MHC class I downregulation on activated HSCs 
In mouse models, deletion of the gene encoding Ly49 receptor (inhibitory receptor on mouse NK cells 
equivalent to KIR in human) increases NK cell killing of HSCs, with fibrosis resolution (Gur et al., 
2012). MHC class 1 is downregulated on activated HSCs thereby hindering engagement of inhibitory 




iii. Influence of inflammatory cytokines  
In addition to high levels of TGFβ produced by activated HSCs influencing NK cell function (Jeong 
et al., 2011), the cytokines produced by NK cells themselves can influence cell dynamics. IFNγ 
produced by NK cells can trigger HSC apoptosis and cell cycle arrest. In addition IFNα can 
upregulate TRAIL on NK cells (Gill et al., 2016, Micco et al., 2013) binding to upregulated TRAIL-
R2 on activated HSCs, thereby propagating NK cell apoptosis (Fasbender et al., 2016). 
 
iv. Activated HSCs express ‘death receptors’ such as Fas and TRAIL-R 
Fas and TRAIL-R are both receptors of the TNF family and initiators of apoptosis. RAE-1 has 
similarly been shown to upregulate TRAIL-R on activated HSCs (Taimr et al., 2003). Another 
apoptotic pathway is via Fas expression on activated HSCs.  
 
In order to determine how to reverse the process of fibrosis, it is important to dissect the particular 
molecular mechanisms and stages of NK cell involvement in this process. Experimentally, the main 
methods to investigate this interaction would be, in vivo via mouse models whereby liver fibrosis can 
be induced by repeated administration of hepatotoxic substrates or in vitro experiments involving 
culturing HSCs isolated from liver tissue.  
 
NK cells appear to preferentially kill early activated HSCs but not quiescent or fully activated HSCs 
(Gao and Radaeva, 2013). Recently we, and others, have identified subsets of human liver resident 
NK (lrNK); their role in liver fibrosis has never been explored. 
 









Figure 1.7: NK cells can interact with their respective receptor/ligand on HSCs to induce 
apoptosis of HSCs and protect the liver from collagen deposition.  
 
In the presence of hepatocyte damage HSCs will become activated. In early activation there 
is downregulation of NK cell inhibition. Activated HSCs will upregulate NKG2D ligands. 
Subsequently the HSC will be killed by receptor/ligand interaction between NK cell and HSC.  
Other mechanisms shown include increased expression of TRAIL-R2 and Fas on HSC 
surface. MHC class 1 is downregulated on activated HSCs so they are easily recognised by 




1.7.1. Discovery and function of LAIR molecule  
  
Meyaard et al were the first to describe the inhibitory receptor named LAIR-1 (CD305) by means of a 
series of experiments isolating the receptor using a mAb (DX26) against LAIR-1 (Meyaard et al., 
1997).  However, it was Poggi et al who originally reported on a mAb that recognised a molecule that 
they called p40 but was later recognised as the same molecule as LAIR-1 (Poggi et al., 1995).  Like 
DX26, p40 mAb inhibited NK cell cytotoxicity (Poggi et al., 1997).  Meyaard et al in 1997 indicated 
cross-linking of DX26 and NK cell Fc-receptor (FcR) was essential and this was demonstrated using 
transfected human FcR-bearing targets by NK cell clones in a mouse compared to a FcR-negative 
parent line that subsequently had no effect on cytotoxicity.  Further functional experiments on human 
peripheral blood mononuclear cells (PBMC) showed more evidence of the presence of DX26 mAb 
inhibiting cytolysis in both resting and activated NK cells.  The functional role of LAIR-1 is described 
in more detail later in this chapter.  
 
Generally knock-out models deficient of an inhibitory receptor are used as affirmation of the 
importance of the receptor. The LAIR-1 knock-out mouse model demonstrated an altered immune cell 
phenotype but otherwise mice were healthy; normal haematopoiesis was not affected and their 
longevity unaffected compared with controls (Tang et al., 2012). A major drawback of this mouse 
model was the failure to consider that an altered immune cell phenotype may only become meaningful 
when a virus or pathogen stresses these cells. Another problem is it fails to take in to account that 




1.7.2. LAIR-1 structure  
  
The structure of LAIR-1 consists of an extracellular immunoglobulin (Ig) domain, short stalk, a 
transmembrane domain and a short cytoplasmic tail containing two immunoreceptor-tyrosine based 
motifs (ITIMs) (Meyaard et al., 1997). The extracellular domain binds to glycine-proline-
hydroxyproline (GPO)-rich segments of collagen. Sophisticated nuclear magnetic resonance (NMR) 
spectroscopy techniques have illustrated complexities of collagen crystal structure, folding and 
differential potential binding sites for collagen receptors like LAIR-1.  
 
Structurally it is related to other inhibitory Ig superfamily members mentioned earlier such as KIRs, 
ILT receptors and the Fc-receptor for IgA (FCAR), which are localised to the same receptor cluster on 
chromosome 19. However, unlike KIRs it does not recognise HLA class 1 molecules. There are only 
two members of the LAIR family; LAIR-1 and LAIR-2.  
 
LAIR-1 can be shed from the cell membrane and released when lymphocytes are activated. Ouyang et 
al observed higher levels of soluble LAIR-1 (sLAIR-1) in patients following kidney transplantation 
who experienced graft rejection, compared to those who did not and healthy individuals (Ouyang et 
al., 2004). They hypothesised that LAIR-1 would be similar to other membrane molecules involved in 
lymphocyte activation which have been seen in the sera of transplant patients, and associated with 
transplant rejection. The authors were keen to study whether sLAIR-1 could be used as a biomarker 
for rejection. They found high levels of serum sLAIR-1 in patients with haemorrhagic fever with renal 
syndrome (HFRS) caused by Hantaan virus, as well as in chronic rejection. LAIR-1 cross-linking in 
vitro inhibited cytotoxicity of CD8+ T cells.   
 
LAIR-2 consists of only an extracellular ectodomain hence no role in signal transduction, but exhibits 
high affinity for collagen molecules (Lebbink et al., 2008). LAIR-2 is a soluble protein, which 
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undergoes renal clearance. Study findings by Meyaard et al demonstrated CD4+ T cells as the main 
producers of LAIR-2 (Olde Nordkamp et al., 2011). It has been suggested that LAIR-2 has a 
regulatory role by preventing LAIR-1 binding to collagen, and also that it may be a urine biomarker in 
rheumatoid arthritis (RA) patients with a greater degree of inflammation when compared to a 
condition with less inflammatory activity, such as osteoarthritis (OA) (Olde Nordkamp et al., 2011).   
 
With the exception of sLAIR-1 these markers have not been investigated in viral infections, where the 
immune system plays a key role.  
 
1.7.3. LAIR-1 Expression 
 
LAIR-1 is an inhibitory receptor expressed on almost all haematopoietic cells. Several studies have 
shown upon maturation or activation expression on neutrophils, T cells and B cells can decrease 
perhaps suggesting a regulatory role of the cell at the level of receptor expression. There is limited 
published data regarding LAIR-1 expression in tissues, other than that described in a study by Zhang 
et al.  In this study, it was shown that the expression of LAIR-1 was low on CD4+/CD8+ T cells from 
RA and OA patients (PBMC) but that levels of LAIR-1 from RA patients were higher than OA when 
assessed by haematoxylin and eosin (H&E) staining of synovial tissue (in a small sample size of six 
patients).  LAIR-1 clustered in areas enriched with CD68 positive macrophages (Zhang et al., 2014). 
On B cells, LAIR-1 expression varies during B-cell differentiation and is lost on a subset of memory 
B cells and plasma cells (van der Vuurst de Vries et al., 1999).  
 
1.7.4. LAIR-1 Ligands  
  
In the literature, collagen has been described as the high affinity ligand for LAIR-1. The relatively 
recent discovery of the ligand of LAIR-1 as collagen (Lebbink et al., 2006), may explain the lack of 
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literature examining their interaction. There is little known about its role in disease. In a healthy liver, 
collagens are secreted into the ECM to maintain tissue integrity, however, in disease states there is 
excess deposition of ECM, mainly type I collagen (Friedman, 2008). As noted, NK cells have the 
capacity to interact with HSCs through a number of receptor-ligand interactions. HSCs play a central 
role in ECM deposition in liver fibrosis. To date, there has been no evidence that NK cells interact 
with HSC-derived collagen and we therefore designed experiments to investigate this possibility.  
  
There are four main classes of transmembrane receptors that specifically bind to collagen; collagen 
binding integrins, discoid domain receptors (DDR), glycoprotein VI (GPVI), and LAIR-1 (Leitinger, 
2011).  LAIR-1 resembles GPVI in structure but is an inhibitory receptor. The receptor is interesting 
for several reasons, highlighted in a review by Meyaard; unlike other inhibitory receptors it does not 
have an extensive subfamily, and the receptor ligand is not cell bound. For this reason regulation of 
the receptor must be tightly controlled as it is ubiquitously expressed on all cells of the immune 
system. Theories for self-regulation include LAIR-2 antagonising collagen-LAIR-1 signalling as a 
competitive inhibitor, and the LAIR-1 ectodomain being shed, thereby preventing transmembrane 
signalling.  
 
There is strong experimental evidence that collagen is the ligand of LAIR-1. LAIR-1 can bind 
multiple types of collagen (Lebbink et al., 2009).  Experiments by Lebbink et al illustrate collagen is a 
‘functional high affinity ligand’ for LAIR-1 (Lebbink et al., 2006). They were able to demonstrate this 
clearly using a number of experimental strategies strengthening their original observations, and 
showed;  
 
i. Different collagens can act as ligands for LAIR-1 by comparing antibody staining by LAIR-1-




ii. Pre-incubating carcinoma cell lines expressing collagen with collagenase, thereby removing 
the ligand for binding, prevented LAIR-1-IgG binding, with reduced MFI by flow cytometry, 
 
iii. High affinity of the collagen-LAIR interaction by surface plasmon resonance (BIAcore), and 
finally,  
 
iv. Demonstrating collagen cross-linking directly inhibited degranulation of cells in an in vitro 
model using a LAIR-1 transfected cell line and plate-bound collagen. Pre-incubation with 
blocking anti-hLAIR-1 F(ab’)2 fragments led to recovery of the inhibition.   
  
It has been speculated that the LAIR-1 collagen interaction can be exploited by tumour cells via a 
mechanism by which they upregulate collagen expression in a number of ways, increasing the 
availability of ligand to bind to LAIR-1 resulting in negative regulation of effector cells and thereby 







Figure 1.8: Potential mechanism of LAIR-1 described in tumour cells.  
Figure adapted from Meyaard et al, J. Leukoc. Biol. 2008. 
 
It has been suggested that a potential mechanism by which tumour cells dampen anti-
tumour responses of immune cells is by upregulation of collagen expression in a number of 
ways i.e. (1) transmembrane collagen, (2) ECM collagen, (3) collagen produced by stromal 
cells, thereby increasing the availability of ligand to bind to LAIR-1 resulting in negative 
regulation of effector cells. 
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The collagen binding properties of LAIR-1 have also been characterised using collagen derived 
synthetic toolkit peptides and reagents that interfere with binding. An elegant study by Brondijk et al 
more precisely characterises the collagen binding sites of LAIR-1 by mapping the crystal structure of 
the receptor using NMR spectroscopy (Brondijk et al., 2010).  
 
More recently C1q (a component of complement) and surfactant protein D (SP-D) have also been 
suggested as potential ligands for LAIR-1. A major constituent of the innate immune system are the 
complement components. It is widely accepted that the role of complement is more than the simple 
‘killing of bacteria’. Complement is involved in opsonisation of pathogens, regulating activity of 
adaptive immune cells such as T and B cells and also implicated in immunopathogenesis of a number 
of autoimmune diseases such as SLE (Merle et al., 2015a).  
 
The pathway involves a multifaceted cascade of plasma proteins and the liver produces the majority. 
These enzymes collaborate together and perhaps due to the complexity of the cascade and the number 
of proteins involved, it has been a more challenging area for immunologists to research. Historically 
three activation pathways have been described; classical, alternative and lectin. Each pathway 
prompts an enzyme cascade that eventually meets at C3.  
 
The classical pathway is triggered via the C1 complex (C1q, C1r and C1s), whereby antigen-antibody 
immune complexes are formed (Merle et al., 2015b). This is of particular interest in this study, as the 
complement sub-component C1q has been described as another functional ligand for LAIR-1. 
Myeloid cells produce C1q and complement activation requires surface bound IgM or IgG molecules 
nearby. Studies by Son et al demonstrate that the C1q-LAIR-1 interaction can directly inhibit 





SP-D is a collectin (collagen-containing c-type lectin). Collectins are part of the innate immune 
system and are soluble pattern recognition receptors (PRRs). They bind pathogen associated 
molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) to trigger an 
inflammatory response to eliminate pathogens. Olde Nordkamp et al demonstrated via binding assays 
that SP-D interacts with LAIR-1 via its collagen domains, inhibits immune activation and production 
of reactive oxygen species (ROS), suggesting a role in lung homeostasis (Olde Nordkamp et al., 
2014). ROS is released by inflammatory cells, along with hydrogen peroxide. Mutations in HBV 
infection have implicated higher endoplasmic reticulum stress and increased ROS production and 
inflammatory cytokines (Lee et al., 2015). SP-D expression has been detected in the lung and GI tract 
(Herias et al., 2007), and their role in the lung has been well established. Saka et al presented 
immunohistochemistry data showing that SP-D is present in the bile ducts of healthy liver from 
children and accumulates in hepatocytes of cholestatic livers, however the authors acknowledge the 
major limitation of small sample sizes  (Saka et al., 2015).  
 
The relationship between SP-D and chronic viral infection has not been investigated. If SP-D is 
present in hepatocytes and the liver, with the collagen domain interaction with LAIR-1, is there a role 
of this molecule in tolerance in the liver? C1q binding to LAIR-1 could also be highly relevant to 








The downstream molecular signalling pathways of LAIR-1 are not known but in-vitro activation of 
LAIR-1 by monoclonal antibodies or binding to collagen induces phosphorylation of ITIM motifs and 
recruitment of Src-homology-2-domain-containing phosphatases (SHP-1 or −2) (Meyaard, 2008) and 
the c-terminal Src kinase (Csk) (Verbrugge et al., 2006b) (Figure 1.9). An experimental demonstration 
of this effect was first carried out by Meyaard et al using sodium pervanadate (induces tyrosine 
phosphorylation) to activate NK cells (Meyaard et al., 1997). Cells were lysed and LAIR-1 proteins 
immune-precipitated with cross-linking mAb DX26. Western blot analysis showed binding of SHP-1 
and SHP-2 phosphatases to LAIR-1 lysates. Many inhibitory receptors have ITIM in their cytoplasmic 
domain triggering a cascade of downstream signalling events that abrogate effector functions of the 
cell. In general there is limited knowledge of LAIR-1 signalling pathway, with little in vivo data.  
 
It has been suggested that given the abundant expression of LAIR-1 on most immune cells, regulation 
can occur at cell receptor level with downregulation upon activation/maturation or via shed receptors 
or soluble proteins that interfere with receptor ligand binding.   
 
1.8.2. Effector functions affected by LAIR-1 
  
Not all inhibitory receptors have a role in exhaustion or compromising the function of cells, for 
example PD-1 has a role in cell activation (Nguyen and Ohashi, 2015). The study of the role of LAIR-
1, has been important, given that it is abundantly expressed on immune cells. In the 1990s several 
studies demonstrated that LAIR-1 cross-linking can inhibit target cell lysis by NK cells, cytotoxic 
activity of effector T cells and downregulate B cell receptor (BCR) signalling (van der Vuurst de 
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Vries et al., 1999). Van der Vuurst were able to demonstrate that in vitro prolonged BCR stimulation 
forces the downregulation of LAIR-1 on naive B cells A limitation of most of these studies is that 
they were performed using cross-linking of LAIR-1 by monoclonal antibody, as the ligand was only 
subsequently identified. Later Poggi et al were able to show Chronic lymphocytic leukaemia (CLL) 
cells that did not have LAIR-1 expression had no inhibitory capacity (Poggi et al., 2008).  
 
Poggi et al showed p40 (later known as LAIR-1) is able to inhibit the cytolytic activity mediated by 
both CD3negCD16pos NK cells and CD3negTCRpos T cells against tumour target cells (Poggi et al., 
1995). Lebbink et al found simultaneous cross-linking of hLAIR-1 using plate-bound anti–hLAIR-1 
mAb or collagen I or III caused marked inhibition of degranulation (they looked at release of b-
glucuronidase) (Lebbink et al., 2006). Experiments by Jansen et al involved healthy PBMC and IFNγ-
Elispot analysis on T cells, which was found to be inhibited by antibody-induced cross-linking of 
LAIR-1 and by collagen (Jansen et al., 2007). Meyaard et al showed that cross-linking can 
downregulate NK cell-mediated cytotoxicity on resting and activated NK cells (Meyaard et al., 1997).  
 
Baseline LAIR-1 expression is low on NK cells in chronic Epstein–Barr virus (EBV) (Aoukaty et al., 
2003) but with high expression on B cells in HIV infection (De Milito et al., 2004). Maasho et al 
(Maasho et al., 2005) and Jansen et al (Jansen et al., 2007) described high levels of LAIR-1 
expression on naive T cells which is in contrast to the expression of other inhibitory receptors, which 
are only expressed upon activation of T cells as a feedback loop to ‘switch off’ T cells preventing 
excess inflammation and immune pathology. However, Maasho et al (Maasho et al., 2005) pointed 
out LAIR-1 cross-linking could inhibit TCR-mediated signals in naive T cells and hypothesised 
LAIR-1 is also a mechanism for inhibiting initiation of immune responses. There is, however 
inconsistency with this theory, as demonstrated by Jansen et al who showed in vitro stimulation of T 
cells resulted in decreased surface expression of LAIR-1.  However these two studies were performed 




It has been speculated that cells that encounter more ligand have a higher threshold for activation and 
therefore comparatively higher expression of inhibitory receptor, and the presence of such high levels 
of LAIR-1 maintains homeostasis and prevents autoimmunity, but this theory requires further 
substantiation.   
 
We were interested to see whether higher LAIR-1 expression correlates with functional impairment of 







Figure 1.9: Structure of LAIR-1 molecule and function.  
 
Ligand binding triggers a cascade of signalling events. LAIR-1-mediated inhibiting signal 
occurs via the recruitment of immunoreceptor-tyrosine inhibiting motif (ITIM) in its 
cytoplasmic tail, with SHP-1 phosphatase.  
• Downregulates cell activation 
       Poggi et al, Frontiers in Imm 2014 
 
• Reduced cytotoxicity of NK cells 
       Meyaard et al, Immunity 1997 
 
• Inhibits cytotoxic activity of effector T cells 
      Jansen et al, Eur J of Imm 2007 
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1.8.3 Role in disease  
  
LAIR-1 captured our interest, as the ligand is abundant in the diseased liver in CHB. Collagen is 
implicated to play a role in several rheumatological diseases and autoimmune conditions. Researchers 
have speculated that the LAIR-1-collagen interaction may have a role in these diseases; however, 
little has been published regarding this. Previously published studies do not show the interaction of 
immune cells directly with collagen. Much of the work to-date has either related to the function of 
ligand binding or the potential of sLAIR-1 or LAIR-2 as biomarkers, speculating but not confirming 
the role of LAIR-1 in disease.  
 
Despite a background of in-vivo and in-vitro data regarding the potent inhibitory potential of LAIR-1 
on cross-linking with collagen there has not been significant progression towards the clinical 
relevance of the role of LAIR-1.  Interestingly, there has been limited focus on the role of LAIR-1 in 
organs where there is collagen deposition.  
 
Simone et al attempted to explore the role of LAIR-2 in organ specific autoimmunity, looking at the 
thyroid gland, which in autoimmune conditions can undergo remodelling (changes in matrix 
structure) and increased inflammatory infiltrate. They found LAIR-2 levels were seen to be increased 
in serum from patients with autoimmune thyroid disease (Simone et al., 2013). Increased LAIR-2 
levels in synovial fluid had been seen in patients with RA and ankylosing spondylitis. Olde Nordkamp 
et al showed synovial fluid from RA patients had higher levels of LAIR-2 compared with OA patients 
(OA patients were used as a control group as this is not an autoimmune disease). The major criticism 
of this study would be that they had a small group of patients, analysing only sixteen subjects 
(Lebbink et al., 2008). They further studied in this disease the role of secreted soluble LAIR-1 and 
LAIR-2 as potential biomarkers (Zhang et al., 2014), (Olde Nordkamp et al., 2011). Study findings 
demonstrated CD4+ T cells were the main producers of LAIR-2 and urine LAIR-2 correlated with 
 72 
  
markers of inflammation. However, whether these markers reflect the level of disease activity and 
damage in patients has yet to be investigated. Similarly high levels of LAIR-2 have been seen in 
ankylosing spondylitis (Diaz-Pena et al., 2012). Theoretically it has been suggested that high levels of 
LAIR-2 might contribute to pathogenesis of disease, acting as a pro-inflammatory mediator, with 
ongoing activation of immune cells as a result of preventing LAIR-1-collagen interaction and thereby 
inhibitory effects to the cell (Olde Nordkamp et al., 2011), (Simone et al., 2013).  
 
There is evidence of inhibitory receptors overriding the mechanisms of activation to dampen anti-
tumour and anti-viral responses. NK cells have a role in controlling tumour cell growth. NK cells 
reside in the liver, as do bone marrow stromal cells that are reported to have a role in haemopoietic 
malignancies and stem cell proliferation (Poggi et al., 2005). The close interaction of NK cells with 
cells that may express collagen has been explored looking at LAIR-1 in Acute myeloid leukaemia 
(AML) and Chronic lymphocytic leukaemia (CLL). Kang et al used a LAIR-1 knock-down model 
achieving deletion of LAIR-1 by silencing expression using Lentivirus-encoded short-hairpin-RNA 
(shRNA) (Kang et al., 2015). Knock-out models remove the gene whereas knock-down models will 
target specific RNA and reduce expression of protein in cells. Limitations of the latter technique can 
result in mice not showing the same phenotype as knock-outs, however Kang et al showed the LAIR-
1 knock-down did not alter the cell cycle state or normal haematopoiesis, consistent with findings 
from knock-out models described earlier. The study identified that the knock-down model in mouse 
and human AML cells markedly increased apoptosis and inhibited growth of leukaemia cells. Given 
inhibition of this receptor does not affect normal haematopoiesis, potentially makes it a more 
interesting therapeutic target for treating leukaemia. CLL is a heterogeneous disease with a variable 
clinical course, akin to CHB, also being heterogeneous and dynamic in nature. Studies have 
consistently shown higher expression of LAIR-1 in early stages of disease and lower expression in 
high-risk CLL patients (Poggi et al., 2008). A simple study of a large cohort of 311 CLL patients 
showed its potential role as a marker to predict advanced disease, using time to first treatment (TTFT) 
as a main parameter (Perbellini et al., 2014). Unfortunately the follow-up of the study was too short to 
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investigate the role of expression and survival of patients, which would be a more robust end point. 
TTFT, however, is a commonly used validated prognostic marker related to tumour progression.  
Interestingly they found only ~60% of patients were LAIR-1 positive (however, the cut-off value of 
30% was used to differentiate LAIR-1 positivity, which was determined as an initial observation from 
the spread of values and then validated using a receiver operating characteristic (ROC) curve for each 
cut-off value), and the ‘negative’ patients had more advanced disease with a tendency for autoimmune 
haemolytic anaemia at presentation. The observation of lower expression of LAIR-1 on B cells 
showing a more aggressive clinical phenotype, could lead us to speculate that these cells are less 
inhibited and cause “more harm to self” in the process of attack against disease. This also provides 
further evidence advocating the important role that LAIR-1 potentially plays in dampening down 
immune responses to maintain haemostasis.  
 
Kennedy et al measured LAIR-1 on global T cells as a marker of exhaustion in a population of young 
adults with CHB (age range 10-30 years) (Kennedy et al., 2012). They found no difference in LAIR-1 
expression between patients and healthy controls on CD4+ or CD8+ T cells. We are the first to 
explore expression of LAIR-1 on NK cells in CHB. Perhaps this receptor has been neglected due to 
the lack of tantalising data on T cells, which have been the main focus of the CHB literature for some 
time.  
 
However, with respect to viral infection, patients with chronic active Epstein-Barr virus (CAEBV), 
which has a more severe and prolonged disease course profile of infectious mononucleosis, had much 
lower expression of LAIR-1 (Aoukaty et al., 2003). Aoukaty et al were able to demonstrate the 
functional role of LAIR-1 in cytotoxicity with addition of mAb (DX26) to human CAEBV NK cells, 
which reduced their cytotoxicity. The degree of impairment was significant, and an isotope control 
did not elicit the same effect. Interestingly NK cells from CAEBV patients also had impaired IFNγ 
secretion, similar to what has been described in CHB, however, they did not differentiate whether this 
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was the CD56bright NK cell subset. These cells had a phenotype that displayed low expression of 















1.9.2.1 Aim 1 
 
Investigate expression of LAIR-1 on NK cells in the periphery and liver of CHB patients. 
 
1.9.2.2 Aim 2 
 
Investigate effect of LAIR-1 expression on NK cell function in CHB. 
 
1.9.2.3 Aim 3 
 
Investigate whether there is cross-talk between collagen producing cells in the liver (HSCs) and 





Chapter 2: Materials and Methods  
 
2.1 Study ethics  
 
Written informed consent was obtained from all patients (study cohorts included those with CHB, 












Figure 2.1: Summary of study cohorts 
 
Summary of the number of patients and HC included in this study. Patients included had 
CHB, NAFLD and HCC.  
 
 
The study has been approved by the local ethics committee (Barts and The London NHS Trust Ethics 
Review Board, REC references pertinent to this study include: P/01/23, 07/Q0604/20, 09/H0717/32, 




2.1.1. Study cohorts 
 
Sixty-nine CHB treatment naive patients attending outpatient clinics and seventeen CHB patients in 
attendance for liver biopsy were screened and invited to participate in the study. These patients 
receive hepatology specialist secondary care at the Royal London Hospital. All patients were 
seropositive for HBsAg and negative for anti–hepatitis D virus, anti-HCV, anti-HIV-1/2, and 
autoantibodies. In order to characterise disease phase, data was collected retrospectively from 
laboratory biochemistry and serology tests. Clinical parameters were repeated at every clinic 
attendance and over the course of a year this data was aggregated in order to clarify the patients’ 
disease profile.  At the time of inclusion in the study, blood sampling was performed.  The mean HBV 
DNA value was calculated using three values from the preceding year. HBV DNA was quantified by 
real-time PCR (Roche COBAS AmpliPrep/COBAS Taqman HBV test v2.0-dynamic range 20 to 
1.7x108 IU/ml-Roche molecular diagnostics, Pleasanton, CA). HBsAg titre (Abbott Architect) was 
also quantified. Serum was tested for HBeAg and Hepatitis B e Antigen antibodies (anti-HBe) with a 
chemiluminescent microparticle immunoassay (Abbott Architect, Abbott Diagnostics, Abbot Park, 
IL). HBV genotype was recorded where available, along with serum transaminases, Ishak fibrosis 
stage and necroinflammatory scores where paired liver biopsies were performed. 
 
The details of study participants with CHB from whom PBMC and paired data was collected is 
summarised in tables 2.1 and 2.2. These tables also summarise data from eight patients with HCC 
who were screened and invited to participate in the study. These patients were HCC treatment naive. 
In addition seven patients with abnormal liver functions in attendance for liver biopsy were screened 
and invited to participate in the study. These patients had NAFLD and were negative for HBsAg, 
anti–hepatitis D virus, anti-HCV as well as anti-HIV-1/2 negative. PBMC were also taken from 
twenty-one healthy, uninfected volunteers and described as the HC cohort within this study as 
























29 (5-68) 55:45 43:57 
 
IT (n=13) 
HBeAg+ IA (n= 17) 
IC (n=20) 









35 (23-52) 57:43 n/a n/a n/a n/a 
HCC 
 n= 8 





Table 2.1: Summary characteristics of study cohorts (PBMC).  
 
Summary characteristics of PBMC taken from study cohorts of CHB and HCC patients, as well as HC.  
Abbreviations: Hepatitis B e Antigen (HBeAg), Hepatitis B surface Antigen (HBsAg), serum alanine transaminase (ALT), not applicable (n/a), 























(out of 18) (n) 
CHB  
n= 17 
29 (25-52) 65:35 41:59 
 
IT (n=1) 
HBeAg+ IA (n= 6) 
IC (n=2) 






















40 (19-79) 43:57 n/a n/a n/a 105 
(37-246) 
All patients had 





Table 2.2: Summary characteristics of the study cohorts (paired data – CHB and NAFLD) 
 
Summary characteristics of the study participants for paired data (blood and liver) in CHB and NAFLD patients.  
Abbreviations: Hepatitis B e Antigen (HBeAg), Hepatitis B surface Antigen (HBsAg), serum alanine transaminase (ALT), not applicable (n/a), 
immune tolerant (IT), HBeAg positive immune active (HBeAg+ IA), inactive carrier (IC), HBeAg negative immune active (HBeAg- IA), 
Necroinflammatory (NI) score. 
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2.1.2 Defining disease phases 
 
CHB is a dynamic disease and patients progress through phases as illustrated in Figure 2.2 (Liaw and 
Chu, 2009). These distinct disease phases are characterised by serum ALT, HBV DNA and HBeAg 
status (detailed in Table 2.3). These clinical parameters are repeated at every clinic attendance and 
over a course of a year these data were aggregated in order to clarify the patients’ disease profile.  
Upon determining these phases treatment decisions are made.  
 
Historically CHB is thought to progress through four disease phases; immune tolerant (IT), HBeAg 
positive immune active (IA), inactive carrier (IC) and in a proportion of patients, immune escape and 
viral reactivation leading to HBeAg negative CHB.  
 
Early infection in childhood is generally associated with high levels of virus, normal ALT, minimal 
inflammation and mild or no fibrosis on liver biopsy. This has been described as the ‘IT’ disease 
phase.   
 
The IA phase is thought to represent an awakening of the immune response with more marked 
immune activity reflected in fluctuation of the serum ALT. Persistence of this disease phase is thought 
to result in progressive liver damage and thus treatment is indicated to prevent the development of 
fibrosis and cirrhosis. HBeAg seroconversion combined with low viral load (<2,000 IU/ml) and 
normal serum ALT represents patients who become IC and have an increased degree of immune 
control. If this occurs before the age of 30 there is reduced risk for the development of HCC.  
 
A proportion of IC will develop disease reactivation with the emergence of viral escape mutants and 
elevated HBV DNA levels and serum ALT reflect this. This is referred to as HBeAg negative CHB as 








Figure 2.2: Diagram of disease phases. 
Adapted from Gill & Kennedy, Clin Med 2015 
 
CHB is a dynamic disease with distinct disease phases; immune tolerant (IT), HBeAg 
positive immune active (IA), inactive carrier (IC) and in a proportion of patients, reactivation 
of the virus occurs leading to HBeAg negative CHB. These phases can be characterised by 













Table 2.3:  CHB disease phases  
 
CHB disease phases are characterised by biochemical and virological markers. For the purpose of this study patients clinical parameters were 
aggregated in order to clarify the patients’ disease profile and categorised in to disease phases in keeping with guidelines. 
Phase HBeAg ALT HBV DNA 
Immune tolerant Positive <40 IU/L HBV DNA > 8 log IU (100,000,000 IU/ml) 
HBeAg positive immune active Positive >40 IU/L Any 
HBeAg negative immune active Negative Any >3.3 log IU (2,000 IU/ml) 
Inactive carrier Negative <40 IU/L <3.3 log IU (2,000 IU/ml) 
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2.2 Sample preparation and isolation 
2.2.1 Isolation of peripheral blood mononuclear cells 
 
PBMC were isolated from whole blood using Ficoll-plaque (GE Healthcare, Buckinghamshire, UK) 
density gradient centrifugation. Blood was taken from patients and healthy controls in 9ml BD 
vacutainer CPT tubes containing sodium heparin. In a 50ml falcon tube the blood was diluted in 
RPMI 1640 (Sigma Aldrich) in a 1:2 ratio and then carefully layered over 12.5ml Ficoll-Plaque. This 
was then centrifuged at 2500 rpm at 20°C for 20 minutes without brakes. Into a new 50ml falcon tube, 
the PBMC layer was aspirated using 2ml Pasteur pipettes whilst leaving the Ficoll-plaque layer 
undisturbed at the interphase. The mononuclear cell layer was diluted with RPMI and washed at 1500 
rpm at 20°C for 5 minutes. The supernatant was removed and the PBMC pellet re-suspended in RPMI 
to be counted prior to a final wash. Cells were diluted 1:9 in trypan blue (Sigma-Aldrich, St Louis, 
USA) and were counted using Neubauer counting chamber under a light microscope. The number of 
cells was determined using the following formula: 
Number of cells/ml = number of cells counted x dilution factor x 104  
 
The cells were washed and either used fresh for staining or re-suspended in heat inactivated foetal calf 
serum (FCS) (Invitrogen™, California, USA) with 10% dimethylsulphoxide (DMSO) (Sigma-
Aldrich, St Louis, USA) and transferred into cryovials (Corning, New York, USA). Cryovials were 
frozen at -80°C in Mr Frosty® (Fisher Scientific, Waltham, USA) before transfer to gas-phase 






For the purposes of serum extraction blood was taken in tubes containing a clot activator. These 
underwent direct centrifugation to remove red blood cells from the serum layer. Serum was removed 




Urine was aseptically collected from HC and patients. Individuals were asked to void directly in to a 
sterile container. Urine was directly aliquoted into 500µl aliquots and stored at -80°C for later use 
ELISA experiments (described in section 2.7).  
 
2.2.4 Liver biopsy sample acquisition 
 
The ratio of liver parenchymal to non parenchymal cells is approximately 70:30 and IHL constitute 
approximately 25% of the non-parenchymal cells (Gao et al., 2008).  Although there has been a 
movement towards non-invasive diagnostic tests, the gold standard to diagnose and assess liver 
fibrosis remains liver biopsy. The technique was first reported in 1923, and subsequently modified but 
is widely used and associated with low mortality (Grant and Neuberger, 1999). At the Royal London 
Hospital, the hepatology department continues to perform percutaneous liver biopsies. Access to this 
tissue is an opportunity to explore the unique phenotype and functional properties of IHL and liver 
resident IHL in diseased liver states. Patients attended the endoscopy unit for this outpatient procedure 
and were consented for complications of bleeding, perforation, infection and pain. A nurse was 
present to assist with the procedure and sample collection. The biopsy site is usually located in the 
seventh or eighth intercostal space in the midaxillary line, and was confirmed using a bedside portable 
ultrasound machine. A sterile field was prepared, and the skin cleaned and infiltrated with local 
anaesthesia administered in both superficial and deep planes extending to the capsule of the liver. A 
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small skin incision aids the biopsy needle to pass more easily through the skin. In our department we 
use the Menghini needle to sample hepatic tissue. The Menghini needle employs a suction technique 
and has a feature with a small stylet that occludes and prevents aspiration of tissue in to the syringe 
preventing disruption of tissue morphology. The Menghini needle is attached to a 10 ml syringe filled 
with 5 mls saline as it is advanced in to the intercostal space with the plunger retracted. On patient 
expiration and with maintained plunger retraction of the syringe a quick movement advancing the 
needle forward in to the liver and then quickly removing it is performed. No more than two passes 
through the liver were taken. The contents of the needle was assessed, and split. At least 20mm of 
liver tissue would be sent to histopathology in a formalin-containing pot and the excess tissue was 
transferred to a saline pot for acquisition of intrahepatic lymphocytes. After the procedure the patient 
is asked to lie in a supine position and has regular observations of pulse and blood pressure as per 
local procedural policy prior to discharge home later that day.  
 
2.2.5 Isolation of intrahepatic lymphocytes 
 
Our lab has expertise in processing liver tissue based on more than ten years of experience.  
Classically techniques involve gentle mechanical dissociation of tissue, which can affect the yield 
from biopsy samples (Morsy et al., 2005). Enzymes for the digestion of tissue were not used in my 
protocol.   
 
In a petri-plate (Sarstedt, Numbrecht, Germany), liver biopsy tissue was suspended in RPMI and 
gently mashed using the back of a 5ml syringe plunger. The cell suspension was then passed through 
a 70µm cell strainer (BD Biosciences) and centrifuged at 1500 rpm for 15 minutes to discard cell 
debris. The cell pellet was resuspended in RPMI for counting. The cells were then used immediately 




2.3 Culturing K562 cell line 
 
Although NK cells produce cytokine their principle effector function is via target cell lysis (Caligiuri, 
2008). This can be assessed using a degranulation assay measuring lysosome-associated membrane 
protein (LAMP)-1 or CD107a expressed on the activated cell surface or a cytotoxicity assay. Previous 
experiments have demonstrated antibody induced cross-linking of LAIR-1 can downregulate NK cell- 
mediated cytotoxicity (Meyaard et al., 1997) and degranulation (Lebbink et al measured release of b-
glucuronidase) (Lebbink et al., 2006). The K562 cell line has attained widespread use as an in vitro 
target for flow cytometry based NK cell cytotoxicity assays (Bryceson et al., 2012). K562 cells belong 
to an immortalised myeologenous leukaemia line. They lack MHC complex required to inhibit NK 
cell activity and therefore are sensitive to killing by NK cells.    
 
For the purposes of NK cell degranulation, the K562 cell line was utilised as the target.  Previously 
cryopreserved K562 were thawed slowly within a 37°C waterbath. These were resuspended in 10ml 
RPMI with 10% FCS and Penicillin/Streptomycin (complete RPMI; cRPMI). This solution was then 
centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and the cellular pellet 
resuspended in 10ml of the cRPMI and transferred into a small (25cm3) cell culture flask and 
incubated at 37°C. These cells progress into log phase in 5 to 7 days. Counting was therefore initiated 
at day 3 when the density had reached 0.7 to 0.8x106/ml. The cells were then split into approximately 
0.4 million cells per ml with fresh cRPMI. From this point the cell count doubles every 24 hours and 
therefore these were split and the media replenished every other day to a volume, which contained 
300,000 cells. These were then used at the appropriate concentration for the degranulation assay as 
described in section 2.5.2. When the total number of cells was more than 3x106/ml, they were frozen 
down as stock in liquid nitrogen at 3 million cells/ml in freeze medium. 
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2.4 Flow cytometry 
 
Flow cytometry is the principal tool used in this thesis to interrogate the phenotype and characteristics 
of cells. Results are based upon light scattering properties of the cells being analysed. Below is a 
discussion of the limitations of fluorescence compensation and non-specific binding, and methods 
incorporated in the experiment protocol to overcome these.  
 
Fluorescence compensation is the concept by which amounts of spectral overlap are estimated and 
subtracted from the total detected signals to generate an estimate of the actual amount of each dye 
(Herzenberg et al., 2006). In order to measure the spectral overlaps, ‘compensation control’ samples 
are used (Hulspas et al., 2009). These control samples are labelled with only one of the fluorochromes 
used in the panel of colours. They are used to estimate the contribution of the spectral overlap to the 
overall positive signal.  
 
Non-specific binding of mAb-fluorochrome conjugates can arise from interactions between probes 
and the cell surface. To overcome this limitation and improve the standard to make the FACS data 
interpretable, control samples are essential in flow cytometry (Kim et al., 2007). We have used 
‘fluorescence minus one’ (FMO) for all antibodies for which the threshold between unstained and less 
fluorescent cells is unclear. The data collected for cells stained with FMO control is compensated and 
gated consistently in the same way as cells stained with the full complement stain set. These control 
samples have been used to check for spectral overlap. An isotope has not been used, as often these are 
more helpful for demonstrating where there is poor blocking of the cells. In addition, the protocol for 





All stains for flow cytometry analysis were performed in 96 U-bottomed plates (Sarstedt, Numbrecht, 
Germany) at 4ºC. 
2.4.1 Extracellular staining of PBMC and IHL 
 
Cells were washed in PBS (Invitrogen™, California, USA) and centrifuged at 1500 rpm for five 
minutes. The supernatant was discarded and cell pellets re-suspended and divided between staining 
wells. The cells were stained with Live/Dead® Cell viability stain (Invitrogen™, California, USA) for 
ten minutes at 4ºC in the dark. Cells were then washed and FcR blocking reagent (Miltenyi) was 
added to the cells to avoid non-specific binding of antibodies at a concentration of 1:10 for a further 
ten minutes, after which the relevant anti-human monoclonal antibodies in PBS were added for thirty 
minutes at 4ºC in the dark, with no washing step in between. Appropriate FMO were used where 
necessary. Post incubation the cells were washed by centrifugation and fixed with 75μl/well of BDTM 
Cytofix-Cytoperm (Beckton Dickinson, Oxford, UK). Cells were transferred to 500μl polystyrene 
tubes for acquisition. Data was acquired on BDTM LSR II flow cytometer using Diva  (Beckton 
Dickinson, New Jersey, USA) and analysed using FlowJo (Treestar Oregon, USA) version X.0.7.  
 
The gating strategy for identification of NK cells within the peripheral and intrahepatic compartment 





Figure 2.3: Gating strategy for identification of NK cells from PBMC. 
 
PBMC were stained for CD56hiCD3neg NK cells after exclusion of doublets and dead cells. 
CD16 was used as a marker to differentiate between CD56bright (CD56hiCD16neg) and 







Figure 2.4: Gating strategy for identification of NK cells and lrNK cells from IHL  
 
IHL were stained for CD56hiCD3neg NK cells after exclusion of doublets, dead cells and 
CD14/19 positive cells. CXCR6 was used as a marker to differentiate between CD56bright 
(CD56hiCXCR6pos) and CD56dim (CD56loCXCR6neg) CD3neg NK cell subsets. CXCR6+ NK 





Figure 2.5: Gating strategy for identification of CD8+ T cells from PBMC.  
 
PBMC were surface stained with mAb CD8 and CD4 to identify CD8+ T cells after excluding 
doublets, dead cells, B cells (CD19) and monocytes (CD14).  
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2.4.2 Intracellular staining of PBMC and IHL   
 
Cells requiring an intracellular stain were surface stained as described above, following which they 
were washed and re-suspended in BDTM Cytofix-Cytoperm for thirty minutes at 4ºC in the dark. After 
permeabilisation and fixation the cells were stained intracellularly using the relevant anti-human 
antibodies in 0.1% saponin (in PBS with 1% FCS) for an additional thirty minutes at 4ºC in the dark. 
Cells were there transferred to tubes for acquisition on LSR II flow cytometer as described earlier in 
section 2.4.1. 
 












Table 2.4: Directly conjugated anti-human mAb  
This table identifies the directly conjugated anti-human mAb against extracellular and 
intracellular antigens used in identification and phenotyping of cells. 
Surface 
Marker 
Fluorochrome Clone Manufacturer Dilution 
Live/Dead UV n/a Fisher Scientific UK Ltd 1.5ul/ml 
CD3 PE-Cy7 UCHT1 eBioscience 1:100 
CD3 BV605 OKT3 Biolegend  
CD56-ECD FITC A82943 Beckman Coulter 2.5:100 
CD56 ECD A82943 Beckman Coulter 3:100 
CD56 PE-Cy7 NCAM16 Becton Dickinson UK   
CD38 PETexasRed HIT2 Becton Dickinson UK  1:200 
CD16 APC-CY7 3G8 Becton Dickinson UK  2:100 
TIM-3 APC F38-2E2 eBioscience 1:100 
LAG-3 APC 3DS223H eBioscience 1:100 
HLADR V500 G46-6 Becton Dickinson UK 1:100 
CD14 V500 M5E2 Becton Dickinson UK  1:100 
CD19 BV510 SJ25C1 Becton Dickinson UK  1:100 
CD4 BV421 OKT4 Biolegend 1:100 
CXCR6 BV421 K041E5 Biolegend 5:100 
CD57 BV605 NK-1 Becton Dickinson UK  2:100 
CD57 FITC TB01 eBioscience  
PD1 PerCP/Cy5.5 EH12.2H7 Biolegend 1:50 
CD8 AF700 OKT8 eBioscience 1:200 
LAIR-1 PE NKTA255 eBioscience 1:100 
CD107a PE H4A3 Becton Dickinson UK 1:100 
CD107a APC H4A3 Becton Dickinson UK   
     
Intracellular 
Marker 
    
IFNγ V450 B27 Becton Dickinson UK  3:100 
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2.5 Functional studies   
 
In order to assess NK cell function the following were measured; 
a) Cytokine production by intracellular staining 
b) CD107a degranulation assay   
 
2.5.1 Cytokine production by intracellular staining: 
 
PBMC were incubated overnight with 5 ng/mL of recombinant human interleukin (rhIL)-12 and rhIL-
18 (R&D Systems) for a total of twenty-one hours at 37°C. The biology of NK cells is regulated by 
interleukins (IL) and IL-12 is a major stimulatory cytokine that is essential for NK cell activation and 
proliferation (Zwirner and Domaica, 2010). Monensin (Golgistop) (4μl for 6ml of cell culture) and 
Brefeldin A (Golgiplug) (BD Biosciences) (1μl for 1ml cell culture) were added for the final three 
hours of incubation. The addition of Monensin prevents CD107a breakdown (see below CD107a 
degranulation assay) and Brefeldin A blocks exocytosis of IFNγ. Cells were stained, thereafter for cell 
surface markers, fixed and permeabilised and then stained for intracellular expression of IFNγ. The 
readout of IFNγ was chosen as it represents the effector cytokine which NK cells secrete and can 
promote engagement of other immune cells (Vivier et al., 2008).  
 
Preliminary experiments used phorbol myristate acetate (PMA) (3ng/ml) and ionomycin (100ng/ml) 
as a positive control to check cytokine and cytotoxic responses from NK cells (example shown in 
Figure 2.6). PMA activates protein kinase C, whilst ionomycin is a calcium ionophore and stimulation 
while these compounds bypasses receptor/ligand interaction and results in activation of NK cells.  
 
Unstimulated samples (i.e. media alone) have been used to define a positive/negative threshold for a 
cytokine response. Functional measures were corrected by subtracting background signals obtained 
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from medium alone sample/cytokine samples. PBMC without stimulation would create an 
environment less artificial but unfortunately has been previously shown to yield minimal amounts of 







Figure 2.6: Optimisation experiment using PMA and ionomycin 
PMA and ionomycin was used as a positive control to verify that cytokine stimulation with 






2.5.2 CD107a degranulation assay   
 
The main assay traditionally used to measure lymphocyte-mediated cytotoxicity included chromium 
(51Cr) release assays, however flow cytometry based assays have become more popular (Zaritskaya 
et al., 2010). Chromium release assays had a number of disadvantages including biohazard and 
disposal problems for the isotope, low sensitivity and poor labelling. The method was based upon 
internalisation and binding of the isotope by target cells, which on lysis released the radioactive 
isotype, allowing it to be quantitatively detected (Brunner et al., 1968). However, unlike the flow 
cytometry assays they are not as robust in reproducibility or as easy to conduct. Betts et al presented a 
novel technique demonstrating CD107a expression as a sensitive marker of cytotoxic CD8+ T cell 
degranulation and this was shortly shown to be similarly as effective as a marker for NK cells (Betts 
et al., 2003),(Alter et al., 2004).  
 
Preliminary experiments on healthy controls were done to check the dose response of interleukin 
stimulation, to avoid overstimulating cells with high dose interleukins (Figure 2.7) and to ascertain an 
optimal effector (E) to target (T) cell ratio for CD107a production (Figure 2.8). A dose of 5ng/ml 
rhIL-12 and rhIL-18 cytokines did not over stimulate NK cells and percentage IFNγ and CD107a are 
in keeping with published data. As seen in Figure 2.7a, a media only well was used as the negative 
control for gating of cytokines and CD107a expression and subtracted in final calculations. Media 
alone, as expected produced none or very minimal amounts of IFNγ and CD107a. No significant 
difference as noted between CD107a expression with effector to target cell ratios of 5:1 versus 10:1. 
A ratio of 5:1 was consistently used for the remainder of experiments as it allowed fewer effector cells 






(b)       (c) 
   
 
Figure 2.7: Cytokine stimulation with serial titration of rhIL-12 and rhIL-18 in HC PBMC.  
 
 
(a) Representative FACS plots from one HC showing %IFNγ production and %CD107a 
expression of PBMC unstimulated and with stimulation with rhIL-12 and rhIL-18 at varying 
doses (2ng/ml, 5ng/ml, 10ng/ml and 50ng/ml). Dose response is shown in graph format for 
(b) %IFNγ and (c) %CD107a with serial titration of cytokines. N=1 therefore unable to show 






Figure 2.8: Optimising Effector:Target ratio for degranulation assay.  
 
Degranulation of NK cells was measured using CD107a, which is extracellularly expressed 
by NK cells and a sensitive marker of cell activity. HC PBMC (n=2) were combined with 
target K562 cells at two different effector to target cell ratios of 5:1 and 10:1. Significance 







PBMC were incubated with K562 cells (5:1, E:T ratio) for 3 hours at 37°C following overnight 
stimulation with a combination of rhIL-12 (5ng/ml) and rhIL-18 (5ng/ml). The effector cells need to 
be activated by rhIL-12, rhIL-18 prior to addition of target cells. Activated NK cells have significant 
killing activity compared with basal NK cells. Flow cytometry allows discrimination between effector 
and target cells, as well as identification of live versus dead cells. This differentiation is on the basis 
of marker expression. CD107a-PE antibody (BD Biosciences), Monensin (4μl for 6ml of cell culture) 
and Brefeldin A (1μl for 1ml cell culture) were added at the same time as the target cells. The flow 
cytometry based NK cell assay for cytotoxicity activity is well described within this field (Bryceson et 







Figure 2.9: Functional study to assess NK cell function 
 
The functionality of NK cells can be measured by cytokine production and cytotoxicity. This 
diagram depicts NK cell assays, which are well described in the literature.
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2.5.3 Experiments involving collagen plates 
 
The above functional experiments were done in the presence and absence of cells incubated on pre-
coated collagen plates (Thermo-Fisher Ltd). Different collagens can act as functional ligands for 
LAIR-1 with high affinity to collagens I and III (Meyaard, 2008, Lebbink et al., 2006). Collagen I, III 
and V are predominant within the liver. In order to measure functional inhibition of NK cells we used 
a two-dimensional (2D) system with plate bound collagen. We chose to use commercial pre-coated 
collagen plates as these are ready to use and quality tested to help ensure consistency. Self-coating 
protocols can be inconsistent. These 96-well plates were pre-coated with collagen I at 5mg/ml 
concentration and can be used with human cells. The disadvantage of commercial bought collagen 
plates is a dosing assay was not performed. A dosing assay would have been optimal but was not 
performed within the limits of time. 1x106 cells were pre-incubated on 96 well plates (with or without 
collagen) for 2 hours prior to adding cytokine and 21 hour incubation at 37°C (experiment 
summarised schematically in Figure 2.10). 
 
 
Figure 2.10: Functional study to assess NK cell function on collagen plates  
 
To measure functional inhibition of NK cells we used a 2D system with plate bound collagen. 
Isolated PBMC and IHL were incubated with media, cytokine and cytokine in a collagen 
plate. In the final three hours of incubation target cells were added and cytotoxicity marked 
by degranulation CD107a measured.  
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2.6 Examine impact of stellate cells or their supernatant on LAIR-1 expression 
 
2.6.1 Isolation and co-culture with pHSC 
 
Experiments using primary human hepatic stellate cells (pHSC) were done in conjunction with Dr 
Laura Pallett, who has expertise in the isolation and culture of these primary cells. Prior to 
experimental use pHSC were cultured by Dr Laura Pallett from frozen cells previously isolated by 
her. 
 
Briefly these cells were isolated and cultured as follows:  
Step 1: Liver digestion and cell suspension 
Healthy margins of metastatic liver tissue were obtained from the Royal Free Hospital from consented 
patients during surgery. Liver tissue was both mechanically and enzymatically digested using 0.001% 
DNAse I (Roche) and 0.01% collagenase IV (Life Technologies) at 37°C for thirty minutes. The 
suspension of liver tissue was filtered under pressure through a 70µM filter (BD) and centrifuged at 
low speeds to remove the hepatocytes and any residual enzymes (500 rpm, two minutes).  
Step 2: Gradient selection 
Stellate cells are the least dense of the non-parenchymal cells (NPC) and unlike the other NPC 
(Kupffer cells and endothelial cells) they can be effectively purified to 90-95% purity using a simple 
density barrier or gradient process (Weiskirchen and Gressner, 2005). 
The remaining pellet comprising NPC were subjected to density centrifugation using OptiPrep® 
(Sigma-Aldrich, St Louis, USA). The pellet was re-suspended and carefully layered in a double 
density gradient; 10 ml of 17% Optiprep® at the bottom (density gradient diluted in PF4) and 10 ml 
of 11.5% of Optiprep® was carefully layered on top of it. An additional 4ml of PF4 was layered on 
top and centrifuged at 2700 rpm for 17 minutes at 20°C without any breaks. The hepatic stellate cell 
fraction on top of the 11.5% optiprep layer was aspirated using a 2ml Pasteur pipette. An equal 
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volume of PF4 was added to it and centrifuged at 1500 rpm for 10 minutes. After isolation pHSC 
pellet was re-suspended in Stellate cell media (ScienCell Research Laboratories).  
Step 3: pHSC culture and activation 
Before freezing, isolated pHSC were washed once in PBS and plated at a density of 5x104 cells/cm2 in 
tissue culture flasks and cultured at 37°C in a humidified atmosphere at 5% CO2 for expansion. 
Previous lab experience in this technique had observed to fully optimise this protocol freshly isolated 
pHSC need to be cultured in flasks rather than plates, which was attributed to plausible reasons of 
surface area available of flask versus plate and the plastic material differing between the two.  The 
cells were left for 24 hours to attach, after which they were washed with media and fresh media 
added. The quiescent hepatic stellate cells start differentiating into an activated state approximately 7 
to 10 days post culture. The cells are then passaged twice before freezing them down using FBS and 
10% DMSO as previously described. Previously, our group have shown that the HSC isolated and 
cultured were uniformly positive for the activated myofibroblast-specific marker anti-smooth muscle 
actin (αSMA, flow cytometric staining and RT-PCR), and microscopically show a characteristic ‘star-
like’ myofibroblast phenotype (Singh et al., 2017).    
 
When used for experimentation, cells were thawed and cultured in 25cm2 tissue culture flasks in 
Stellate Cell Media to approximately 80% confluency. Cells were then detached with trypsin and re-
plated in 24 well plates at 25,000 cells/well and left for 24 hours to reattach. Prior to use in co-cultures 
the Stellate cell media was removed and replaced with cRPMI without disturbing the adherent pHSC 
layer. 
 
Fresh PBMC were cultured overnight with rhIL-12 and rhIL-18. Approximately ten million cells per 
patient were prepped overnight either in media or with cytokine. These were then co-cultured with 
supernatant from activated pHSC alone or in direct contact with activated pHSC. Co-culture 
experiments were undertaken using twenty-four well plates. Approximately 25,000 pHSC were 
incubated with one million PBMC overnight in 500µl of fresh cRPMI with or without cytokine. After 
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twenty-four hours the cells were removed by pipetting and transferred to ninety-six round well plates 










Figure 2.11: NK cells and pHSC co-culture 
 
 
NK cells were activated and observed as to whether LAIR-1 expression was affected by 
pHSC or their supernatant. 
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2.7 LAIR-2 ELISA  
 
Paired urine and serum were utilised from fifteen patients with CHB, with an additional eight samples 
(n=23) for serum without paired urine. These patients (n=23) were categorised by disease phase; of 
which thirteen were immune active and ten inactive carriers. Paired samples of urine and serum were 
also utilised from HC subjects (n=5) for comparison. 
 
On the day of ELISA (Enzyme-Linked Immunosorbent Assay) experiments; aliquots of sera were 
thawed to room temperature. Urine aliquots were thawed and centrifuged for ten minutes at 1000 rpm 
to remove particulates and the supernatant was used for assaying. Human LAIR-2 (CD306) ELISA kit 
(LifeSpan BioSciences. Inc.) assay has been manufactured for use with serum and urine samples. The 
ELISA was used as per the manufacturers instructions. Briefly, for the ELISA a two-step protocol was 
undertaken; standard preparation and then sample preparation. Preparation of the standard dilution 
series as per manufacturers protocol was used to generate the standard curve. Standard stock solution 
1,000pg/ml was resuspended with 1ml of sample diluent and incubated at room temperature for ten 
minutes. Eight standards including zero standard were made up as per the manufacturers instructions.  
 
Initial optimisation was to perform a sample dilution series to identify optimal dilution. Sample 
dilutions were made up to 1:1, 1:100, 1:10,000, and 1:1,000000. All samples were run in duplicate to 
provide adequate data for statistical validation of the results. No interpretable concentration was 
elicited at dilutions less than 1:1 (see Figure 2.12.1).  
 
The samples were diluted in the same buffer as the standard used to generate the standard curve (see 
Figure 2.12.2). The standard curve was used to determine the concentration of target antigen in 
unknown samples. The standards were also undertaken in duplicate, and average of standards 
absorbency values taken for the known concentrations as prepared earlier with the average zero 
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standard optical density subtracted. The concentrations of each of these standards were in pg/ml. A 
standard curve was created by reducing the data using PRISM software capable of generating a four 








Figure 2.12.1: ELISA assay optimisation – sample dilution  
 
Concentrations of samples at varying sample dilutions made up to 1:1, 1:100, 1:10,000, 






Figure 2.12.2: Standard curve for ELISA assay 
 
Sample dilutions of less than 1:1 did not generate an interpretable concentration and 






As outlined in Table 2.5, a complete list of the full details of manufacturers and catalogue numbers for 
reagents used throughout the study.  
Table 2.5: Details of reagents 
 
 
This table lists the reagents used throughout the study. 
Product Manufacturer Catalogue No. 
BD TM compensation beads (anti mouse IgG) BD Biosciences 51-90-9001229 
Brefeldin-A (Golgiplug) BD Biosciences 555029 
Collagen I, Coated Plate, 24 well Life TechnologiesTM A1142802 
Collagen I, Coated Plate, 96 well Life TechnologiesTM A1142803 
Cryovials Nunc V7509 
DMSO Sigma-Aldrich D2650 
FcR Blocking Reagent, human, 2ml Miltenyi Biotec 130-059-901 
Fetal Calf Serum (FCS) – Heat inactivated Life Technologies TM 10108-165 
Ficoll-Plaque  GE Healthcare 17-1440-03 
Fixation/Permeabilization Solution 125mL Becton Dickinson Uk Ltd 554722 
Human IL-2 PeproTech EC Ltd 200-02-10 
Human IL-8 PeproTech EC Ltd 200-08 
Human LAIR ELISA kit Lifespan Biosciences Ltd LS-F6502 
Ionomycin Molecular Probes (Life Tech) I24222 
Monensin (Golgistop) BD Biosciences 554724 
PBS Life TechnologiesTM 15575-020 
Penicillin/Streptomycin Life Technologies TM 15140-122 
PMA Sigma-Aldrich P8139 
Recombinant Human IL-12 Protein R & D Systems Europe Ltd 219-IL-005/CF 
Recombinant Human IL-15 Protein, CF, 5ug R & D Systems Europe Ltd 247-ILB-005/CF 
Recombinant Human IL-18 Protein R & D Systems Europe Ltd B001-5 
Recombinant Human TGF-beta, CF Cambridge Bioscience 580702 
RPMI 1640 Life Technologies TM 21875-054 
Saponin Sigma-Aldrich 47036-50G-F 
Stellate cell media ScienCell Research Laboratories 5301 
Trypan Blue Life Technologies TM 15250-061 
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2.9 Statistical analysis 
 
Statistical analysis was performed using GraphPad prism software. Normal distribution was tested 
with the Kolmogorov–Smirnov test. Non-parametric statistical tests were used since the assumption 
of normally distributed data was not met within all cohorts being compared. For all tests p values less 
than 0.05 were considered significant. Significance levels were defined as *p<0.05, **p<0.01, 
***p<0.001 and **** p<0.0001. 
 
Mann–Whitney test was used for comparison between independent data groups/unpaired sample 
groups. 
 
Wilcoxon paired tests was used for comparison between different NK cell subsets of the same patient 
and used for paired liver and PBMC samples from the same individual.  
 
Kruskal–Wallis (one-way ANOVA) with Dunn’s/Tukey’s multiple comparison groups test used to 
compare two or more unpaired sample groups. 
 
Friedman with Dunn’s multiple comparison test was used to compare repeated measures and matched 
data. i.e. multiple cytokines or conditions within the same patient.  
 
Two-way ANOVA with Tukey’s multiple comparison test was used to analyse incubation intervals 
with and without collagen.  
 








Co-inhibitory receptors and blockade of their pathways, both individually and synergistically, have 
been described extensively in the literature. However, the dominant focus of research has been on T 
cells, where these receptors have been widely studied.  
 
Some of these inhibitory receptors and the role they play are described in the introduction. These 
immune cell surface receptors act as rheostats in maintaining balance and facilitating the recognition 
of damaged and healthy cells. Inhibitory receptors are an important mechanism to prevent 
autoimmunity and an exaggerated inflammatory response. In viral infection it has been shown that 
these receptors can be upregulated on effector T cells, dampening down their overall response. 
Previous studies have shown that exhausted T cell responses are defined by the complex array of 
inhibitory receptors. There is limited evidence to suggest NK cells are also subject to 
exhaustion/inhibition but this has not been examined thoroughly in any persistent viral infection. 
 
This chapter focuses on a comprehensive investigation of the expression of co-inhibitory receptors on 
NK cells in healthy and HBV-infected subjects. 
 
3.2 NK cell frequency and subsets 
 
Before exploring the concept of NK exhaustion/inhibition through receptor expression we analysed 
peripheral NK cell frequencies and subsets, in a cohort of twenty-one healthy controls and sixty-nine 
CHB patients. PBMC were isolated and stained for CD56hiCD3neg NK cells. On analysing frequencies 
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of NK cells in the periphery, a wide variability was noted in both healthy controls and patients with 
CHB, with no significant differences between them (Figure 3.1). The percentage of circulating NK 
cells varied from 2.4% to a maximum of 25.5% amongst patients with CHB. To see if this large 
spread of frequencies was related to clinical correlates such as age or disease activity we analysed the 
data according to age, and repeated measurements of viral load and liver inflammation (ALT). The 
frequency of circulating NK cells showed no significant association with age (Figure 3.2a), ALT 
(Figure 3.2b) or viral load (Figure 3.2c).   
 
We then analysed the frequency of CD56bright and CD56dim NK cells in the same cohort of twenty-one 
controls and sixty-nine patients with CHB. NK cells were divided into subsets based on expression of 
CD56 and CD16, allowing them to be differentiated as CD56bright (CD56hiCD16neg) and CD56dim 
(CD56loCD16pos) NK cells. As shown in Figures 3.3a and 3.3b, there was no difference in the 
proportion of these subsets between controls and patients. However a small subset of patients with 
CHB (highlighted on Figure 3.3a) had a higher frequency of circulating CD56bright NK cells; further 
analysis according to ALT (Figure 3.3c) and viral load (Figure 3.3d) did not reveal any clinical factors 
driving an expansion of CD56bright NK cells. 
 
Analysis of the activation marker human leucocyte antigen- antigen D related (HLA-DR) on 
circulating NK cells revealed higher frequencies of HLA-DR-expressing NK cells in CHB patients 
(mean 6.102%) than healthy controls (mean 4.058%) (Figure 3.4a). To explore this increase further, 
we analysed the expression of NK cell HLA-DR according to viral load and ALT within the CHB 
















Figure 3.1: Comparison of proportion of circulating NK cells between HC and CHB patients.  
 
PBMC were isolated and stained from twenty-one HC and sixty-nine CHB patients. PBMC 
were stained for CD56hiCD3neg NK cells after exclusion of doublets and dead cells. Error 
bars represent the mean ± SEM. HC; 12.72 ± 1.269, CHB; 12.17± 0.753. Significance 












Figure 3.2: Analysis of CHB data to explore heterogeneity of NK cell frequency in CHB  
 
PBMC were isolated and stained from sixty-nine CHB patients. PBMC were stained for 
CD56hiCD3neg NK cells after exclusion of doublets and dead cells. The percentage of NK 
cells was correlated with clinical variables (a) age (b) ALT and (c) viral load. Spearman 




(a)      (b) 
   
 
 
(c)      (d) 
 
Figure 3.3: Comparison of percentage of peripheral (a) CD56bright and (b) CD56dim NK cells 
between HC and CHB patients, with correlations of CD56bright NK cell subset in CHB with (c) 
ALT and (d) viral load.  
 
PBMC were isolated and stained from twenty-one HC and sixty-nine CHB patients. NK cells 
were divided into subsets based on expression of CD56 and CD16, allowing them to be 
differentiated as (a) CD56bright (CD56hiCD16neg) CD3neg NK cells and (b) CD56dim 
(CD56loCD16pos) CD3neg NK cells. Error bars represent the mean ± SEM. (a) CD56bright HC; 
6.724 ± 0.542, CHB; 6.731 ± 0.568. (b) CD56dim HC; 91.2 ± 0.823, CHB; 89.54 ± 0.708. 
Significance testing was carried out using Mann Whitney test and deemed non significant.  
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The %CD56bright NK cell subset was correlated with clinical variables (c) ALT and (d) viral 
load. Spearman correlation analysis was performed between variables and deemed non 






(a)       
  
 
(b)       (c) 
  
 
Figure 3.4: Comparison of expression of activation marker HLA-DR on total NK cells 
between HC and CHB patients and the relationship of HLA-DR with clinical correlates in 
CHB patients. 
 
PBMC were isolated and stained for HLA-DR from sixteen HC and twenty-six CHB patients. 
HLA-DR expressing NK cells were gated as positive for HLA-DR staining on CD56hiCD3neg 
NK cells after exclusion of doublets and dead cells.   
(a) Comparison of expression of HLA-DR on total NK cells between HC and CHB patients. 
Error bars represent the mean ± SEM. HC; 4.058 ± 1.31, CHB; 6.102 ± 0.981. Significance 
testing was carried out using Mann Whitney test. Significance is indicated as * p<0.05.  
Correlation of expression of HLA-DR on total NK cells with clinical correlate (b) ALT and (c) 
viral load in CHB patients.  
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Expression of HLA-DR was correlated with ALT and viral load level in twenty-six CHB 
patients. Spearman correlation analysis was performed between variables and deemed non 
significant.   
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3.3 Co-inhibitory receptors on NK cells 
 
NK cells express an array of receptors but there is limited literature regarding the expression of these 
‘classical’ co-inhibitory or exhaustion receptors. Initially, we explored the repertoire of co-inhibitory 
receptors on global NK cells: PD-1, TIM-3, LAG-3 and LAIR-1 in HC versus CHB patients. The NK 
cell expression of the receptor LAIR-1 in CHB has never been investigated previously.  
 
For the surface staining of some receptors, FMO was required as a control to help identify and gate 
the positive cells for respective antibodies where spread/shift can occur due to multiple fluorochromes 
in the panel. An example of gating using FMO for LAIR-1 is illustrated in Figure 3.5a. As LAIR-1 
has not been explored in CHB previously, staining was checked on both fresh and frozen samples. 
Summary data in Figure 3.5b shows no significant difference in levels of LAIR-1 expression when the 










Figure 3.5: Optimisation of staining.  
 
(a) Representative plots of inhibitory receptors PD-1, TIM-3, LAG-3 and LAIR-1 on NK 
cells from PBMC.  
FMO used for gating. PBMC were stained for CD56hiCD3neg NK cells after exclusion of 
doublets and dead cells.  
 
(b) Descriptive statistic comparing %LAIR-1 NK cell positive (LAIR-1+NK) expression 





PBMC were isolated and stained from thirteen HC and thirty CHB patients. There was no significant 
difference in PD-1 expression on NK cells between HC and CHB patients (Figure 3.6). However, 
there was greater variability of expression amongst CHB patients with a range between 0.28% and 
maximum 7.65%. PD-1 expression also varied on CD56bright and CD56dim NK cell subsets (Figure 
3.6). To see if this variability was related to clinical correlates such as disease activity we analysed the 
data according to CHB disease phase. The expression of PD-1 on circulating NK cells in CHB 




PBMC were isolated and stained from thirteen HC and twenty-four CHB patients. There was no 
significant difference in TIM-3 expression on NK cells between HC and CHB patients (Figure 3.7). 
There was variability of expression amongst HC and CHB patients (range for HC between 0.22% and 
7.16% and in CHB between 0.3% and 13.9%). TIM-3 expression also varied within CD56bright and 
CD56dim NK cell subsets. To see if this variability was related to clinical correlates such as disease 
activity we re-analysed the data according to repeated measurements of viral load and liver 
inflammation (ALT). The expression of TIM-3 on circulating NK cells in CHB showed no significant 




PBMC were isolated and stained from thirteen HC and thirty CHB patients. There was a non-
significant trend towards an increase in LAG-3 expression on NK cells in CHB patients compared to 
HC (Figure 3.8). LAG-3 expression on HC was negligible with a mean expression of 0.53%.  
However, there was greater variability of expression amongst CHB patients with a range between 
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2.07% and maximum 20.1%. This variability was also seen in when analysing NK cells by subset. To 
see if this variability was related to clinical correlates such as disease activity we re-analysed the data 
according to repeated measurements of viral load and liver inflammation (ALT). The expression of 
LAG-3 on circulating NK cells in CHB showed no significant association with viral load or ALT 
(data not shown).   
 












Figure 3.6: Comparison of percentage PD-1 positive (PD-1+) on total NK cells and within 
CD56bright and  CD56dim NK cell subsets between HC and CHB patients.  
 
PBMC were isolated and stained from thirteen HC and thirty CHB patients. PBMC were 
stained for PD-1 expression on CD56hiCD3neg NK cells, CD56bright  and CD56dim NK cells.  
HC vs CHB patients, error bars represent the mean ± SEM, CD56hiCD3neg; 1.305±0.257 vs 
1.469±0.305, CD56bright; 0.594±0.173 vs 0.866±0.253, CD56dim; 1.318±0.261 vs 












Figure 3.7: Comparison of percentage TIM-3 positive (TIM-3+) on total NK cells and within 
CD56bright and  CD56dim NK cell subsets between HC and CHB patients.  
 
PBMC were isolated and stained from thirteen HC and twenty-four CHB patients. PBMC 
were stained for TIM-3 expression on CD56hiCD3neg NK cells, CD56bright and CD56dim NK 
cells. 
HC vs CHB patients, error bars represent the mean ± SEM, CD56hiCD3neg; 1.825±0.636 vs 
3.605±0.9, CD56bright; 5.508±2.959 vs 4.760±1.66, CD56dim; 1.548±0.573 vs 3.124±0.843. 














Figure 3.8: Comparison of percentage LAG-3 positive (LAG-3+) on total NK cells and within 
CD56bright and  CD56dim NK cell subsets between HC and CHB patients.  
 
PBMC were isolated and stained from thirteen HC and thirty CHB patients. PBMC were 
stained for LAG-3 expression on CD56hiCD3neg NK cells, CD56bright and CD56dim NK cells.  
HC vs CHB patients, error bars represent the mean ± SEM, CD56hiCD3neg; 0.53±0.057 vs 
2.858±0.967, CD56bright; 0.06±0.036 vs 0.71±0.509, CD56dim; 0.573±0.063 vs 2.913±0.948. 





Figure 3.9 illustrates that NK cells from all patients with CHB infection express LAIR-1 and the mean 
expression is higher in CHB than HC. PBMC were isolated and stained from twenty-one HC and 
sixty-nine CHB patients. Circulating NK cells revealed higher frequencies of LAIR-1-expressing NK 
cells in CHB patients (mean 40%) than healthy controls (mean 30%). Compared to the other 
inhibitory receptors investigated, the mean expression of LAIR-1 is much higher on both HC and 
CHB patients. In CHB patients there is heterogeneity and some overlap, with a range between 7.68% 
and maximum 74.9%. On further analysis in CHB, CD56bright NK cells have significantly higher mean 
expression of LAIR-1 of 36% compared to 24% in HC (Figure 3.9). CHB CD56dim NK cells also had 
significantly higher mean expression of LAIR-1 of 40% compared to 31% in HC (Figure 3.9).  
 
Given the striking finding of higher LAIR-1-expressing NK cells in CHB patients we compared 
expression of LAIR-1 on other immune cells. In a smaller cohort of patients, PBMC were isolated and 
stained from thirty-four CHB patients. Within the same donors PBMC were surface stained with mAb  
CD8 and CD4 to identify CD8+ T cells. LAIR-1 expression was gated on CD8+ T cells and NK cells 
(Figure 3.10a). CD8+ T cells were chosen due to their key role in controlling and eradicating viral 
infection. A similar high expression and variability was observed on CD8+ T cells with a range 
between 9.42% and 63.1%, however mean LAIR-1 expression of 46% was higher on NK cells than 
CD8+ T cells (mean 35%). Notably as shown in Figure 3.10b there was no difference in LAIR-1 
expression on CD8+ T cells in CHB compared to HC. 
  
Traditionally CD56bright NK cells are functionally distinct and potent cytokine producers and on 
further probing as depicted in Figure 3.11 there was a weak but significant inverse correlation 
showing that NK cells with higher LAIR-1 expression displayed impaired cytokine production. To 
conduct this experiment, baseline ex-vivo LAIR-1 expression was compared to the amount of IFNγ 
production by NK cells after whole PBMC were incubated with rhIL-12 and rhIL-18 for 21 hours. No 
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correlation was seen with cytotoxicity (data not shown) in keeping with the observation that in CHB 
NK cells have impaired cytokine production but maintain cytotoxicity (Peppa et al., 2010). 
 
Expression of inhibitory receptors has been widely explored but there is limited data regarding the co-
expression patterns of these receptors on NK cells. Blackburn et al observed that in an LCMV mouse 
model there was the presence of increased expression of inhibitory receptors 2B4 and CD160 in 
conjunction with PD-1, especially on the more terminally exhausted CD8+ T cells (Blackburn et al., 
2009). Figure 3.12 illustrates the analysis of co-expression of NK cell PD-1 and LAIR-1. PBMC was 
stained for PD-1 and LAIR-1 expression in the same cohort of 30 CHB patients. Although there was 
no significant correlation between PD-1 and LAIR-1 co-expression, there is a weak trend for NK cells 
















Figure 3.9: Comparison of percentage LAIR-1 positive (LAIR-1+) on total NK cells and 
within CD56bright and  CD56dim NK cell subsets between HC and CHB patients.  
 
PBMC were isolated and stained from twenty-one HC and sixty-nine CHB patients. PBMC 
were stained for LAIR-1 expression on CD56hiCD3neg NK cells, CD56bright and CD56dim NK 
cells.  
HC vs CHB patients, error bars represent the mean ± SEM, CD56hiCD3neg; 29.9±2.45 vs 
39.87±2.06, CD56bright; 23.8±2.41 vs 35.64±1.95, CD56dim; 31.05±2.7 vs 40.27±2.1. 







(a)     (b) 
  
 
Figure 3.10: Comparison of percentage LAIR-1+ on (a) CD8+ T cells versus total NK cells in 
CHB patients (b) CD8+ T cells in HC and CHB patients.  
 
PBMC were isolated and stained from thirty-four CHB patients and six healthy controls. (a) 
Within the same donors PBMC from CHB patients were surface stained with mAb CD8 and 
CD4 to identify CD8+ T cells (after excluding doublets, dead cells and monocytes) and NK 
cells were identified as CD56hiCD3neg NK cells (after exclusion of doublets and dead cells).  
LAIR-1 expression was gated on CD8+ T cells and NK cells. (a) CD8+ T cells vs NK cells in 
CHB, error bars represent the mean ± SEM, 34.99±2.24 vs 45.9±2.24. (b) HC vs CHB 
patients, error bars represent the mean ± SEM, CD8+ T cells; 26.37±6.2 vs 34.99±2.247. 








Figure 3.11: Investigation of the expression of LAIR-1 on NK cells and cytokine production 
in CHB.  
 
PBMC from thirty-eight CHB patients were incubated overnight with rhIL-12 and rhIL-18 for a 
total of 21 hours. Cells were thereafter fixed and permeabilised and then stained for 
intracellular expression of IFNγ. Baseline surface LAIR-1 expression was compared to the 
amount of IFNγ expression of NK cells. Significance testing was carried out using Spearman 















Figure 3.12: Correlation between PD-1 and LAIR-1 co-expression on NK cells in CHB  
 
PBMC were isolated and stained from thirty CHB patients. NK cells were identified as 
CD56hiCD3neg NK cells after exclusion of doublets and dead cells. The same cohort of PBMC 
were stained for PD-1 and LAIR-1 expression. Significance testing was carried out using 
Spearman correlation. Significance was measured at p<0.05. 
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3.4 LAIR-1 expression according to disease phase 
 
All patients with CHB express LAIR-1 with the mean being higher within this group compared to 
HC. We sought to investigate whether heterogeneity of expression was caused by different disease 
phases of CHB or clinical correlates. CHB as mentioned earlier is a dynamic disease and patients 
progress through phases, illustrated in Figure 2.2 (Liaw and Chu, 2009). These distinct disease phases 
are characterised by ALT, HBV DNA and HBeAg status.  
 
To determine if the expression of LAIR+ NK cells, with the wide frequency range noted, was related 
to disease activity we analysed the data after dividing patients into distinct clinical stages based on 
repeated measurements of expression of HBeAg, liver inflammation (ALT) and viral load. Patients 
were categorised as defined in Table 2.3, according to European Association for the Study of the 
Liver (EASL) clinical practice guidelines (EASL, 2012) 
 
**Since the writing of this thesis updated clinical practice guidelines have been published by EASL 
on the management of HBV infection (EASL, 2017). The most relevant change is the disease phases 
have been renamed. The new nomenclature takes into account the presence or absence of liver 
inflammation and defines this as hepatitis versus infection.  Table 2.3 has been amended to 
demonstrate the new changes in nomenclature and shown in Table 3.1. 
 
There was uniformity in the spectrum of LAIR-1 expression across disease phases (Figure 3.13a). 
Similarly there was no correlation of LAIR-1 with other clinical correlates such as age, ALT, HBV 
DNA or HBsAg (Figure 3.13b).  
 
We were interested in the expression pattern of LAIR-1 and other inhibitory molecules during disease 
phases. NK cells most frequently expressed significantly higher LAIR-1 in all disease phases in 
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contrast to PD-1, TIM-3 and LAG-3 (Figure 3.14). There was a trend for HBeAg- IA and IC phases 






Phase EASL 2017 - New nomenclature HBeAg ALT HBV DNA 
Immune tolerant HBeAg positive chronic infection Positive <40 IU/L HBV DNA > 8 log IU (100,000,000 IU/ml) 
HBeAg positive immune active HBeAg positive chronic hepatitis  Positive >40 IU/L Any 
HBeAg negative immune active HBeAg negative chronic hepatitis Negative Any >3.3 log IU (2,000 IU/ml) 
Inactive carrier HBeAg negative chronic infection Negative <40 IU/L <3.3 log IU (2,000 IU/ml) 
 





















r -0.1630 0.1824 0.1697 0.1963 
P (two-tailed) 0.1810 0.1337 0.1634 0.1115 
No. of XY pairs 69 69 69 67 
 
Figure 3.13: Analysis of LAIR-1 expression with clinical correlates 
 
PBMC were isolated and stained from sixty-nine CHB patients. PBMC were stained for 
LAIR-1 expression on CD56hiCD3neg NK cells. 
(a) LAIR-1 expression during the different disease phases of CHB was measured. There is 
no significant difference between disease phases (p=0.51). Error bars represent the mean ± 
SEM. Kruskal-Wallis statistical test was used.  
(b) LAIR-1 expression with clinical correlates such as age, ALT, HBV DNA and HBsAg was 
measured. Significance testing was carried out using Spearman correlation coefficient (Age: 
n=69, ALT: n=69, HBV DNA: n=69, qHBsAg n=67, qHBsAg not known for two patients). 










Figure 3.14: Comparison of percentage LAIR-1+ with other inhibitory receptors on (a) 





PBMC were isolated and stained from a total of thirty-two CHB patients: four IT, four HBeAg 
positive immune active (eAg+ IA), eight HBeAg negative immune active (eAg- IA) and 
sixteen IC. PBMC were stained at the same time for PD-1 (white bars), TIM-3 (red bars), 
LAG-3 (blue bars) and LAIR-1 (black bars) expression on CD56hiCD3neg, CD56bright and 
CD56dim NK cells. Multiple comparisons were made between the different groups with 
Kruskal-Wallis testing and deemed non significant. 
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3.5 LAIR-1 on intrahepatic NK cells 
 
Staining experiments thus far had exclusively been done on peripheral blood but unique access to 
surplus liver tissue from percutaneous liver biopsies enabled us to undertake paired analysis of tissue 
and blood. This is advantageous as it enables the investigation of tissue NK cells that have a distinct 
phenotype and function compared to those in the periphery and allows closer evaluation of the site of 
CHB infection. Paired PBMC and IHL were isolated and stained from seventeen patients with CHB. 
 
The CD56bright NK cell subset, which are efficient cytokine producers are described as more 
preferentially enriched within the liver compared to the periphery and our data was comparable with 
this as illustrated in Figure 3.15 the mean expression of CD56bright NK cells in the liver was 51.79% 
compared to 10.77% of CD56bright NK cells in the periphery. In the liver the percentage of CD56bright 
and CD56dim NK cells is equal with no significant difference between the two (Figure 3.15b).  
 
Bonorino et al observed an altered phenotype of intrahepatic NK cells and showed HBV patients had 
reduced intrahepatic NKG2A+ NK cells (Bonorino et al., 2009). Paired analysis data shown in Figure 
3.16 depicts LAIR-1 expression on total NK cells is significantly lower in the liver (mean 22.76%) 
compared to the periphery (mean 40.58%). The range in the periphery is much wider between 10.1% 
and 70% maximum compared to the intrahepatic compartment with a range of 3.12% and 49%.  
 
Paired analysis data shown in Figure 3.17 illustrates there is significantly higher expression of LAIR-
1 on CD56bright NK cells in the periphery (mean 35.8%) compared to intrahepatic compartment  (mean 
15.21%) mirroring the data seen for global NK cells. 
 
We were interested to observe whether LAIR-1 is associated with liver residency. The homing marker 
CXCR6 was used as a marker for liver residency, based on recent studies (Stegmann et al., 2016, 
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Harmon et al., 2016). A smaller subset of paired samples (n=5) was stained with this marker. Figure 














Figure 3.15: Comparison of frequency of circulating versus intrahepatic NK cell subsets. 
 
Paired PBMC and IHL were isolated from seventeen patients with CHB. CD56hiCD3neg NK 
cells were analysed after exclusion of doublets and dead cells. NK cells were divided into 
subsets based on expression of CD56 and CD16, allowing them to be differentiated as 
CD56bright and CD56dim NK cells. Paired Wilcoxon test used. Significance indicated as: **** 
p=<0.0001.  
(a) CD56bright and CD56dim NK cells in blood, mean ± SEM, 10.77±1.732 and 88.11±1.570 












Figure 3.16: Comparison of percentage LAIR-1+ on total circulating versus intrahepatic NK 
cells in CHB. 
 
Paired PBMC and IHL were isolated from seventeen patients with CHB. PBMC and IHL 
were stained for LAIR-1 on CD56hiCD3neg NK cells.  
Paired Wilcoxon test used. Significance indicated as: *** p=<0.001.  
















Figure 3.17: Comparison of percentage LAIR-1+ on circulating versus intrahepatic NK cell 
subsets in CHB. 
 
Paired PBMC and IHL were isolated and stained from seventeen patients with CHB. NK 
cells were gated for LAIR-1 positive cells on (a) CD56bright (b) CD56dim NK cells. Paired 
Wilcoxon test used. Significance indicated as: *** p=<0.001.  
(a) LAIR-1+ CD56bright NK cells; PBMC vs liver, mean ± SEM, 35.85±3.817 and 15.21±2.430.  
















Figure 3.18: Comparison of percentage LAIR-1+ IHL with liver residency marker CXCR6 in 
CHB. 
 
IHL were isolated and stained from five patients with CHB. The homing marker CXCR6 was 
used as a marker for liver residency. 
Wilcoxon paired test used. Significance indicated as: ** p=<0.01.  





Significant evidence from NK cell descriptive phenotypic/functional studies support a significant role 
for NK cells in HBV infection. There are many comprehensive analyses of NK cell frequency and 
subset distribution. In this study, the frequencies of total NK cells in the periphery and respective 
CD56bright and CD56dim NK cell subsets showed no significant difference in CHB patients compared to 
HC. Bonorino et al also observed no frequency differences in CD56hiCD3neg NK cells and 
differentiation subsets in a much smaller cohort of nineteen patients (Bonorino et al., 2009).  
 
HBV is a dynamic disease, NK activity is reported to be different in various phases of infection, and a 
number of studies have analysed the impact of HBV on NK cell frequency and phenotype with 
polarised results. Oliviero et al found the percentage of peripheral NK cells in HBV was significantly 
lower compared to HC (Oliviero et al., 2009). In children no difference was seen between the 
proportions of NK cells (Heiberg et al., 2015). A recent meta-analysis aimed to tease out these 
inconsistencies, attributed them to differing patient cohorts, and disease phases (Zhang et al., 2016). 
Zhang et al reviewed 1237 studies, of which 19 were deemed methodologically appropriate to include 
in the meta-analysis. It is a comprehensive review that summarises peripheral NK cells in CHB exist 
at a lower frequency with a more activated phenotype compared with HC, with a higher proportion of 
peripheral CD56bright NK cells.  
 
In keeping with the literature, we show HLA-DR expression was higher in CHB patients compared 
with HC. HLA-DR molecules are upregulated in response to signalling and therefore a marker for 
immune stimulation. We chose to analyse the expression of HLA-DR to assess the activation state of 
NK cells, however frequencies of other markers such as CD38 and CD69 can also be used. The 
increased expression of activation markers on NK cells in CHB patients may be more suggestive of an 
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‘inflammatory phenotype’ in these patients, however no correlation was seen with ALT, used as a 
crude marker of liver inflammation, or viral load. 
 
In chronic viral infection the upregulation of inhibitory receptors is believed to be a mechanism 
contributing to cell exhaustion and impaired function. Previously, great efforts have been undertaken 
to examine the expression of various individual inhibitory receptors on T cells. The most cited 
receptor is PD-1. In several inflammatory and chronic viral infections NK cell PD-1 expression (PD-
1+ NK cells) is higher than in HC and higher on the CD56bright NK cell subset (Alvarez et al., 2010), 
(Golden-Mason et al., 2008), (Norris et al., 2012). The levels are variable and can be near negligible 
with the lowest expression levels described in HIV positive treatment naive patients with median 
0.1%, range 0.02–1.7%, although this is higher than seronegative controls (median 0.05%, range 
0.01–0.6%) (Norris et al., 2012). In TB the percentage of PD-1+ NK cells in peripheral blood had a 
higher mean of 11%.  In our analysis, a low range of PD-1 expression was seen on NK cells, with no 
difference observed between HC and CHB patients, and no significant change within CD56 subsets.  
 
Increased TIM-3 expression on NK cells has been described in HCV (Golden-Mason et al., 2015), 
HIV (Finney et al., 2013) and HBV (Ju et al., 2010). However, we did not note any significant 
difference of TIM-3 expression on total NK cells between HC and CHB patients. The mean 
expression levels of TIM-3 in our cohort; 1.825% in HC vs 3.605% in CHB patients, were marginally 
higher than previously displayed in the published literature. Ju et al described mean TIM-3 expression 
of 0.89% in HC and 1.40% in CHB. This disparity may be due to differences in patient cohort 
composition and staining with a different clone of TIM-3. 
 
The expression of LAG_3, directly ex-vivo, has been shown by Juno et al, demonstrating that it is 
expressed at low frequency on all NK cell subsets in healthy individuals. LAG-3 levels were 
expressed at higher levels on invariant NKT cells than T cells or NK cells in HIV infection (Juno et 
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al., 2015). There is limited literature on LAG-3 expression in CHB. Similar to Juno et al our data 
showed no difference between LAG-3 expression on total NK Cells between HC and CHB patients, 
nor between CD56bright/dim NK cell subsets. 
 
Of the array of inhibitory receptors that have been shown to play an important role in T cell 
exhaustion, interestingly the least described, LAIR-1, revealed its increased frequency in CHB  
compared to healthy controls suggesting a potential role in CHB. LAIR-1 has not previously been 
studied on NK cells in CHB. Kennedy et al measured LAIR-1 on global T cells as a marker of 
exhaustion in a population of young adults with CHB (age range 10-30 years) (Kennedy et al., 2012). 
They found no difference in LAIR-1 expression between patients and healthy controls on CD4+ or 
CD8+ T cells. We found higher mean expression of LAIR-1 on NK cells compared with CD8+ T 
cells, however we did not look at HBV-specific CD8+ T cells as the LAIR-1 expression was not as 
striking on global CD8+ T cells as on NK cells. LAIR-1 expression was higher on NK cells and this 
piqued our interest in exploring the role of this receptor, further on NK cells. This had never been 
described or evaluated previously. 
 
In this study HC and CHB patients were not matched for age and we were aware this could be a 
potential confounder and might affect co-inhibitory receptor expression. The role of NK cell 
senescence and associations with a change in the repertoire of receptors, despite percentage of NK 
cells increasing with age is described in the literature (Naumova et al., 2016). We did not observe a 
similar correlation in the frequency of circulating NK cells with age, however this may be explained 
by the lack of older patients in our study cohorts; the maximum age range for HC was fifty-two years 
and in CHB patients was sixty-eight years. LAIR-1 expression did not correlate with age. Noting the 
potential confounder of age and change in the repertoire of receptors, the isolated increase of NK cell 
LAIR-1 expression (not seen with other inhibitory receptors PD-1, LAG-3 and TIM-3) in CHB 




Meyaard et al describe LAIR-1 as a broadly expressed antigen on ninety-five to one hundred percent 
of CD56hiCD3neg NK cells from healthy donors. In our population there is a broader expression of 
LAIR-1 on PBMC from HC, than suggested by Meyaard et al however higher expression in their 
study could be attributed to a gating strategy that did not exclude dead cells and a different clone of 
the LAIR-1 antibody (Meyaard et al., 1997).  
 
Despite the variability in expression, LAIR-1 is an inhibitory receptor that is highly expressed on NK 
cells in both HC and CHB patients, especially when compared to the restricted expression of other 
inhibitory receptors. Although we do not have a positive control, as seen further on in chapter 5 
LAIR-1 expression was also high on NK cells in NAFLD and HCC.  
 
Another potential confounder explored was regarding whether increased LAIR-1 expression could be 
attributed to human CMV serostatus. In a healthy person CMV will be latent but persist life-long. The 
particular relationship between CMV and CHB is not completely understood but CMV infection has 
been shown to induce the expression of NKG2C, an activatory receptor, in HC and trigger NK cell 
expansion (Guma et al., 2004). Beziat et al showed similar results in chronic hepatitis patients but 
there was heterogeneity in expression (Beziat et al., 2012). In this study data was not available on 
CMV status for HC. However, ninety-nine percent of a cross-sectional cohort of patients with CHB 
had evidence of CMV seropositivity implying it is unlikely to account for the wide variability in 
LAIR-1 expression within the CHB cohort. 
 
It is possible to speculate that perhaps such high levels of expression of LAIR-1 regulate peripheral 
NK cells when they enter tissues such as the liver on exposure to high levels of the ligand, collagen. 
Thus these expression levels may represent a mechanism of tolerance, to prevent cellular activation 




Amongst the CHB patients there was heterogeneity and some overlap of LAIR-1 expression in HC. 
To evaluate whether this heterogeneity may be explained by the phases of CHB infection, patients 
were classified by disease phase, and no clear relationship was observed. There was uniformity in the 
spectrum of LAIR-1 expression across disease phases. Similarly there was no correlation of LAIR-1 
with other clinical correlates such as age, ALT, HBV DNA or HBsAg.  
 
The literature demonstrates an association between the profile of receptors on immune cells and cell 
exhaustion. For example, Bengsch et al observed in their analysis of thirty-eight patients with chronic 
hepatitis C infection a subset of HCV-specific T cells, identified using CD127 as a marker, expressed 
a greater array of inhibitory receptors and were more functionally impaired in vivo (Bengsch et al., 
2010). Kennedy et al found PD-1 was the only inhibitory receptor with increased expression on T 
cells in young patients compared to age-matched HC, and they exhibited an exhausted profile, 
although not to the same degree of impairment as in older patients (Kennedy et al., 2012). We looked 
at whether within disease phases NK cells have a differing inhibitory profile, specifically in regards to 
LAIR-1. Although LAIR-1 expression was significantly higher than PD-1, TIM-3 and LAG-3 within 
disease phases, there was no difference of LAIR-1 expression across the disease phases.  
 
In CHB the changes in NK cell phenotype are associated with altered function. NK cells are described 
as functionally impaired in CHB (Peppa et al., 2010) and we had hypothesised there would be higher 
expression of LAIR-1, as evident in collective studies observing expression of other inhibitory 
receptors such as PD-1, TIM-3 and NKG2A. TIM-3 was found to be increased on peripheral and 
intrahepatic NK cells in forty CHB patients compared with HC and patients with NAFLD (Ju et al., 
2010).  
 
In line with studies showing higher expression of LAIR-1 on immature and naive cells (Meyaard, 
2008), we also found mean LAIR-1 expression was also higher on CD56bright NK cells. High cell 
surface expression of LAIR-1 has been reported to be associated with a phenotype of cells that are 
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less differentiated. Naïve B cells express high levels of LAIR-1 with absent expression in at least half 
of memory B cells and plasma cells (van der Vuurst de Vries et al., 1999). Similarly in T cells, LAIR-
1 expression is high on naïve cells (Jansen et al., 2007). 
 
The literature indicates that CD56bright NK cells express high levels of CD94/NKG2A but virtually no 
KIRs, raising the possibility that perhaps LAIR-1 is another potential mechanism of NK cell 
regulation. In CHB, cytokine production from CD56bright NK cells is diminished, and are therefore 
indirectly believed to contribute to persistence of infection by preventing promotion of T cell 
responses (Maini and Gehring, 2016). There was a weak but significant inverse correlation showing 
that those NK cells with higher LAIR-1 expression have impaired cytokine production. 
 
The phenotype of intrahepatic NK cells varies from circulating NK cells in CHB. The difficulty in 
analysing the intrahepatic compartment stems from the limited yield and viability of these cells. In the 
absence of infection, inflammation or disease peripheral NK cells will express a higher level of 
inhibitory receptors, as there is limited requirement for their on-going activation (Rehermann, 2015). 
A number of studies demonstrate higher expression of activatory receptors (NKp30, NKp46 and 
NKG2C) and lower inhibitory receptor expression on peripheral NK cells in CHB compared with 
HCV-infected patients and healthy controls (Rehermann, 2013). Although NK cells are activated, this 
does not correlate with inducing effector function as would be expected. Largely, intrahepatic NK 
cells are more activated, and show higher cytotoxic capacity compared to peripheral NK cells, despite 
a higher proportion of CD56bright NK cells in the liver. Interestingly, we observed much lower LAIR-1 
expression on total NK cells in the liver compared to the periphery.  
 
We were interested to observe whether LAIR-1 is associated with liver residency. Initially described 
in mice, a population of lrNK cells has recently been identified in humans (Marquardt et al., 2015). 
Stegmann et al found the homing marker CXCR6 could identify a unique subset of lrNK that use a 
different transcriptional profile that is eomesodermin (EOMES) predominant rather than T-bet. 
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Anderson et al proposed inhibitory receptors are hierarchical in order of importance, with certain 
receptors having a more dominant function (Anderson et al., 2016). In keeping with this theory we 
could speculate liver resident cells that encounter their ligand more readily have a higher threshold for 
activation and therefore comparatively have a higher expression of inhibitory receptors, and the 
presence of such high levels of LAIR-1 maintains a balanced/tolerant environment and prevents 
autoimmunity. Generally, liver NK cells are perceived to be more activated with greater cytotoxicity 
than peripheral NK cells but lrNK cells are only weakly cytotoxic, perhaps adapted for a role in the 
maintenance of liver tolerance. In order to establish whether there was a high predominance of LAIR-
1 on cells that are thought to have a role in hepatic tolerance we stained a smaller subset of paired 
samples with the CXCR6 marker and found LAIR-1 expression was also lower on liver resident cells. 
This is an interesting observation given other inhibitory receptors such as TIM-3 are enriched on the 
liver infiltrating subset. There is no previous data with regards to LAIR-1 expression in collagen-rich 
organs. In this regard, we went on to further hypothesise that hepatic NK cells downregulate LAIR-1 









Important summary findings from the first results chapter indicated: 
i. Higher expression of LAIR-1 on NK cells in CHB patients compared with HC. 
ii. Downregulation of LAIR-1 expression on NK cells in the liver compared with the periphery.  
 
We hypothesised that the lower NK cell expression of LAIR-1 in the liver may be due to hepatic NK 
cells being continuously exposed to collagens, antigens and pro-inflammatory cytokines, thereby 
downregulating LAIR-1. A series of functional experiments were designed to investigate this further.  
 
4.2 LAIR-1 expression in the presence of different cytokines 
 
The microenvironment of the liver plays a key role in maintenance of homeostasis as a metabolic and 
immunological organ. The environment is cytokine and chemokine rich (Heymann and Tacke, 2016). 
Liver resident cells produce these as do circulating immune cells. To evaluate whether the cytokine 
milieu of the liver may play a role in the lower expression of LAIR-1 on NK cells from the 
intrahepatic compartment compared with peripheral NK cells, whole PBMC were incubated 
overnight, in combination or individually with other liver-relevant cytokines of interest for 21 hours 
and then stained for surface LAIR-1. Both activatory and immunosuppressive cytokines were 
investigated.  
 
Figure 4.1a summarises findings of incubation with pro-inflammatory cytokines IL-12 and IL-18, 
cytokines used commonly to activate NK cells. There was no significant change in surface LAIR-1 
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expression with standard rhIL-12 and rhIL-18 cytokine stimulation. However, the liver has a unique 
cytokine milieu so further investigation was carried out to assess the surface expression of LAIR-1 in 
the presence of different cytokines. These were all liver relevant cytokines, including 
immunosuppressive cytokines such as TGFβ and IL-10, which are abundant in the liver. IL-10 is 
produced by Kupffer cells (the local resident macrophage population) and TGFβ by HSCs. IL-15 
similar to IL-12 and IL-18 is an activator cytokine used to prime NK cells. IL-2 levels are high in 
inflammation. IL-8 expression has been reported to be higher in CHB patients, with serum and hepatic 
IL-8 expression correlating with severe inflammation and fibrosis (Yang et al., 2014). Figure 4.1b 




























Figure 4.1: Surface expression of NK cell LAIR-1 in the presence of different cytokines 
 
Whole PBMC were incubated overnight in combination with liver relevant cytokines before 
extracellular staining for surface LAIR-1 on CD56hiCD3neg NK cells 
 
(a) Expression of NK cell LAIR-1 in the presence of rhIL-12 and rhIL-18.   
PBMC were isolated and stained from fifteen CHB patients. Paired Wilcoxon test used.  
(b) Expression of NK cell LAIR-1 in the presence of other liver-relevant cytokines.  
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PBMC were isolated and stained from three CHB patients. Analysed with Friedman test and 




4.3 LAIR-1 expression and collagen 
 
4.3.1 LAIR-1 expression and fibrosis  
 
We postulated that since the ligand of LAIR-1 is collagen, LAIR-1 might correlate with fibrosis stage 
and act as a crude biomarker. To test this, CHB patients were divided on the basis of their fibrosis 
stage (Ishak score 0 or ≥1). Patients were analysed within these cohorts, as patients with fibrosis stage 
greater than one would be considered for closer monitoring or further investigation and if LAIR-1 
correlated with fibrosis, this could be used to further guide management, i.e. where an invasive test 
such as liver biopsy should be readily used to assess the degree of fibrosis and progression of disease.  
 
The Ishak score is a histological scoring system used in chronic viral hepatitis to methodically assess 
the degree of inflammation and scarring of liver biopsies (Goodman, 2007). A score is given to 
separate components (periportal or periseptal interface hepatitis, necrosis, focal inflammation and 
portal inflammation) and the stage of fibrosis (Table 4.1). Fibrosis is graded on a scale from zero to 
six.   
 
There was no difference in LAIR-1 expression on total NK cells within the periphery or liver by these 





Ishak stage Score 
No fibrosis 0 
Fibrous expansion of some portal areas 1 
Fibrous expansion of most portal areas 2 
Fibrous expansion of most portal areas with occasional portal to portal 
bridging 
3 
Fibrous expansion of portal areas with marked bridging 4 
Marked bridging with occasional nodules 5 
Cirrhosis  6 
 










(a)           Blood   (b)                        Liver 
 
               
 
 
Figure 4.2: Comparison of LAIR-1 expression on NK cells with fibrosis stage. 
 
Paired PBMC and IHL were isolated from seventeen patients with CHB. PBMC and IHL 
were stained for LAIR-1 expression on CD56hiCD3neg NK cells. These patients were divided 
on the basis of their fibrosis stage (Ishak score 0 or ≥1) established by histopathological 
staging. Mann-Whitney statistical test has been used. 
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4.3.2 LAIR-1 expression and collagen  
 
In order to investigate the outcome of the interaction between LAIR-1 and whether collagen binding 
effected surface expression, we examined the effect of collagen-coated plates on LAIR-1. Several 
types of collagen exist that can be used, but there is convincing experimental evidence of type 1 
collagen, as one of the high affinity collagen ligands for LAIR-1 (Lebbink et al., 2006), (Brondijk et 
al., 2010). In the diseased liver the most predominant collagens are collagen I, III, IV and V (Rojkind 
et al., 1979), and they have been seen to be localised to different areas. Immunohistochemical studies 
from the 1970s isolated collagen I to the liver capsule, portal stroma, sinusoidal wall and in Disse’s 
space where there is direct contact with the plasma membrane of hepatocytes, whereas collagen IV is 
highly detected in basement membranes (Martinez-Hernandez, 1984). To analyse the effect of 
collagen on LAIR-1 we chose to use type I collagen in our experimental design.  
 
Figure 4.1 depicts the experiments that demonstrated NK cell surface expression levels of LAIR-1 did 
not change on incubation with different cytokines. Therefore to investigate whether collagen binding 
affects surface expression we performed a series of experiments to examine the effect of collagen-
coated plates on incubation with PBMC. PBMC from four CHB patients were used rather than 
healthy controls. As a consequence of earlier experiments that had shown CHB patients have higher 
mean expression of NK cell LAIR-1, an apparent downregulation would have been easier to observe. 
PBMC were also incubated for two hours versus six hours to determine whether duration of collagen 
exposure made a difference. 96-well pre-coated collagen plates were used. Figure 4.3a shows there 
was no change in NK cell surface LAIR-1 on pre-coated collagen plates. The PBMC did not show any 
difference at six-hour incubation either. 
 
Although there was no difference in the surface expression of LAIR-1 on peripheral NK cells, we 
tested whether intrahepatic NK cells might downregulate NK cell surface LAIR-1 on exposure to 
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collagen (Figure 4.3b). IHL from five CHB patients were incubated for two hours with or without 
collagen. After the two-hour incubation period they were surface stained for LAIR-1. The IHLs  were 
not exposed to collagen for longer than two hours, as attempted with PBMC. This is due to the lower 
number of IHL obtained from liver biopsy tissues, which limits the experimental conditions that can 







Figure 4.3: Investigating effect on (a) PBMC and (b) IHL NK cell LAIR-1 surface expression in 
the presence of collagen.  
 
PBMC and IHL were incubated in the absence and presence of collagen (96-well pre-coated 
collagen plates) and surface stained for LAIR-1 expression on CD56hiCD3neg NK cells.  
(a) PBMC; PBMC from four CHB patients were incubated in the presence and absence of 
collagen for 2 hours vs 6 hours to determine whether duration of collagen exposure made a 
difference. Analysed with two-way ANOVA (Tukey’s multiple comparison test) deemed not 
significant.  
(b) IHL; IHL from five CHB patients were incubated in the presence and absence of collagen 
for 2 hours. Paired Wilcoxon test used and deemed not significant.
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4.4 NK cell function in CHB 
 
Before investigating mechanism and functional role of LAIR-1 we wanted to ascertain NK cell 
activity in our study cohort of CHB patients and compare to findings elsewhere in the literature. NK 
cell function can be measured by cytokine and cytotoxicity of NK cells and subsets.  
 
NK cells are potent producers of IFNγ, which can mediate non-cytolytic antiviral effects. The 
percentage of IFNγ expression of NK cells was calculated after whole PBMC from twenty-nine CHB 
patients were incubated with rhIL-12 and rhIL-18 for 21 hours. There is variability amongst patients 
and IFNγ production from circulating NK cells varied from 3.85% to a maximum of 68.2% (Figure 
4.4). Although the CD56bright NK cell subset is the principal IFNγ producing subset (mean 64.23%), 
the CD56dim NK cell subset does also contribute to producing IFNγ (mean 14.39%).  
 
The cytotoxic potential of NK cells was measured by determining degranulation capacity evident by 
CD107a expression following stimulation of PBMC with rhIL-12, rhIL-18 and K562 target cells. As 
shown in Figure 4.5 PBMC from thirty-four CHB patients were used. Circulating NK cell CD107a 
expression varied between 12% and 70% (mean 44.64%). Differential NK cell subset analysis showed 
both the CD56bright and CD56dim NK cell subsets have cytotoxic potential. There was a significant 
difference in the proportion of CD107a expression between subsets. CD56bright NK cells had a higher 
mean expression of 49.68% versus 32.57% in the CD56dim NK cell subset. This is surprising as the 
literature shows that the CD56bright NK cell subset as the more efficient cytokine producer with less 












Figure 4.4: Comparison of percentage of IFNγ expression of peripheral NK cells and NK cell 
subsets (CD56bright and CD56dim) in CHB patients.   
 
PBMC from twenty-nine CHB patients were incubated overnight with rhIL-12 and rhIL-18 for 
a total of 21 hours. Cells were thereafter fixed and permeabilised and then stained for 
CD56hiCD3neg NK cells divided into subsets based on expression of CD56 and CD16, 
allowing them to be differentiated as CD56bright and CD56dim NK cells and intracellular 
expression of IFNγ. CD56hiCD3neg NK cells vs CD56bright vs CD56dim NK cells, mean ± SEM, 
27.6±3.568 vs 64.2±3.813 vs 14.39±2.494. Analysed with Kruskal-Wallis (one-way ANOVA) 





















Figure 4.5: Comparison of percentage of CD107a expression of peripheral NK cells and NK 
cell subsets (CD56bright and CD56dim) in CHB patients.   
 
PBMC from thirty-four CHB patients were incubated overnight with rhIL-12 and rhIL-18 for a 
total of 21 hours and in the last three hours of incubation target cells added. Cells were 
thereafter fixed and stained for CD56hiCD3neg NK cells divided into subsets based on 
expression of CD56 and CD16, allowing them to be differentiated as CD56bright 
(CD56hiCD16neg) and CD56dim (CD56loCD16pos) NK cells and expression of CD107a. 
CD56hiCD3neg NK cells vs CD56bright vs CD56dim NK cells, mean ± SEM, 44.64±2.691 vs 
49.68±3.775 vs 32.57±2.755. Analysed with Kruskal-Wallis (one-way ANOVA) test. 




4.5 Function of LAIR-1 / Function of NK cells on collagen 
 
The next sets of experiments performed were to investigate the function of LAIR-1. A number of 
studies described in detail in the main introduction demonstrate that LAIR-1 cross-linking with 
collagen can downregulate NK cell-mediated cytotoxicity (Lebbink et al., 2006), (Meyaard et al., 
1997), as well as production of IFNγ by T cells (Jansen et al., 2007). We carried out cytokine 
production and CD107a degranulation assays in the presence and absence of collagen I coated plates 
to assess whether there was a functional change in NK cells when exposed to collagen. 
 
Despite no change in surface LAIR-1 expression with a differing cytokine milieu or on incubation 
with collagen plates we further investigated whether NK cell function changed in the presence of 
collagen. Lebbink et al had previously demonstrated collagens can inhibit immune cell function by 
binding to LAIR-1 and this effect was pertinent to the LAIR-1-collagen interaction as pre treating the 
cells with blocking anti-hLAIR-1 F(ab’)2 (8A8) fragments reversed this inhibition (Lebbink et al., 
2006). In particular it was cell degranulation that was inhibited and reversed.  
 
To measure this effect NK cell degranulation was assessed by measuring CD107a as a readout on the 
surface of NK cells. Whole PBMC from six CHB patients were incubated on pre-coated collagen 
plates or uncoated plates for two hours and thereafter incubated overnight with cytokine before a 
three-hour co-incubation with target cell line K562. Preliminary experiments on PBMC from CHB 
patients, indeed demonstrated downregulation of CD107a on NK cells in CHB upon collagen pre-
coated plates (Figure 4.6). The range of inhibition was between 10.7% and maximum 22.4% (mean 
14.7%). however there was no correlation between degree of inhibition and surface expression of 




In parallel the percentage of IFNγ expression of NK cells was also evaluated. These data are from 
whole PBMC from five of the above CHB patients that had shown change in NK cell degranulation. 
Whole PBMC were incubated on pre-coated collagen plates or uncoated plates for two hours and 
thereafter incubated overnight with cytokine. Figure 4.8 demonstrates variability, with only two 
patients showing downregulation in function (6.5% in patient 2 and 7.48% in patient 3). Thus whilst 
the cytotoxicity capacity of NK cells was significantly altered by collagen stimulation, cytokine 
production did not significantly change. 
 
As previously noted, we demonstrated a weak but significant inverse correlation showing that NK 
cells with higher LAIR-1 expression have impaired cytokine production. However, in keeping with 
the lack of significant change in NK cells producing IFNγ on incubation with collagen, no correlation 
was noted between the expression of LAIR-1 on NK cells and cytokine production in the presence of 
















Figure 4.6: Investigation of NK cell CD107a expression in the presence of collagen.  
 
PBMC from six CHB patients were pre-incubated on 96 well plates (with or without collagen) 
for 2 hours prior to adding rhIL-12 and rhIL-18 and incubated overnight for a total of 21 hours 
and in the last three hours of incubation target cells added. Cells were thereafter fixed and 
stained for CD56hiCD3neg NK cells and expression of CD107a. Paired Wilcoxon test used. 








Figure 4.7: Investigation of the expression of LAIR-1 on NK cells and degree of inhibition. 
 
PBMC from six CHB patients were incubated overnight with rhIL-12 and rhIL-18 for a total of 
21 hours and in the last three hours of incubation target cells added. Cells were thereafter 
fixed and stained for CD56hiCD3neg NK cells and expression of CD107a. The degree of 
inhibition was correlated against surface expression of LAIR-1. Significance testing was 














Figure 4.8: Investigation of NK cell IFNγ expression in the presence of collagen.  
 
PBMC from five CHB patients were pre-incubated on 96 well plates (with or without 
collagen) for 2 hours prior to adding rhIL-12 and rhIL-18 and incubated overnight for a total 
of 21 hours. Cells were thereafter fixed and stained for CD56hiCD3neg NK cells and 
intracellular expression of IFNγ. Paired Wilcoxon test used. Significance was measured at 







Figure 4.9: Investigation of the expression of LAIR-1 on NK cells and cytokine production in 
the presence of collagen.  
 
Baseline surface LAIR-1 expression was compared to the % IFNγ expression of NK cells 
after whole PBMC were incubated with rhIL-12 and rhIL-18 for 21 hours in the presence of 
collagen. PBMC from thirteen CHB patients were used. Cells were thereafter fixed and 
permeabilised and then stained for intracellular expression of IFNγ. Significance testing was 





4.6 LAIR-1 and HSCs  
 
Several studies have highlighted a role for receptor-ligand interactions between NK cells and HSCs, 
demonstrating increased NK cell stimulation and reduced NK cell inhibition, with a shift in the 
balance of activating and inhibitory signals, thereby reducing liver fibrosis by increasing HSC death 
(Melhem et al., 2006). There are several strategies by which HSCs can interact with NK cells but it is 
not a straightforward mechanism involving one particular pathway. It is also not known which 
population of liver NK cells is responsible for curtailing fibrosis and whether this is a potential role of 
the more recently identified lrNK cells.  
 
Results have shown that collagen-LAIR-1 interactions can inhibit cell activation and potentially 
dampen immune cell responses (Lebbink et al., 2006). In chronic liver damage ongoing stimulation of 
activated HSCs results in excess production of ECM products, particularly type I collagen. Activated 
HSCs in this situation can persist for longer periods surrounded by type I collagen, which may prevent 
access of NK cells to their target (Fasbender et al., 2016).  
 
We had hypothesised that a possible mechanism that protects activated HSCs from clearance is via 
collagen produced by over activated HSCs inhibiting NK activity by directly binding with LAIR-1. 
To analyse whether HSCs might be capable of cross-linking LAIR-1 PBMC were co-cultured with 
media alone, cytokine alone, and cytokine with activated pHSC or pHSC supernatant. These 
experiments were done in conjunction with Dr Laura Pallett (Mala Maini group, UCL). There was no 
convincing downregulation of LAIR-1 upon co-culture with pHSC or pHSC supernatant (Figure 
4.10), but it is possible that the function of NK cells could be altered if there was ligand engagement. 








Figure 4.10: Analysis of surface NK cell LAIR-1 expression after co-culture with pHSC or 
pHSC supernatant.  
 
PBMC (n=2 CHB) were incubated overnight with media as negative control or cytokine to 
activate the NK cells. They were then co-cultured with media alone, activated pHSC or 






The function of NK cells in CHB patients was verified using assays to measure their cytokine 
production and cytotoxic potential. Here, we were able to reproduce results similar to those reported 
in the literature. In the periphery the CD56bright NK cell subset were more IFNγ producing but findings 
also showed them to be capable of degranulation, marked by CD107a. There was variability amongst 
patients and although the mean for CD107a expression was higher on CD56bright NK cells than in 
other studies this can be easily explained by differences in patient cohorts, different E:T ratios and a 
new batch of rhIL-12 and rhIL-18 cytokines that were used. 
 
Given other studies have proposed that on maturation or activation LAIR-1 expression is reduced on 
neutrophils, T cells and B cells as a mechanism for regulation at the level of the receptor, we were 
keen to investigate the effect on NK cells. Results from previous studies have been contradictory, with 
regards to change in LAIR-1 expression upon stimulation (van der Vuurst de Vries et al., 1999, 
Verbrugge et al., 2006a). Jansen et al (2007) summarised that in vitro stimulation of T cells resulted in 
decreased surface expression of LAIR-1 (human T cells stimulated with anti-CD3 (aCD3) and anti-
CD28 antibodies), whereas Maasho et al (2005) had shown TCR stimulation increases cell surface 
expression of LAIR-1 (cells stimulated with aCD3 and rhIL-12) (Jansen et al., 2007, Maasho et al., 
2005). Our results showed no significant change in surface NK cell LAIR-1 expression with standard 
rhIL-12 and rhIL-18 cytokine stimulation. We had hypothesised that perhaps as a consequence of the 
cytokine milieu in the liver being different to the periphery (liver resident cells can produce 
immunosuppressive cytokines e.g. Kupffer cells produce IL-10 and TGFβ, which can tolerise local 
NK cells) this could explain the downregulation of LAIR-1 on liver NK cells. However, there was 
also no change with other liver relevant cytokines. One of the reasons for this may be that NK cells 
are more sensitive to membrane bound cytokine e.g. cell surface transpresentation of IL-15 or perhaps 
it could be due to differing circulating cytokine profile in chronic hepatitis B patients. Bertoletti et al 
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were able to show that different cytokine profiles exist within the HBV infected liver (Bertoletti et al., 
1997).  
 
Although there was no change in LAIR-1 expression with cytokine stimulation we wanted to further 
dissect why there was evidence of downregulation of LAIR-1 in the liver compared to the periphery 
and postulated this may be due to encountering of the ligand collagen which is more abundant in the 
liver. However, we discovered there was no change in surface LAIR-1 expression on incubation with 
pre-coated collagen plates. The duration of exposure of PBMC to collagen also did not show any 
difference. 
 
We wondered whether LAIR-1 might have useful clinical significance, as a potential non-invasive test 
that could represent a crude biomarker indicating severity of fibrosis, in the knowledge the ligand is 
collagen. However, there was no difference within fibrosis groups or NK cell LAIR-1 expression in 
the periphery or liver. Limitations include the lack of normal controls and small patient numbers, 
however another major limitation of this analysis is that most patients who underwent biopsy in this 
study displayed only minimal to moderate levels of fibrosis and thus it is difficult to ascertain such a 
correlation without a more broad range of patients, to obtain a normal distribution. The potential use 
of collagen proportionate area (CPA) for fibrosis assessment in the patients detailed in Table 2.2 
could be explored further. CPA is a well-validated method of fibrosis quantification, and offers 
increased accuracy in calculating the parenchymal fibrous tissue collagen (Tsochatzis et al., 2014). 
Additional work looking at non-invasive serum biomarkers of fibrosis such as hyaluronic acid, pro-
collagen III N-peptide or aspartate platelet ratio index (APRI), and transient elastography of the 
patient cohorts in Table 2.1 and 2.2 would be another strategy to determine whether LAIR-1 can be 




Peppa et al were the first in this field to describe the functional impairment and reversal of exhaustion 
of NK cells in CHB. They showed the CD56bright/dim NK cell subsets have marked impaired capacity to 
produce IFNγ in CHB and immunosuppressive cytokines selectively suppress NK cell IFNγ 
production, whilst cytotoxicity is maintained (Peppa et al., 2010). Blocking of inhibitory receptors 
such as TIM-3 on NK cells has shown enhancement of cytotoxicity (Ju et al., 2010). When we 
explored whether NK cell function changed in the presence of collagen, preliminary experiments on 
PBMC from CHB patients showed downregulation of CD107a on NK cells in CHB upon collagen 
pre-coated plates. In these experimental designs collagen was coated on plastic plates and cells were 
incubated together with an activating stimulus. Other authors investigating the function of LAIR-1 
had previously used this method. Of course it is contentious as to whether this represents how 
immune cells interact with collagen in vivo and the response of immune cells in the presence of ECM 
collagens or transmembrane collagens would need to be studied in much greater detail to address this. 
In this experimental design there was overall downregulation of NK cell degranulation in six patients 
(PBMC). Future studies are underway utilising liver scaffolds containing ECM in a more 
physiological three-dimensional (3D) structure to investigate its impact on LAIR-expressing NK cells 
(see future directions chapter 7).  
 
These data are promising as they are consistent with previous studies by Lebbink et al demonstrating 
collagens can inhibit immune cell function by binding to LAIR-1 (Lebbink et al., 2006). Further work 
would be to look at other aspects of cytotoxicity. NK cell cytotoxicity is a stepwise combined process 
including adhesion, activation and secretion of lytic granules, thus CD107a as a readout, is not the 
only correlate of cytotoxicity. We would also want to look specifically at whether LAIR-1 positive 
NK cells tend to degranulate less. We would repeat these experiments using intrahepatic lymphocytes. 
These experiments used whole PBMC rather than sorted fractions of NK cells as this provides a more 
physiological environment. Moving forward, experiments would involve observing whether pre-







Results – Chapter 5: Expression of LAIR-1 in patients with liver 




5.1.1 HBV and HCC 
 
HCC is an aggressive disease with rising incidence and mortality. An estimated 600,000 deaths per 
year are attributed to cirrhosis and HCC complicating HBV (Liaw and Chu, 2009), (Stanaway et al., 
2016).  There are a number of liver diseases that can predispose to HCC, however the majority require 
architectural change in the form of advanced fibrosis or cirrhosis to have already occurred. Chronic 
viral infection is an important risk factor for HCC development, with HBV accounting for 50% of 
cases (Bosetti et al., 2008), (Parkin, 2006). The new developments in oral antivirals for HCV may 
reduce incidence of HCC from HCV, however in areas such as Asia and Africa where HBV is highly 
endemic, it is the primary cause of HCC. Some recent studies have demonstrated that the newer more 
potent NUCs for HBV may prevent the development of HCC but this needs to be substantiated in 
large robust clinical trials (Hosaka et al., 2013), (Lai and Yuen, 2013). Hepatitis B is unique in that it 
is pro-oncogenic and patients can develop HCC despite not having cirrhosis. 
 
A meta-analysis of studies in China showed the risk for HCC in HBV is 15 to 20 times more than the 
general population (Shi et al., 2005). Other risk factors for HCC are genetic and environmental. In 
HBV, factors that increase risk include demographics (male gender, older age, family history of 
HCC), viral (co-infection, genotypes C&D, longer duration of infection) and lifestyle factors 
(exposure to Aflatoxin, alcohol excess, smoking) (Chen et al., 2006). HBV integration was shown to 
drive oncogenic change in a large study of patients with HCC (Zhao et al., 2016). Approximately one 
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third of patients who acquire HBV perinatally or in early childhood are at risk of death due to HBV 
related liver cirrhosis or HCC (Beasley et al., 1981).  
 
5.1.2 Treatment and screening for HCC in HBV 
 
Current treatments for HCC are medical, a combination of locoregional therapies; radiofrequency 
ablation and transarterial chemoembolization; in addition to systemic targeted chemotherapy like 
Sorafenib and surgical approaches.  The median survival following diagnosis is between 6 and 20 
months. Although surgical resection can result in 5-year survival rates of better than 70%, patients 
with cirrhosis are at high risk of decompensation and therefore this option is restricted to a small 
number of patients. Surgical resection and liver transplantation are the only curative options. 
European and international guidelines agree screening should occur in high risk patients with CHB 
defined as Asian/African origin, age >40 years and male, age >50 years and female (EASL, 2012), 
(Sarri et al., 2013), (Terrault et al., 2016). Screening is carried out using a combination of using serum 
alpha fetoprotein (AFP) tumour marker and interval radiology imaging, using ultrasound as the first-
line, but often other modalities such as computed tomography (CT) or magnetic resonance imaging 
(MRI) are employed. AFP is used but suboptimal in isolation, as it has a sensitivity of only 60% 
(Singal et al., 2009). Specificity of diagnosing HCC increases with AFP greater than 400ng/ml (cut-
off is 20ng/ml) (Taketa et al., 1993).  Currently we do not have an accurate biomarker that can be 
used alone to identify patients who have HCC (Forner and Bruix, 2012).  
 
5.1.3 Immunology of HCC 
 
HCC development is believed to be a multistep complex process involving altered growth and 
survival signalling pathways, activation of inflammatory pathways, formation of free radicals and 
mutations within the tumour microenvironment and the tumour cells (Forner et al., 2012). The main 
mutations are in tumour suppressor gene TP53 and the gene for beta-catenin CTNNB1. Key 
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oncogenes are altered. HCC is a highly vascular tumour and angiogenesis pathways are altered. 
Studies in a mouse model of HBV-related HCC have shown a role for platelet-mediated hepatic T cell 
accumulation in driving pro-inflammatory carcinogenesis (Sitia et al., 2012). Microarray gene studies 
are being used to help provide prognostic information and guide therapeutic intervention.  
 
There is heterogeneity within the stromal tumour microenvironment but it overall consists of immune 
cells and several cell types including HSCs, macrophages and endothelial cells (Heindryckx and 
Gerwins, 2015). Tumour and stromal cells exploit the host immune response creating an environment 
rich in immunosuppressive molecules dampening effector cell function. Cancer cells can evade 
recognition by CTLs by downregulating or loss of MHC class I, although this can be a double edged 
sword resulting in killing by NK cells, which play a key role in cancer immune surveillance. 
However, tumour production of ligands such as soluble MHC class I polypeptide-related sequence A 
(MIC-A) and unique long 16 binding protein (ULBPs) can result in downregulation of NKG2D and 
impaired NK cell function (Prieto et al., 2015). Inhibitory pathways are altered. There have been a 
number of studies looking at the PD-1-PD-L1 pathway as described earlier with interest in anti-PD-1 
and anti-CTLA-4 mAbs. Tumours upregulate PD-L1 and high expression of the ligand in HCC has 
been associated with tumour aggressiveness and post resection recurrence (Gao et al., 2009).    
 
It has been speculated that the LAIR-1 collagen interaction can be orchestrated to the advantage of 
tumour cells via a mechanism by which they upregulate collagen expression in a number of ways, 
increasing the availability of ligand to bind to LAIR-1, resulting in negative regulation of effector 
cells and thereby dampening anti-tumour responses (Meyaard, 2008). A study by Mailloux et al 
showed that the collagen matrix protects tumour cells from death. They observe the HepG2 HCC cell 
line, which does not produce any collagen in the absence of activated HSCs, is susceptible to killing 
by NK cells. Their results suggest collagen derived from HSCs may contribute to the dysfunction of 
NK cells in HCC and LAIR-1 plays a key role in this process. They found bioartificial collagen 
matrix significantly inhibited human NK cell proliferation, however, NK cells isolated from LAIR-1 
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germline knock-out mice were not inhibited by collagen (Mailloux and Epling-Burnette, 2013). The 
abstract is however a stand alone meeting abstract and due to this it is difficult to tease out 
methodology and other studies are needed to confirm the role of LAIR-1 as a potential mediator of 
immune suppression by the local collagen environment in HCC and fibrosis. These are however very 
interesting and striking observations.  
 
Thus far we have seen LAIR-1 expression on total NK cells in patients with CHB is significantly 
lower in the liver compared to the periphery. We did not have access to ‘healthy’ liver tissue for 
comparison, and thus to investigate whether the effects of LAIR-1 downregulation in the intrahepatic 
compartment in CHB were unique to viral infection, we utilised samples (blood and liver) from 
patients without evidence of chronic viral infection. For this purpose, we utilised paired blood and 
liver samples from patients with NAFLD. In addition to this we also utilised samples from the 
periphery of HCC patients to determine the expression of LAIR-1 in advanced liver disease (some of 
these patients were infected with HBV or HCV). There is a clear unmet need for a predictive 
biomarker within this field. The predictive value of negative PD-L1 staining is not precise enough to 
be able to exclude patients from treatment with checkpoint inhibitors (Postow et al., 2015). We 






5.2 NK cell LAIR-1 expression in NAFLD patients 
 
Thus far we have seen in LAIR-1 expression on total NK cells in CHB patients is 
significantly lower in the liver compared to the periphery. We further analysed paired blood 
and liver samples from patients with fatty liver disease. These samples were stained for 
LAIR-1 and analysed. The full characteristics are shown in Table 5.1. PBMC and IHL were 
analysed from seven paired samples. Summary of patient data is shown in Table 5.1.1 
 
 
Sex Age (years) mean ALT 
(IU/L) 
F 52 111 
F 35 37 
M 54 59 
F 19 246 
M 25 105 
M 40 140 
F 79 63 
 
Table 5.1: Full details of the study participants with NAFLD  
 

















Table 5.1.1: Summary of NAFLD cohort paired data 
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LAIR-1 was increased on circulating NK cells in NAFLD (mean 57%) compared to healthy controls 
(29.9%) (Figure 5.1). The higher frequencies of LAIR-1-expressing NK cells in NAFLD were also 
significantly higher than CHB patients (mean 39.5%). In NAFLD LAIR-1 expression on both 
CD56bright and CD56dim NK cell subsets displayed mean values of 45.16% and 58.01% respectively. 
LAIR-1+ CD56bright NK cells were significantly higher in NAFLD (mean 45.16%) patients compared 
with those with CHB (mean 35.6%) and HC (mean 23.8%). The highest mean expression of LAIR-1 
was observed on CD56dim NK cells in NAFLD.   
 
Paired analysis of blood and liver shown in Figure 5.2 depicts LAIR-1 expression on total NK cells in 
patients with NAFLD, which is significantly lower in the liver (mean 34.63%) compared to the 
periphery (mean 57.04%). The range in the periphery is between 45.1% to 75.6%, compared to the 
intrahepatic compartment with a range of 16.2% and 46.8%. Interestingly, although not significant 
there is a trend for higher LAIR-1 expression on intrahepatic NK cells in NAFLD (mean 34.63%) 
than in CHB (mean 22.76%) (Figure 5.3).   
 
In CHB patients, LAIR-1 expression was also lower on lrNK cells (Figure 3.18 - mean 18.74%). 
Samples from patients with NAFLD were also analysed using CXCR6, and similar to that seen in 
CHB, there was a significant downregulation of LAIR-1 on lrNK cells (Figure 5.4). Mean expression 







Figure 5.1: Comparison of percentage LAIR-1+ on total peripheral NK cells and within  
CD56bright and  CD56dim NK cell subsets between HC, CHB and NAFLD patients.  
 
PBMC were isolated and stained from twenty-one HC, sixty-nine patients with CHB and 
seven patients with NAFLD. PBMC were stained for LAIR-1 expression on CD56hiCD3neg NK 
cells, CD56bright and CD56dim NK cells. HC vs CHB vs NAFLD, patients mean ± SEM, 
CD56hiCD3neg; 29.9±2.45 vs 39.87±2.06 vs 57.04±4.23, CD56bright; 23.8±2.41 vs 35.6±1.95 
vs 45.16±3.11, CD56dim; 31.05±2.7 vs 40.27±2.1 vs 58.01±4.46. Error bars represent the 
mean ± SEM. Analysed with Kruskal-Wallis (one-way ANOVA) test. Significance is indicated 






Figure 5.2: Comparison of percentage LAIR-1+ on total circulating versus intrahepatic NK 
cells in NAFLD patients. 
Paired PBMC and IHL were isolated and stained from seven patients with liver disease from 
NAFLD. PBMC and IHL were stained for LAIR-1 expression on CD56hiCD3neg NK cells. 
Paired Wilcoxon test used. Significance indicated as * p=<0.05. LAIR-1+ NK PBMC vs IHL, 




Figure 5.3: Comparison of percentage LAIR-1+ on intrahepatic NK cells in NAFLD versus 
CHB patients. 
IHL were isolated and stained for LAIR-1 expression on CD56hiCD3neg NK cells from seven 
patients with liver disease from NAFLD and compared to the cohort of IHL that were isolated 
and stained from seventeen patients with CHB. Significance testing was carried out using 
Mann Whitney test.  Significance indicated as * p=<0.05. LAIR-1+ NK CHB vs NAFLD, mean 












Figure 5.4: Comparison of percentage LAIR-1+ intrahepatic NK cells with liver residency 
marker CXCR6, in NAFLD patients. 
 
IHL were isolated and stained from seven patients with NAFLD. Paired Wilcoxon test used. 






5.3 NK cell LAIR-1 expression in HCC 
 
PBMC from eight treatment naive HCC patients were used. The aetiology of HCC differed between 
patients and is shown in Table 5.2. Patients were HCC treatment naive, as treatment could have been 














Table 5.2: Details of the study participants with HCC  
 








Table 5.2.1: Summary of study participants with HCC  
Aetiology HBeAg ALT Segment & Size AFP Background Viral suppression 
HBV neg 109 segment 6, 90mm 3 cirrhotic  on entecavir  
HBV neg 10 segment 4b, 20mm 22.8 cirrhotic  on entecavir  
HBV neg 23 segment 8, 34mm  1.5 not cirrhotic (Ishak 2/6 ) not on treatment 
HBV neg 83 segment 8, 25mm  201 not cirrhotic  on tenofovir 
HCV n/a 35 segment 6, 16mm  3.5 cirrhotic  not on treatment 
HCV n/a 77 segment 4a, 30mm  16.6 cirrhotic  no viral load 
HCV n/a 33 segment 5, 33mm  7 cirrhotic  not on treatment 
ALD n/a 24 multifocal HCC not done cirrhotic  n/a 














We compared peripheral NK cell frequencies in eight patients with HCC against the previous cohorts 
shown for CHB, NAFLD and HC. PBMC were isolated and stained for CD56hiCD3neg NK cells. The 
percentage of circulating NK cells in HCC varied from 4.9% to a maximum of 37.8%, with a mean 
expression of 21.4%, which was not found to be significantly higher than HC, CHB and patients with 
NAFLD (Figure 5.5a).  
 
Earlier analysis using the activation marker HLA-DR on circulating NK cells revealed higher 
frequencies of HLA-DR-expressing NK cells in CHB patients (mean 6%) than healthy controls (mean 
4%) (Figure 3.4a). Although we noted variability in the expression of HLA-DR+ NK cells amongst 
HCC patients with a range between 1.6% and 21.8% maximum, the mean expression of ~8% was not 
significantly different from CHB patients (mean 6.8%) (Figure 5.6).  
 
PBMC from eight patients with HCC were isolated and stained for LAIR-1 on NK cells. Figure 5.7 
demonstrates all patients with HCC express LAIR-1 and circulating NK cells display higher 
frequencies of LAIR-1-expressing NK cells in HCC (mean 59.2%) than CHB patients (mean 39.5%) 
and healthy controls (mean 29.9%). In HCC both CD56bright and CD56dim NK cell subsets had high 
mean expression of 51.93% and 64.45% respectively. CD56bright NK cells had significant differences 
in LAIR-1 expression between HC (mean 23.8%), CHB (mean 35.6%) and HCC (mean 51.93%) 
patients. The highest mean expression of LAIR-1 was observed on CD56dim NK cells in HCC. LAIR-
1 expression on NK cells in HCC patients was marginally higher than those seen on circulating NK 
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Figure 5.5: Comparison of proportion of (a) total circulating NK cells and subsets (b) 
CD56bright and (c) CD56dim NK cells between HC, CHB, HCC and NAFLD patients.  
 
PBMC were isolated and stained from twenty-one HC, sixty-nine CHB patients, eight HCC 
patients and seven NAFLD patients. PBMC were stained for (a) CD56hiCD3neg NK cells after 
exclusion of doublets and dead cells. NK cells were further divided in to subsets based on 
expression of CD56 and CD16, allowing them to be differentiated as (b) CD56bright and (c) 
CD56dim NK cells. Error bars represent the mean ± SEM. (a) HC; 12.72±1.269, CHB; 
12.17±0.753, HCC; 21.4±4.33, NAFLD; 9.79±1.304. (b) HC; 6.32±0.764, CHB; 6.72±0.543, 
HCC; 3.92±1.238, NAFLD; 9.24±2.63. (c) HC; 91.2±0.823, CHB; 89.54±0.708, HCC; 
95.45±1.336, NAFLD; 87.29±2.684. Analysed with Kruskal-Wallis (one-way ANOVA) test. 










Figure 5.6: Comparison of expression of activation marker HLA-DR on total NK cells 
between CHB and HCC patients. 
 
PBMC were isolated from thirty-two CHB patients and eight HCC patients. PBMC were 
stained for HLA-DR. HLA-DR expressing NK cells were gated as positive for HLA-DR 
staining on CD56hiCD3neg NK cells after exclusion of doublets and dead cells. Error bars 
represent the mean ± SEM. CHB; 6.809±1.124, HCC 8.155±2.477. Significance testing was 









Figure 5.7: Comparison of percentage LAIR-1+ on total peripheral NK cells and within  
CD56bright and  CD56dim NK cell subsets between HC, CHB and HCC patients.  
 
PBMC were isolated from twenty-one HC, sixty-nine patients with CHB and eight patients 
with HCC. PBMC were stained for LAIR-1 expression on CD56hiCD3neg NK cells, CD56bright 
and CD56dim NK cells. HC vs CHB vs HCC, patients mean ± SEM, CD56hiCD3neg; 29.9±2.45 
vs 39.87±2.06 vs 59.21±3.59, CD56bright; 23.8±2.41 vs 35.6±1.95 vs 51.93±3.62, CD56dim; 
31.05±2.7 vs 40.27±2.1 vs 64.45±4.34. Error bars represent the mean ± SEM. Analysed with 
Kruskal-Wallis (one-way ANOVA) test. Significance is indicated as * p<0.05, ** p<0.01, 





Thus far we have seen LAIR-1 expression on total NK cells in CHB patients is significantly lower in 
the liver compared to the periphery. We further investigated the expression of LAIR-1 on PBMC and 
IHL in patients with NAFLD was studied. LAIR-1 was increased on circulating NK cells in NAFLD 
compared to HC and significantly higher than expression in CHB. Similar to CHB, in NAFLD there 
was downregulation of LAIR-1 on liver resident (CXCR6+) NK cells, indicating downregulation of 
LAIR-1 in the liver may be organ specific rather than disease specific. 
 
To explore the expression of NK cell LAIR-1 further, we also analysed PBMC from patients with 
HCC. There are a number of key associations that link NK cells and progression of HCC. Firstly, NK 
cells are the dominant immune cell accounting for 25-50% of IHL suggesting they have a role in liver 
immunity (Gao et al., 2008). Secondly, the frequency of NK cells in the circulation and tissue of HCC 
patients is positively correlated with survival and prognosis (Chew et al., 2012). Thirdly, adoptive 
transfer of genetically modified ‘enhanced’ NK cells has shown promise in preventing recurrence and 
regression of HCC (Sun et al., 2015b). However, the mechanisms linking NK cells and HCC remain 
unclear.  
 
Here, we showed total NK cell frequency is higher in HCC patients but does not reach significance, 
likely due to the wide spread of percentage frequency within this group. The heterogeneity within the 
group could possibly be explained by unknown variables, such as different stages of disease 
progression in HCC. Cai et al observed varying frequencies of circulating NK cells with lower 
frequencies in patients with more advanced HCC disease (Cai et al., 2008). Interestingly Cai et al also 
observed, on analysing 110 HCC patients at different disease stages, a reduction in peripheral 
CD56dim NK cells. In our cohort of patients this subset is increased compared to CHB and NAFLD 




There is strong evidence that in addition to the abnormal frequency of NK cells in HCC they are also 
functionally impaired. The activation of NK cells is governed by the balance of activatory and 
inhibitory receptors. Increased levels of the latter skewing the balance can limit tumour immune 
surveillance by NK cells in HCC patients. Previous studies have shown upon maturation or activation, 
LAIR-1 expression on immune cells reduces (Olde Nordkamp et al., 2011). Compared to HC, in CHB 
and HCC patients there was significantly higher LAIR-1 expression on CD56dim NK cells, could 
potentially be a mechanism by which they are constrained. However, it is important to note that there 
was significant heterogeneity of the clinical features of the HCC population of patients and therefore 
limitations on HCC-specific interpretations of LAIR-1 on NK cells as a result.  
 
It is believed downregulation of the receptor is a mechanism of autoregulation. However, if NK cells 
are poorly functioning in CHB and HCC perhaps this mechanism is impaired. Olde Nordkamp et al. 
were able to show the levels of soluble LAIR-1 were increased in patients with chronic inflammation.  
We demonstrate high levels of LAIR-1 on total NK cells and their respective NK cell subsets in HCC. 
In HCC, the inflammatory microenvironment can stimulate and exacerbate injury. Most HCC occur in 
the context of chronic inflammation and liver injury, which has led to cirrhosis. In HBV the virus is 
non-cytopathic and the oncogenic role is understood to be a change of direct and indirect effects of the 
virus as HCC can occur without underlying cirrhosis (Hanahan and Weinberg, 2011). Unfortunately 
the cohort of HCC patients was not large enough to determine if LAIR-1 expression is different in 
those of HBV aetiology and without cirrhosis, however, the two patients with HBV without cirrhosis 
expressed the lowest LAIR-1 expression in the cohort of 8 patients.  
 
LAIR-1 is preferentially expressed on CD56dim NK cells at higher levels in HCC.  This is contrary to 
literature that suggests LAIR-1 is higher on CD56bright NK cells and other such immature immune 
cells. However, LAIR-1 has only been shown to have a role in inhibiting cytotoxicity, and CD56dim 
NK cells are traditionally viewed as those with more cytotoxic potential. Several studies in animals 
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and humans have demonstrated abnormal NK cytolytic function and NK cell exhaustion in advanced 
stages of HCC. There is a large body of evidence that NK cells from PBMCs in HCC patients are 
defective in cytotoxic potential and cytokine production compared to healthy donors (Hoechst et al., 
2009). Hoechst et al provided an interesting insight in to the role of MDSCs inhibiting NK cells, 
which was mediated via the receptor NKp30 requiring direct cell-to-cell contact. Paradoxically 
NKp30 is an activating receptor, and co-culture resulted in inhibition of NK cell function. In further 
work it would be interesting to probe whether LAIR-1 and NKp30 are co-expressed on NK cells and 
if LAIR-1 contributes to diminishing the response against clearance of tumour cells.  
 
The cohort of patients with HCC stained with LAIR-1 is small and would need to be expanded; so far 
preliminary results indicate that LAIR-1 is higher in HCC, suggesting a potential role in pathogenesis. 
HSCs are important in the stromal tumour microenvironment and impairment of NK cell function in 
fibrosis and HCC could be due to collagen deposition by HSCs and NK cell LAIR-1-collagen 
interaction. Tumour cells themselves are also known to upregulate collagen and may use the 
interaction to dampen anti-tumour responses. It would be interesting to look at tumour progression in 
these HCC patients and survival, and to investigate the correlation with LAIR-1. Evaluation of the 
intrahepatic compartment and HCC tissue would be interesting to see whether there is any correlation 
or mirroring of data from the periphery.  
 
Along with the increase of LAIR-1+ NK cells in HCC subjects, we also noted an increase in this cell 
population in patients with NAFLD. We did not have the opportunity to sample NAFLD cirrhotic 
patients with HCC, which would be of interest. However, the markedly elevated frequency of LAIR-1 
expression on NK cells in NAFLD compared to patients with CHB and healthy controls is intriguing.  
 
The reason for this expression is not entirely clear and there may be multiple factors contributing to 
increased LAIR-1 in NAFLD, in relation to the pathogenesis of the disease. Of note, none of the 
patients analysed had any evidence of fibrosis on liver biopsy and only steatohepatitis. Thus, the 
 193 
  
overall degree of collagen may be low and not present to bind to its receptor, resulting in higher 
circulating levels of LAIR-1. It would be interesting to determine the expression of other NK cell 
receptors, especially activating C-type lectins or natural cytotoxicity receptors (NCRs) in relation to 
LAIR-1. A recent study showed that the increased expression of the NCR, NKp46 was associated 
with the attenuation of liver fibrosis in metabolic liver disease by regulating macrophage activation in 
mice (Tosello-Trampont et al., 2016). The co-expression of NKp46 with LAIR-1 would be worth 
pursuing further. It is possible that NK cell NKp46 may be low in these patients, and negatively 
correlate with LAIR-1 which may be a poor prognostic disease feature. In this regard it would 
therefore be interesting to analyse the expression of LAIR-1 in patients with NAFLD cirrhosis.  
 
In line with this it would also be interesting to analyse serum levels of pro-collagen type III N-
terminal peptide (P3NP) as this has been shown to be elevated in certain populations of patients with 
NAFLD (Hamza et al., 2016) and observe if there is a correlation with LAIR-1 that could further aid 
in disease management. As NAFLD is an inflammatory liver disease, it is possible that the 
cytokine/chemokine milieu in the circulating environment is markedly different to that seen in CHB, 
which is not reported, and this may be another reason for the variation in LAIR-1 expression in these 
liver diseases. The metabolic/hypoxic environment in non alcoholic steatohepatitis (NASH) may also 
be a contributory factor and thus the further investigation of metabolic components (fatty acid 
markers, glucose metabolic etc.) along with hypoxia would be an interesting avenue of study in 











Unlike other inhibitory receptors that belong to a family of several receptors, there are only two 
members of the LAIR family; LAIR-1 and LAIR-2.  As mentioned earlier in the introduction LAIR-2 
consists of only an extracellular ectodomain and therefore has no role in signal transduction, but 
exhibits high affinity for collagen molecules (Lebbink et al., 2008). LAIR-2 is a soluble protein, 
cleared from the body by the kidneys. Study findings by Meyaard et al demonstrated CD4+ T cells 
were the main producers of LAIR-2 (Olde Nordkamp et al., 2011) and it has been suggested that 
LAIR-2 has a regulatory role by preventing LAIR-1 binding to collagen, and that it may be a urine 
biomarker in rheumatoid arthritis patients with a greater degree of inflammation (Olde Nordkamp et 
al., 2011).   
 
Another inhibitory receptor that also has a natural soluble form is LAG-3, which has high affinity 
binding to the same ligand as membrane bound LAG-3. Triebel et al showed subgroups of patients 
with breast cancer who had detectable levels of sLAG-3 at time of diagnosis had better disease-free 
and overall survival rates (Triebel et al., 2006). Further studies in mice and phase 1 clinical trials have 
explored the potential of sLAG3-immunoglobulin as an immune adjuvant, indirectly enhancing anti 
tumour T cell function in combination with vaccination (Anderson et al., 2016). 
 
There is no known role for sLAIR-2 in directly inhibiting immune cells but it is possible that sLAIR-2 
can affect the interaction of LAIR-1 with collagen and indirectly affect NK cell function. However, 
initially we explored whether LAIR-2 is differentially expressed in CHB patients compared with 
healthy controls, as seen with LAIR-1.  
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6.2 Serum and Urine LAIR-2  
 
In order to determine whether LAIR-2 has a possible role in the pathogenesis of CHB or use as a 
biomarker, we investigated the presence of LAIR-2 in a smaller number of HC and CHB patients 
(Table 6.1). ELISA can measure LAIR-2 concentrations in both serum and urine. LAIR-2 was 
detected in the serum and urine of all healthy controls (n=5). LAIR-2 was also detectable in serum 
(n=23) and urine (n=15) from CHB patients. Although there was no significant difference between 
LAIR-2 concentration in serum (Figure 6.1) or urine (Figure 6.2) of HC and CHB patients, the 
circulating levels of LAIR-2 in CHB patients were higher than the urine (serum mean concentration 
of 2.091 pg/ml vs urine mean concentration of 1.567 pg/ml, p=0.0049).  
 
To investigate whether LAIR-2 is related to inflammation in CHB patients, we sought to investigate 
whether heterogeneity of expression segregated with different disease phases of CHB. Serum from 
thirteen IA and ten IC patients was analysed for LAIR-2. These two phases were chosen as they have 
opposing level of circulating virus and ALT. No significant difference was seen between these phases 
(Figure 6.3a). A trend towards lower serum LAIR-2 concentration was found in IA HBeAg negative 
CHB when compared to IA HBeAg positive patients, however, this difference was not significant 
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Figure 6.1: Comparison of serum LAIR-2 concentration between HC and CHB patients. 
 
ELISA was performed on sera from five HC and twenty-three CHB patients. Error bars 
represent the mean ± SEM. HC; 2.116 ± 0.1466, CHB; 2.091± 0.056. Significance testing 














Figure 6.2: Comparison of urine LAIR-2 concentration between HC and CHB patients. 
 
ELISA was performed on urine from five HC and fifteen CHB patients. Error bars represent 
the mean ± SEM. HC; 1.734 ± 0.292, CHB; 1.567± 0.184. Significance testing was carried 












Figure 6.3: Comparison of serum LAIR-2 concentration between disease phases in CHB 
patients. 
 
ELISA to quantify LAIR-2 were performed on serum from patients in different disease 
phases of CHB. Error bars represent the mean ± SEM. Significance testing was carried out 
using Mann Whitney test. 
(a) Comparison of serum LAIR-2 concentration between IA and IC disease phase. ELISAs 
were performed on serum from thirteen IA and ten IC patients. IA; 2.046 ± 0.06, IC; 
2.149± 0.104.  
(b) Comparison of serum LAIR-2 concentration between HBeAg positive and negative IA 
disease phase. ELISAs were performed on serum from six HBeAg IA positive and 











Figure 6.4: Comparison of urine LAIR-2 concentration between disease phases in CHB 
patients. 
 
ELISA to quantify LAIR-2 were performed on urine from patients in different disease phases 
of CHB. Error bars represent the mean ± SEM. Significance testing was carried out using 
Mann Whitney test. ELISAs were performed on urine from ten IA and five IC patients. Error 
bars represent the mean ± SEM. IA; 1.639 ± 0.261, IC; 1.424± 0.207. Significance testing 





There is limited data on soluble LAIR-1 and LAIR-2 production in vivo. However, some studies do 
suggest that LAIR-2 levels are significantly elevated in inflammatory conditions. The expression of 
LAIR-2 has been described in inflammatory arthritis and autoimmune thyroid disease. Both are 
autoimmune disorders resulting in destruction and remodelling of a localised affected area. LAIR-2 
levels were compared in patients with inflammatory RA and non-inflammatory OA. Olde Nordkamp 
et al concluded in their study that LAIR-2 has a regulatory role by preventing LAIR-1 binding to 
collagen, and also that it may be a urine biomarker in RA patients with a greater degree of 
inflammation (Olde Nordkamp et al., 2011). Previously the group had shown synovial fluid from RA 
patients had higher levels of LAIR-2, and noted increased levels of LAIR-2 in pregnant women 
(Lebbink et al., 2008). Serum LAIR-2 levels have also been demonstrated to be higher in autoimmune 
thyroid disease patients compared to healthy donors, and this effect was not thought to be attributed to 
change in thyroid function as LAIR-2 levels in non autoimmune hyperthyroid patients were similar to 
healthy subjects (Simone et al., 2013).     
 
We were the first to look at LAIR-2 as a biomarker in the urine and serum of CHB patients. Although 
the cohorts of patients are small, similar to previous studies, LAIR-2 was detected in healthy 
individuals. However, there was no difference in serum or urine LAIR-2 concentrations between CHB 
and HC. In addition serum and urine LAIR-2 concentrations in the IA and IC disease phases were no 
different suggesting no role for LAIR-2 as a meaningful biomarker in distinguishing these two phases. 
These phases were chosen as IA patients are characterised by fluctuating levels of liver enzymes and 
viral load indicative of on going immune activity and inflammation. Perhaps there was no apparent 
difference between phases as the inflammation was not significant enough to show a true difference. 
ALT is often considered a suboptimal surrogate for inflammation and the mean ALT of this group of 
CHB patients did not exceed 85. Perhaps CHB is an indolent disease and although inflammation is 
chronic, it is not significant enough to cause raised levels of LAIR-2.  
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Chapter 7: Final Conclusions and future directions 
7.1 Summary and overall discussion of work presented 
 
In CHB both innate and adaptive immunity are impaired (Ferrari, 2015). It has been observed that 
altered function of adaptive and innate immune cells contribute to the persistence of viral infection. 
NK cells have been implicated in the control of HBV in mouse models and are involved in liver 
pathogenesis (Tian et al., 2013). Specific to CHB, NK cells may contribute to viral persistence by 
deleting HBV-specific T cell responses. Peppa et al observed upregulation of TRAIL-R2 receptor on 
intrahepatic virus-specific CD8+ T cells rendering the virus-specific T cells susceptible to apoptosis 
by TRAIL-expressing NK cells (Peppa et al., 2013). TRAIL-expressing NK cells were also shown to 
be capable of killing TRAIL-R2-expressing hepatocytes in CHB, thereby potentially exacerbating 
liver damage (Dunn et al., 2007). Despite preserved NK cell cytotoxicity, IFNγ production by NK 
cells in HBV infection is suppressed which may impair viral control (Maini and Gehring, 2016). 
There has been significant interest in the role of inhibitory receptors. Conventionally NK cells are 
activated when there is a reduction in the signal from inhibitory receptors. There are arrays of 
potential receptors that have shown to be overexpressed on functionally impaired immune cells. On 
blockade these receptors have demonstrated reversal of exhaustion. This work predominately focuses 
on the role of LAIR-1, an inhibitory receptor, in CHB. To our knowledge, this is the first investigation 
of LAIR-1 on NK cells in CHB.  
 
7.1.1. Aim 1: Investigate expression of LAIR-1 on NK cells in periphery and 
liver of CHB patients. 
 
In Chapter three we reviewed some of the most commonly investigated inhibitory receptors and 
explored the expression of co-inhibitory receptors on NK cells in CHB. Interestingly, the least studied 
inhibitory receptor is LAIR-1 but LAIR-1 prompted our interest, as the ligand is abundant in the 
diseased liver in CHB. Collagen is implicated in several rheumatological diseases i.e. RA, SLE and 
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autoimmune conditions, and the receptor has been explored in this context but has received limited 
focus in liver disease. We show in LAIR-1 expression on total NK cells, and both CD56bright and 
CD56dim NK cell subsets is significantly higher in CHB patients than HC, suggesting a potential role 
for this receptor in this chronic viral infection. The receptor is also expressed at much higher 
frequency than other receptors. Perhaps there is higher LAIR-1 expression on NK cells as they 
differentiate and mature in the bone marrow where they can encounter stromal cells, and potentially; 
as these bone marrow stromal cells produce collagen, circulating NK cells have a higher LAIR-1 
expression in line with their requirement for a high threshold for activation. This hypothesis however 
requires further investigation.  
 
There was no correlation with clinical parameters such as age, disease phase or fibrosis stage. 
However, the inhibitory receptor LAIR-1 was increased on CD56bright NK cells from patients with 
CHB. One of a number of ways NK cells can contribute to viral persistence in CHB is via an 
impaired/exhausted CD56bright NK cell cytokine response failing to promote responses of lymphocytes 
of the adaptive immune system (Peppa et al., 2010). Functional inhibition of NK cells by LAIR-1 (as 
shown previously by Lebbink et al) may occur in CHB as supported by our finding of an inverse 
correlation between NK cell LAIR-1 expression and effector function. 
 
A number of studies demonstrate higher expression of activatory receptors (NKp30, NKp46 and 
NKG2C) and lower inhibitory receptor expression on peripheral NK cells in CHB compared with 
HCV-infected patients and healthy controls (Rehermann, 2013). In general (not specific to viral 
infection) intrahepatic NK cells are more activated (Huang et al., 2017), showing higher cytotoxic 
capacity than peripheral NK cells (Fasbender et al., 2016). Interestingly, intrahepatic NK cells had a 
different phenotype compared to circulating NK cells, with downregulation of LAIR-1, and LAIR-1 
was strikingly further downregulated on liver resident versus non-resident NK cells. LAIR-1 is also 
preferentially expressed on CD56bright NK cells within the HBV-infected liver, where we could 




These data point to a role for the liver milieu downregulating LAIR-1, either by promoting 
internalisation or shedding. In Chapter four we probed whether this downregulation was due to 
exposure to collagen, the cytokine milieu or crosstalk with HSCs. NK cells are believed to maintain 
liver homeostasis/tolerant environment by their interaction with other cell types and the presence of 
soluble factors like cytokines can influence the phenotype of NK cells (Shi et al., 2011). Findings 
from murine models suggest that cytokines may impair NK cell function by modifying their surface 
receptor expression. Lassen et al demonstrate this by showing that IL-10 contributed to the regulation 
of intrahepatic NK cells by maintaining a higher percentage of the less responsive NKG2A+Ly49− 
subset of NK cells (Lassen et al., 2010). Antiviral therapy in CHB has been linked to the 
downregulation of NKG2A and partial recovery of NK cell IFNγ production (Tjwa et al., 2011). The 
impaired function of NK cells in CHB has also been attributed to the capacity of TGFβ to 
downregulate the inhibitory NKG2D/DAP10 and 2B4/SAP pathways (Sun et al., 2012). Shi et al 
demonstrated that in HBV, plasmacytoid dendritic cells (pDC) could impair NK cell IFNγ production 
without affecting NK cell cytotoxicity (Shi et al., 2012). This cross talk of immune cells could be a 
potential escape mechanism for the virus, perpetuating chronicity. 
 
7.1.2. Aim 2: Investigate effect on LAIR-1 expression on NK cell function in 
CHB. 
 
In this study no consistent data was identified supporting collagen or liver-relevant cytokines in 
downregulating the surface expression of NK cell LAIR-1. When we further explored whether NK 
cell function changed in the presence of collagen, preliminary experiments on PBMC from CHB 
patients demonstrated a downregulation of CD107a on NK cells upon collagen pre-coated plates. This 
is consistent with previous studies by Lebbink et al demonstrating collagens can inhibit immune cell 




Further work would be to look specifically at LAIR-1 positive NK cells and other aspects of 
cytotoxicity to observe whether pre-incubation with blocking anti-hLAIR-1 F(ab’)2 (8A8) fragments 
reverses inhibition. It may be difficult however to block this interaction because there is no 
commercially available blocking antibody and only a very limited supply from one lab. To overcome 
this hurdle we may need to consider use of small interfering RNA (siRNA) for knock-down instead. 
Son et al who transfected human monocytes with LAIR-1 siRNA with a moderate 40% efficiency 
used this technique (Son and Diamond, 2015). Kang et al silenced the expression of LAIR-1 in vitro 
by introducing Lentivirus-encoded shRNA into human leukaemia lines (Kang et al., 2015). Both 
techniques have been used previously with regards to LAIR-1 and have their respective limitations, 
but nevertheless are important in furthering the understanding of the biology of this receptor.  
 
7.1.3. Aim 3: Investigate whether there is cross talk between collagen 
producing cells in the liver (HSCs) and LAIR-1 on NK cells.  
 
NK cells are enriched in the liver and there is growing evidence that they impact the function of HSCs 
in liver fibrosis, playing a protective role by removing activated HSCs to limit fibrosis (Fasbender et 
al., 2016). In experimental mouse models, depletion of NK cells leads to fibrosis. NK cells act via 
crosstalk with other immune cells and cytolytic attack against HSCs can prevent collagen deposition 
and fibrosis (Friedman, 2008). Furthermore we know NK cells are impaired in function in chronic 
liver injury, and a number of studies have shown their antifibrotic function is impaired through 
downregulation of receptors such as NKG2D and 2B4. It has been suggested that collagen fibre 
scaffolds laid down in progressive fibrosis prevent NK cells from accessing their target cells 
(Fasbender et al., 2016).  
 
In Chapter four we described experiments involving co-culture of PBMC with pHSC and pHSC 
supernatant. There was no change in LAIR-1 surface expression, but it is possible that the function of 
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NK cells could be altered if there was ligand engagement. This would be of interest for investigation 
in due course. 
 
In Chapter five we explored the expression of LAIR-1 on circulating NK cells from patients with 
HCC and NAFLD. LAIR-1 expression was significantly higher in the HCC cohort and preferentially 
expressed on CD56dim NK cells. In HCC the inflammatory microenvironment can stimulate and 
exacerbate injury. Most HCC occur in the context of chronic inflammation and liver injury, which has 
led to cirrhosis. There is strong evidence that NK cells in HCC and in liver cirrhosis are functionally 
impaired. Early observations by Chuang et al in the 1990s showed that in a small subset of twenty-
nine cirrhotic patients, impaired NK cell activity in severe liver disease demonstrated with 
cytotoxicity assays, have been further corroborated in later studies (Chuang et al., 1991). In the 
diseased liver and stromal tumour microenvironment HSCs play an important role in depositing 
collagen fibres. Impairment of NK cell function in fibrosis and HCC, and the observation of high 
expression of LAIR-1 on NK cells in HCC led us speculate whether these changes could be attributed 
to collagen deposition by HSCs and a potential role of NK cell LAIR-1-collagen interaction. 
However, the experiments in chapter four did not find a cause for downregulation of LAIR-1 on 
intrahepatic NK cells. We were unable to show in co-culture experiments that collagen derived from 
HSCs influences the expression of LAIR-1 on NK cells and this remains to be determined.  
 
Finally in chapter six we were the first to look at LAIR-2 as a biomarker in the urine and serum of 
CHB patients. Similar to previous studies LAIR-2 is detected in healthy individuals. However, there 
was no difference in serum or urine LAIR-2 concentrations between CHB and healthy controls. It 
would be interesting to re-examine LAIR-2 levels during marked hepatic flares of CHB, and whether 




7.2 Questions and future direction 
 
 
7.2.1. Investigating role of immune complex bound complement component 
C1q as another LAIR-1 ligand in CHB  
 
 
The interplay between NK cells and dendritic cells (DC) has been shown to be crucial to innate and 
adaptive responses against infection (Andoniou et al., 2005). Plasmacytoid DC (pDC) are a 
subpopulation of cells that can directly inhibit viral replication via their production of type 1 
interferons. They can also prime and recruit NK cells to become more cytotoxic in vivo. Early work 
by Poggi et al showed engagement of LAIR-1 inhibited differentiation of peripheral blood monocytes 
toward dendritic cells in vitro (Poggi et al., 1998). At this time the ligand of LAIR-1 had not been 
identified and therefore mAb was used for cross-linking, these experiments have not been repeated 
since the discovery of collagen as the ligand of LAIR-1.  
 
A number of years later preliminary experiments by Son et al showed human pDCs produced less 
IFNα with the addition of C1q (Son et al., 2012). In the knowledge that monocytes have high 
expression of LAIR-1, Son et al set out to investigate how C1q mediates suppression of function of 
human monocytes via LAIR-1. Their experiments involved using synthetic oligonucleotides that 
contain CpG motifs, which would normally mimic the activity of CpG motifs in bacterial DNA to 
trigger monocytes. In their follow-up paper they were able to show addition of C1q and anti-LAIR-1 
mAb suppressed production of type 1 interferons by monocytes. They demonstrated the importance of 
LAIR-1 since C1q-mediated suppression did not occur in cell lines transfected with LAIR-1 siRNA. 
Interestingly, they also observed the engagement between C1q and LAIR-1 inhibits toll-like receptor 




Focusing specifically on what we know about the role of complement in influencing cells of the 
adaptive immune system, complement has been demonstrated to regulate CD4+ and CD8+ T cell 
functions but there is no literature regarding regulation of NK cells (Stoermer and Morrison, 2011). 
Could C1q binding to LAIR-1 have a role in the regulation of NK cells? C1q bound to immune 
complexes merits investigation as a potential ligand for LAIR on NK cells in CHB. 
 
Of interest investigating the role of immune complex bound complement component C1q in CHB 
could also be highly relevant to CHB due to the presence of circulating immune complexes in the 
periphery, and whether this regulates LAIR-expressing NK cells in the periphery rather than the liver. 
 
Shi et al demonstrated that in HBV pDC could impair NK cell IFNγ production but without affecting 
NK cell cytotoxicity (Shi et al., 2012). It would be interesting to investigate if this was due to the 
higher expression of LAIR-1 on CD56bright NK cells. Cross talk between immune cells could be a 










7.2.2. LAIR-1 in other diseases 
 
LAIR-1 captured our interest as the ligand is abundant in the diseased liver in CHB. Collagen is 
implicated to play a role in several rheumatological diseases and autoimmune conditions. Researchers 
have speculated that the LAIR-1-collagen interaction may have a role in these diseases, however, little 
has been published regarding this.  
 
Organ failure due to fibrosis is the main cause of morbidity and mortality in patients with systemic 
sclerosis (LeRoy et al., 1988). Samples have shown increased accumulation of types one and three 
collagen in gastric wall of systemic sclerosis patients. Gastrointestinal (GI) involvement affects 9 out 
of 10 patients with SSc. Interestingly in these patients the liver is not affected. It has not previously 
been investigated whether LAIR-1 could be a biomarker of GI involvement in systemic sclerosis or 
correlate with severity of involvement. The presence of myofibroblasts in the skin of patients with 
SSc has been extensively investigated (Abraham and Varga, 2005); it would be interesting to see 




7.2.3. Functional consequences of LAIR-1  
 
It would be useful to look at histopathology sections for LAIR-1 staining (by immunohistochemistry) 
to determine the spatial relationship between LAIR-1 expressing NK cells and HSCs. It is well 
described that cytotoxicity is a less efficient process compared to cytokine-mediated antiviral effects, 
as the former requires one-to-one interaction between cells. It would be interesting to focus on the 
spatio-temporal relationships between HSCs and NK cells when architectural changes occur in liver 
damage in fibrosis and HCC.  
 
In CHB virus-specific T cells are deleted or become dysfunctional and their role in suppressing virus 
infection is compromised. One of the mechanisms by which this occurs is via co-inhibitory receptors 
like PD-1. Kennedy et al analysed the expression of LAIR-1 on circulating global CD4+ and CD8+ T 
cells (Kennedy et al., 2012), but it would also be pertinent to look at LAIR-1 on virus-specific T and 
B cells in CHB to see if it is constraining these. 
 
We did not have the opportunity to perform collagen functional studies with intrahepatic 
lymphocytes. There is no known role for sLAIR-2 in directly inhibiting immune cells and it is 
possible that sLAIR-2 can affect the interaction of LAIR-1 with collagen and indirectly affect NK cell 
function. Blockade studies with F(ab’)2 fragments would help to dissect this. In a similar way, an 
experimental design using matrix metalloproteases or collagenase to break down collagen on the pre-
coated plate may also help.  
 
A more sophisticated but complex experimental plan (currently in progress) involves using three-
dimensional liver scaffolds in collaboration with Pinzani & Mazza. These scaffolds can be designed to 
have collagen in the correct spatial configuration to bind LAIR-1 and repopulated with HSCs and 
HCC cell lines to observe their effect on NK cell function through LAIR-1. The process of 
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decellularisation maintains the scaffold microarchitecture but destroys immune cells within the 
matrix, enabling a ‘clean slate’ for observational and functional studies. Mazza et al have previously 
shown decellularised human liver scaffolds could be repopulated with liver resident cell lines and 
recreated a bioartificial environment in vitro. Collagen type I, III and IV were preserved following 
decellularisation (Mazza et al., 2015).  Exciting preliminary data show a clear down-regulation of NK 
cell LAIR-1 upon engagement with collagen in this more physiological configuration.  
 
Based on the current knowledge, this study has explored LAIR-1 in CHB for the first time. The novel 
findings of high expression on NK cells in CHB and a correlation between expression and effector 
function suggest this inhibitory receptor could have a potential role in exhaustion of NK cells in CHB. 
We found NK cell function downregulated upon collagen interaction and ongoing work with liver 
scaffolds has shown LAIR-1 is downregulated on NK cells in this environment supporting the ex vivo 
observations on intrahepatic NK cells. This further work confirms our hypothesis that the hepatic 
collagen matrix can shape NK cells through LAIR-1. Additional experiments to determine the specific 
functional relevance of LAIR-1 downregulation are underway.  
 
Figure 7.1 is an overview of the functional significance of potential LAIR-1-collagen interactions. 
 
Future research should investigate the potential role of high expression of LAIR-1 in HCC and 
whether the tumour microenvironment exploits the LAIR-1-collagen interaction dampening anti-
tumour responses. Further work may facilitate our understanding of the complexities and interplay 




7.2.4. Targeting LAIR-1 as a therapeutic strategy 
 
The ultimate end-point would be to develop a novel approach targeting LAIR-1, similar to PD-1 and 
CTLA-4 checkpoint inhibitors. For example it would be of interest to explore LAIR blockade as a 
potential therapeutic strategy in HCC as an adjunct to existing checkpoint inhibitors, which are only 
successful in a fraction of cases. To elaborate further it would be helpful to explore whether LAIR-1 
is also increased on T cells in HCC and whether expression is also increased on tumour-infiltrating 
NK and T cells in HCC.  
 
Some collagen inhibitors have been developed for use in liver fibrosis such as Hsp47 but efficacy has 
not yet been demonstrated. It is important to understand the mechanisms of ligand receptor 
interactions between HSCs and NK cells as several other ligands have been noted to be present on 
HSCs as well as hepatocytes (MIC-A, TRAIL receptor, FAS) but we need to be mindful that 
therapeutic strategies that activate NK cells could result in hepatocytes also being targeted which may 
lead to further liver damage.  
 
The advantage of targeting LAIR-1 is that therapy would not be affecting collagen per se, rather 
simply the interaction of LAIR-1 on immune cells. Risks would be related to loss of tolerance. 
However, reassuringly debilitating autoimmunity has not precluded the use of PD-1 blockade as a 
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